

# POSTER SESSION GUIDELINES

## OVERVIEW

Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

### Note:

Neither ISPE nor the Hynes Convention Center will be responsible for any poster that is left up overnight or is lost or damaged.

## POSTER SESSION

Posters will be displayed in Hall D of the Hynes Convention Center, August 24-26. Each day will have a separate poster session. All posters for a specific day's session must be removed at the end of that day.

- Monday, August 24.....Poster Session A
- Tuesday, August 25.....Poster Session B
- Wednesday, August 26.....Poster Session C

### 1. SET UP:

7:00am-8:00am; all posters must be in place by 8:00am. Poster sessions will be held in Hall D of the Hynes Convention Center.

### 2. HOURS:

Posters will be displayed from 8:00am-6:00pm on Monday and Tuesday, and 8:00am-1:45pm on Wednesday.

### 3. DISCUSSION TIME:

General: Presenters should be at their posters between 12:15-1:15pm on Monday (A) and Wednesday (C); and between 11:45-12:45pm on Tuesday (B).

**Spotlight Sessions:** Organized by the ISPE Special Interest Groups (SIGs). Presenters should be at their posters between 12:15-1:15pm on Monday (A) and Wednesday (C); and between 11:45-12:45pm on Tuesday (B).

#### Spotlight Session Prizes

A group of judges will select the best poster for each Spotlight Session. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The winners will be announced and certificates presented during The Final Word at 4:45pm, Wednesday, August 26.

The spotlight sessions offer pre-selected presenters the opportunity to present their work and to discuss their results with an audience. When the session chair and audience stop at your poster, please give a brief, 3-minute, presentation and be prepared to answer questions about your research.

- Monday**
- Biologics
  - Drug Utilization/Health Services Research
  - Molecular Epidemiology, Biomarkers and Pharmacogenetics
  - Vaccines

- Tuesday**
- Asian Pharmacoepidemiology Network (AsPEN)
  - Comparative Effectiveness Research
  - Medical Devices
  - Pediatrics
  - Pregnancy

- Wednesday**
- Adherence
  - Benefit Risk Assessment, Communication and Evaluation (BRACE)
  - Database

### 4. TAKE DOWN:

- All posters must be taken down by 6:30pm on Monday and Tuesday, and by 5:00pm on Wednesday.

## NUMBERING SYSTEM

Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster on that day as listed in the **Final Program**. The **POSTER BOARD** number is the first number listed. The **PUBLICATION NUMBER**, for use in locating abstracts in the **Final Program** or in *Abstracts2view*, is listed after the abstract title in brackets [ ].

### Example

**97 Characteristics of Patients with Depression Who Initiate Antidepressant and Benzodiazepine Therapy Simultaneously, Compared with Antidepressant Monotherapy [176]**  
Greta A Bushnell, Alice White, Til Stürmer, Bradley N Gaynes, Virginia Pate, Deborah Azrael, Matthew Miller. (United States)

### Key

**97** POSTER BOARD Number  
**176** PUBLICATION Number

### 1. Poster Specifications

Posters must be designed to fit a freestanding poster board approximately **4 feet WIDE x 8 feet HIGH (1.2 meter WIDE x 2.4 meters HIGH)**. Only **VERTICAL/ PORTRAIT** posters will be allowed.

### 2. Disclosure Statement

A disclosure statement must accompany each abstract. This statement should follow the title page and should be a positive disclosure of all funding sources for the current project as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the one-year period before the annual meeting. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed.

### 3. Call4Posters

Posters ordered through Call4Posters can be picked up in Hall D of the Hynes Convention Center beginning Sunday afternoon, August 23, at 1:00pm.

#### Poster Pick Up Schedule:

Sunday, August 23rd: 1:00pm to 5:00pm  
Monday, August 24th: 7:00am to 1:00pm  
Tuesday, August 25th: 7:00am to 1:00pm  
Wednesday, August 26th: 7:00am to 12:00pm



## Spotlight Session-Biologics

1. **Risk of Non-Melanoma Skin Cancer Recurrence With the Use of Immunosuppressant and Biologic Agents in Autoimmune Disease [80]**  
Frank I Scott, Ronac Mamtani, Colleen M Brensinger, Kevin Haynes, Zelma C Chiesa-Fuxench, Jie Zhang, Lang Chen, Fenglong Xie, Huifeng Yun, Mark T Osterman, Timothy Beukelman, David J Margolis, Jeffrey R Curtis, James D Lewis. (United States)
2. **Active Surveillance of Skin Toxicities Through Web-Based Patient-Reported (PRO) Toxicity Reporting Tool in Outpatient Cancer Patients on EGFR Tyrosine Kinase Inhibitors (TKI): A Feasibility Study [81]**  
Tian Qi Wang, Hagit Bergman, Catherine M Brown, Ashlee Vennettilli, Devalben Patel, Jack T Seki, Andrea Perez-Cosio, Doris Howell, Geoffrey Liu. (Canada)
3. **Patterns of Granulocyte Colony-Stimulating Factor Use Among Older Women With Breast Cancer: An Analysis of SEER-Medicare Linked Data, 2001-2009 [82]**  
Wan-Ju Lee, Stephen M Schwartz, Gregory S Calip. (United States)
4. **Occurrence of Acute Renal Failure (ARF) on the Same Day as Immune Globulin (IG) Product Administrations During 2008-2014 [83]**  
Bola Ekezue, Gayathri Sridhar, Richard Forshee, Nandini Selvam, Dorothy Scott, Steven Anderson, Mikhail Menis. (United States)
5. **Occurrence of Hemolytic Reactions (HRs) on the Same Day as Immune Globulin (IG) Product Administrations During 2008-2014 [84]**  
Bola Ekezue, Gayathri Sridhar, Richard Forshee, Nandini Selvam, Steven Anderson, Mikhail Menis. (United States)
6. **Majority of Patients Do Not Store Their Biological Disease Modifying Antirheumatic Drugs Within Recommended Temperature Range [85]**  
Nicolaas D Vlieland, Helga Gardarsdottir, Marcel L Bouvy, Antoine CG Egberts, Bart FJ van den Bemt. (Netherlands)
7. **Prevalence and Overlap of Asthma Phenotypes in a General Asthma Population [86]**  
Trung N Tran, Christine K Ward. (United States)

## Biologics

8. **Insulin Treatment and Breast Cancer Risk; a Systematic Review of In Vitro, Animal and Epidemiological Evidence [87]**  
Heleen K Bronsveld, Bas ter Braak, Øystein Karlstad, Peter Vestergaard, Jakob Starup-Linde, Marloes T Bazelier, Marie L de Bruin, Anthonius de Boer, Christine LE Siezen, Bob van de Water, Jan Willem van der Laan, Marjanka K Schmidt. (Netherlands)
9. **Patient-Reported Health Utility Scores (HUS) in Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Mutations By Drug Therapy [88]**  
Erin L Stewart, Catherine Labbe, Catherine Brown, Andrea Perez-Cosio, Ashlee Vennettilli, Devalben Patel, Nicholas Cheng, Mindy Liang, Gursharan Gill, Yvonne Leung, Nicole Mittmann, Hiten Naik, Geoffrey Liu. (Canada)
10. **Frequency and Trends of Disease-Modifying Antirheumatic Drug (DMARD) Use in Germany [89]**  
Alexander M Fassmer, Edeltraut Garbe, Niklas Schmedt. (Germany)
11. **Clotting Factor Utilization Among the U.S. Elderly as Recorded in Medicare Databases During 2008-2013 [90]**  
Mikhail Menis, Steven A Anderson, Stephen McKean, Rob Warnock, Mikhail V Ovanosov, Paul D Mintz, Sumit Verma, Natalie Norton, Zebulun Kessler, Hector S Izurieta, Christopher M Worrall, Jeffrey A Kelman, Richard A Forshee. (United States)
12. **Comparison of Patients Initiating Abatacept and TNFs Enrolled in MarketScan and the ARTIS Registry [91]**  
Nicole Baker, Thomas Frisell, Johan Askling, Hugh Kawabata, Teresa A Simon. (United States)

## Spotlight Session-Drug Utilization Research/Health Services Research

13. **Did the Introduction of Mandatory Offer of Generic Substitution Have a Quantifiable Effect in South Africa? [195]**  
Andrew L Gray, Yared Santa-Ana-Tellez, Veronika J Wirtz. (South Africa)
14. **Identifying Potential Spill-Over Effects of the Maryland Prescription Drug Monitoring Program [196]**  
Ting-Ying Huang, Patience Moyo, Sarah Tom, Linda Simoni-Wastila. (United States)

15. **Spontaneous Adverse Event Reports Associated With Apixaban and Potentially Inappropriate Medicine Use: An International Comparison [197]**  
Gillian E Caughey, Lisa M Kalisch Ellett, John D Barratt. (Australia)
16. **Patterns of Intravenous Corticosteroid Utilization in Patients Undergoing Coronary Artery Bypass Grafting Surgery in the US [198]**  
Macarius M Donneyong, Joshua J Gagne. (United States)
17. **Antiepileptic Drug Utilization Across 15 Years for Epilepsy and Non-Epilepsy Indications in a Canadian Province: A Population-Based Study [199]**  
Christine Leong, Muhammad M Mamdani, Tara Gomes, David N Juurlink, Erin M Macdonald, Marina Yogendran. (Canada)
18. **Trends in the Consumption of Antiepileptic Drugs in Portugal, 2004-2014 [200]**  
Carla Torre, Jose Pedro Guerreiro, Marta Gomes, Suzete Costa. (Spain)
19. **National Use of Testosterone Replacement Therapy: Annual Trends and Response To Recent Evidence [201]**  
Eleanor Lucas, Matthew Daubresse, Sonal Singh, Randall Stafford, G Caleb Alexander. (United States)
20. **Risk of Fall-Injury Associated With Psychotropic Drugs Among People Aged 65 Years or Older in Sweden [202]**  
Annica Bergendal, Pınelopi Lundquist, Julius Collin, Gudrun Jonasdottir Bergman, Peter Salmi, Natalia Borg, Bengt Danielsson. (Sweden)

## Drug Utilization Research Health Services Research

21. **Dyslipidaemia in HIV-Positive Patients Treated With Protease Inhibitors in the Cape Metropole Region: Preliminary Results [92]**  
Pierre Mugabo, Richard Madsen. (South Africa)
22. **Changes in Glucose Lowering Drug Use Before and After a Cancer Diagnosis Among Individuals With Diabetes [93]**  
Marjolein Zanders, Harm Haak, Myrthe van Herk-Sukel, Ron Herings, Lonke van de Poll-Franse, Jeffrey Johnson. (Netherlands)
23. **Implementation of a Comprehensive Treatment Center on Hemophilia CITH With Follow-Up Results at the First Year [94]**  
Fernando Guerrero, Carlos Ramirez, Juliana Jacome, Victor Machado, Diana Ramos, Fabian Beltran. (Colombia)





24. **Impact of a Decree on ACE Inhibitors/ARBs in Cardiovascular Secondary Prevention in the Lazio Region: A Pre-Post Analysis [95]**  
Flavia Mayer, Ursula Kirchmayer, Mirko Di Martino, Nera Agabiti, Danilo Fusco, Maria Davoli. (Italy)
25. **Withdrawn By Author**
26. **Impact of a Public Intervention in the Media on the Use of Statins in Patients at Various Cardiovascular Risks [97]**  
Julien Bezin, Florence Francis, Nam Vinh Nguyen, Nicholas Moore. (France)
27. **The Impact of Direct-to-Consumer Advertising on Testosterone Testing and Initiation in the United States [98]**  
J Bradley Layton, Yoonsang Kim, Glen Szcypka, G Caleb Alexander, M Alan Brookhart, Matthew Daubresse, Sherry L Emery. (United States)
28. **Patient Characteristics and Prior Total Knee Arthroplasty Opioid Use Are Associated With Post-Operative Opioid Use [99]**  
Maria CS Inacio, Robert S Namba, Anshuman Singh, Cheetham T Craig, Elizabeth W Paxton. (Australia)
29. **Acetaminophen Overdosing in Hospitalized Patients: Retrospective Analysis and Implementation of Preventive Semi-Automated Alerts [100]**  
David F Niedrig, Guido Bucklar, Michael Fetzer, Sarah Maechler, Carmen Goett, Gerd A Kullak-Ublick, Stefan Russmann. (Switzerland)
30. **Changes in US Oral Anticoagulant Drug Prescription Patterns During Period of FDA Actions [101]**  
Cathy Anne Pinto, Yong Chen, Jianmin Wu, Tarek Hammad. (United States)
31. **Impacts of Established Academic Detailing Programs on Prescribing Across Canada [102]**  
David Blackburn, Nancy Blythe, Michael Allen, Anne Nguyen, Tanya MacLeod, Loren Regier, Michelle Boudreau, Tom Briggs, Malcolm Maclure. (Canada)
32. **Effect of Prescription Drug Coupons on Statin Utilization and Expenditures: A Retrospective Cohort Study [103]**  
Matthew Daubresse, Martin Andersen, Kevin R Riggs, G Caleb Alexander. (United States)
33. **An Intervention To Optimise Medication Use in Nursing Home Residents With Advanced Dementia: OptimaMed [104]**  
Edeltraut Kroeger, Mabelle Wilchesky, Philippe Voyer, Michèle Morin, Nathalie Champoux, Johanne Monette, Anik Giguère, Michèle Aubin, Pierre Durand, Marcel Arcand, René Verreault. (Canada)
34. **Impact of Academic Detailing Program To Primary Care Providers About Antipsychotic Medication [105]**  
Eimir Hurley, Connie DiCocco, Michael Fischer, Niteesh Choudhry, Jerry Avorn. (United States)
35. **Induction Agent Use in Older Kidney Transplant Recipients [106]**  
Mara A McAdams-DeMarco, Xun Luo, Dorry Segev. (United States)
36. **Antibiotic Utilization Trends in the Veterans Affairs (VA) New England Healthcare System [107]**  
Ajinkya M Pawar, Haley J Morrill, Kerry L LaPlante, Aisling R Caffrey. (United States)
37. **Effectiveness of Interventions for Drug Prescribing Improvement in Primary Health Care [108]**  
Marco A Zavala-Gonzalez, Carlos E Cabrera-Pivaral, Maria J Orozco-Valerio. (Mexico)
38. **Effects of Over-The-Counter Sales Restriction of Antibiotics on Substitution With Analgesics, Non-Steroidal Anti-Inflammatory Products and Cough and Cold Medication in Mexico and Brazil [109]**  
Yared Santa-Ana-Tellez, Aukje K Mantel-Teeuwisse, Hubert GM Leufkens, Veronika J Wirtz. (Netherlands)
39. **Drug Safety Manager - Development of an Integrated Concept and Application for Drug Safety Analyses, Interventions and Outcomes Research in Hospitals [110]**  
Stefan Russmann, David F Niedrig, Gyorgy Olah, Luzi Zappa. (Switzerland)
40. **Improving Use of Medicines By Using Commitment Questions in Patient Response Forms: An Evaluation [111]**  
Nicole L Pratt, Lisa M Kalisch Ellett, Janet K Sluggett, Emmae N Ramsay, Mhairi Kerr, Vanessa T LeBlanc, John D Barratt, Elizabeth E Roughead. (Australia)
41. **Retrospective Mass-Analysis of Hospital Prescription Data for Medication Errors and Subsequent Development of Highly Specific Alert Algorithms With ID PHARMA CHECK® [112]**  
David F Niedrig, Andre Sander, Daniel Diekmann, Stefan Russmann. (Switzerland)
42. **Pharmacists' Perspective of Self-Medication With Prescription Only Medicines, Among Patrons of Community Pharmacies in Jos, Nigeria [113]**  
Maxwell Patrick Dapar, Benjamin Nasara Joseph, Mohammed Umar, Meshak Alex Dayol, Noel Nenman Wannang. (Nigeria)
43. **Natural Behavioral Triggers of Adherence: Evidence from Time Shocks [114]**  
Zirui Song, Macarius M Donneyong, Niteesh K Choudhry. (United States)
44. **Gender Differences in Early Access To Medicines: The Case of Diabetes Trials [115]**  
Yaser T Bazargani, Anthonius deBoer, Hubert GM Leufkens, Aukje Mantel-Teeuwisse. (Netherlands)
45. **Compliance To National Directives from the French Ministry of Health for the Control of Antibiotic Utilization in Healthcare Organizations of Paris City and Inner Suburbs [116]**  
Jean-Frederic Westphal. (France)
46. **Regional and Setting Variation of Antipsychotic Prescribing To Elderly Patients Across Ontario [117]**  
Mina Tadrous, Diana Martins, Zhan Yao, Kimberly A Fernandes, Nathan Herrmann, David N Juurlink, Muhammad M Mamdani, Tara Gomes. (Canada)
47. **Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Law on Opioid Prescribing and Utilization [118]**  
Matthew Daubresse, Lainie Rutkow, Hsien-Yen Chang, Daniel Webster, Elizabeth Stuart, G Caleb Alexander. (United States)
48. **Prescription Drug Monitoring Program and Drug Arrests in Florida: Spatial Analysis [119]**  
Juan M Hincapie Castillo. (United States)
49. **The 2010 FDA Drug Safety Recommendations and LABA Dispensing Pattern Changes in Adult Asthma Patients During 2003–2012 [120]**  
Esther H Zhou, Elizabeth M Kang, Sally Seymour, Margie Goulding, Solomon Iyasu. (United States)
50. **Hospital Discharge Medicines Information: From Trial To Policy [121]**  
Alice V Gilbert, Michael Roberts, Des Williams, Andrew L Gilbert. (Australia)
51. **Diabetes Secondary Prevention: Are We Getting the Right Services To the Right People at the Right Price? [122]**  
Eric Romo, Kate L Lapane, Aimee R Kroll-Desrosiers, Allison B Rosen. (United States)



- 52. Evaluation of Antimicrobial Stewardship Programs in Makkah Region Hospitals, Kingdom of Saudi Arabia [123]**  
Abdul Haseeb, Mohamed Azmi Ahmed Hassali, Abdulrahman Bakhsh, Hani Saleh Faidah, Waleed Hassan Almalki, Mahmood Essam Uddin El Raghal. (Saudi Arabia)
- 53. Proton Pump Inhibitors – Should More Care Be Taken With Prescribing for Older Women? [124]**  
Susan E Tett, Marielle MC van der Hoorn, Annette J Dobson, Geeske GMEE Peeters. (Australia)
- 54. Metformin Utilization Patterns in Pediatric Population Aged 10-19 Years in the US: 2009-2013 [125]**  
Tongtong Wang, Ann Marie McNeill, Yong Chen, Ravi Shankar. (United States)
- 55. The Irrational Use of Antibiotics in Sudan [126]**  
Isam Eldin Mohammed Ali Mustafa. (Sudan)
- 56. Pharmacist-Led Educational Interventions on Antibiotics Use and Their Resistance Among Geriatric Diabetes Patients in Malaysia [127]**  
Muhammad Shahid Iqbal, Muhammad Waseem Iqbal, Muhammad Zahid Iqbal, Mohd Baidi Bahari. (Malaysia)
- 57. Prescribing Quality of Antimalarial Medicines in Sudan: A National Study at National Health Insurance Fund in 2013 [128]**  
Isam Eldin Mohammed Ali Mustafa. (Sudan)
- 58. Evaluation of Vancomycin Pharmacokinetics in Coronary Care Units, Kingdom of Saudi Arabia [129]**  
Abdul Haseeb, Abdulrahman Bakhsh, Hani Saleh Faidah, Aljoharh Abdulrahman Alziady, Walaa Dhaifallah Alnemari, Marwah Hassan Mustafa Barnawi, Rozan Mohammed Radwan, Mahmood Essamuddin El Raghal. (Saudi Arabia)
- 59. Antimicrobial Prescribing Pattern for Upper Respiratory Tract Infections in Ambulatory Care Settings, Kingdom of Saudi Arabia [130]**  
Abdul Haseeb, Abdulrahman Bakhsh, Muhammed Tarique Imam, Jehan Rostom, Shahd Khan, Shehana Aljarbou, Rehab Alotaibi, Amal Alotaibi. (Saudi Arabia)
- 60. First-Line Therapy of Metastatic Colorectal Cancer in Elderly Patients: Experience of a French Centre [131]**  
Amaury Daste, Pernelle Noize, Magali Rouyer, Eric Terrebbonne, Alain Ravaud, Annie Fourier-Réglat, Denis Smith. (France)
- 61. Oncopharmacoepidemiology: 10-Year Experience of a French Research Platform [132]**  
Pernelle Noize, Magali Rouyer, Angela Grelaud, Cécile Droz, Régis Lassalle, Jérémy Jové, Marie-Agnès Bernard, Amandine Gouverneur, Pauline Bosco-Lévy, Julien Bezin, Denis Smith, Alain Ravaud, Nicholas Moore, Annie Fourier-Réglat. (France)
- 62. Utilisation and Safety of Deferasirox (Exjade®): Results from an Observational Cohort Study in England [133]**  
Vicki Osborne, Miranda Davies, Deborah Layton, Saad AW Shakir. (United Kingdom)
- 63. Anticoagulant Treatment After VTE in the Netherlands [134]**  
Irene D Bezemer, Elsa J van den Berg, Kerstin Folkerts, Luke Bamber, Fernie JA Penning-van Beest, Michiel Coppens, Ron MC Herings. (Netherlands)
- 64. Antihypertensive Drug Use and Blood Pressure Control in Nigeria [135]**  
Onyinye O Akunne, Aduragbenro D Adedapo. (Nigeria)
- 65. Impact of Comorbid Diabetes Mellitus on Adjuvant Chemotherapy Selection in Older Rectal Cancer Patients [136]**  
Phyo T Htoo, Hannah K Sanoff, Jennifer L Lund. (United States)
- 66. An Investigation of the Concomitant Use of Angiotensin-Converting Enzyme Inhibitors, Non-Steroidal Anti-Inflammatory Drugs and Diuretics in Romania [137]**  
Camelia Bucsa, Daniela C Moga, Andreea Farcas, Cristina Mogosan, Dan L Dumitrascu. (United States)
- 67. Evaluating Prescriber Concordance With Prescribing: Results from a Post-Marketing Study [138]**  
Deborah Layton, Naseer Qayum, Claire Doe, Shayne Freemantle, Saad AW Shakir. (United Kingdom)
- 68. Effect of Hospital Admission on Antihypertensive Medication Utilization Among Older Persons [139]**  
Tariq M Alhawassi, Ines Krass, Lisa G Pont. (Australia)
- 69. Concomitant Prescription of QT-Prolonging Drugs in Dronedarone Users [140]**  
Chuntao Wu, Andrew Koren, Jane Thammakhoune, Hayet Kechemir Kechemir, Stephanie Tcherry-Lessenot, Stephen Lin, Juhaeri Juhaeri. (United States)
- 70. Aspirin and Risk of Cancer Among French Population: A Population Based Cohort Study [141]**  
Aya Ajrouche, Candice Estellat, Carine Roy, David Hajage, Marie Dalichamp, Florence Tubach. (France)
- 71. Drug Utilization Patterns of Azilsartan Medoxomil in Primary Care Setting in Germany [142]**  
Birgit Ehlken, Margarita Shlaen, Juliana Rex, Paul Dolin. (Germany)
- 72. Association Between Analgesic Use and Daytime Sleepiness in People With and Without Dementia in Aged Care Facilities [143]**  
Edwin CK Tan, Renuka Visvanathan, Sarah N Hilmer, Agnes Vitry, J Simon Bell. (Australia)
- 73. Potential for Underdosing of Antipsychotics (AP) in Primary and Mental Health Care: Findings from Post-Authorisation Safety Studies Conducted on Seroquel XL © [144]**  
Deborah Layton, Vicki Osborne, Miranda Davies, Ian Ratcliffe, Sarah Clarke, Saad AW Shakir, Joe Reilly, Tony Hale. (United Kingdom)
- 74. Factors Associated With High Anticholinergic Burden in Aging Adults With Intellectual Disabilities: A Cross-Sectional Study [145]**  
Maire O'Dwyer, Ian Maidment, McCallion Philip, McCarron Mary, Henman Martin, Kathleen Bennett, Jure Peklar. (Ireland)
- 75. Use of Benzodiazepines in Combination With Other Addictive Drugs [146]**  
Christian Berg, Svetlana Skurtveit, Solveig Sakshaug, Vidar Hjellvik, Marte Handal. (Norway)
- 76. Patterns and Predictors of Persistent Opioid Use Following Hip or Knee Arthroplasty [147]**  
Seoyoung C Kim, Jessica M Franklin, Katsiaryna Bykov, Huichuan Lii, Michael A Fischer, Niteesh K Choudhry, Brian T Bateman. (United States)
- 77. Description of Antiparkinsonian Drug Use in US Medicare Claims Database: A Feasibility Assessment [148]**  
Catherine B Johannes, Brian Calingaert, Catherine W Saltus, Sigal Kaplan, Elizabeth Grubb, James A Kaye, Elizabeth B Andrews. (United States)
- 78. Utilisation of a New Once Weekly Injection for Type 2 Diabetes Mellitus (T2DM): Interim Results from an Observational Cohort Study of Exenatide (Bydureon®) in England [149]**  
Vicki Osborne, Naseer Qayum, Abigail Coughtrie, Deborah Layton, Saad AW Shakir. (United Kingdom)
- 79. Withdrawn By Author**



- 80. Utilisation of Asenapine in the Mental Health Care Setting in England and Wales: First Results from a Specialist Cohort Event Monitoring (SCEM) Study [151]**  
Vicki Osborne, Jan Slade, Deborah Layton, Saad AW Shakir, Joseph Reilly. (United Kingdom)
- 81. Adherence To Guidelines and the Screening Tool of Older Persons' Potentially Inappropriate Prescriptions Criteria for Colchicine Dosing for Gout Treatment in Beneficiaries of the Nova Scotia Seniors' Pharmacare Program [152]**  
Emily Black, Ingrid Sketris, Chris Skedgel, Erica MacLean, John Hanly. (Canada)
- 82. Ontario MedsCheck Annual Pharmacy Medication Review Service: A Comparison Between Initial and Well Established Implementation Periods [153]**  
Lisa Dolovich, Giulia P Consiglio, Lusine Abrahamyan, Elizabeth A Bojarski, Linda D MacKeigan, Petros Pechlivanoglou, Nedzad Pojskic, Valeria E Rac, Jiandong Su, Murray D Krahn, Suzanne M Cadarette. (Canada)
- 83. Pharmaceutical Opinions in Ontario: A Descriptive Analysis Using Administrative Claims Data [154]**  
Lisa Dolovich, Giulia P Consiglio, Elizabeth A Bojarski, Andrew J Calzavara, Linda D MacKeigan, Nedzad Pojskic, Lori MacCallum, Suzanne M Cadarette. (Canada)
- 84. Predictors of Ontario's Medication Review Program (MedsCheck Annual Service) Utilization Among Ontario Seniors [155]**  
Petros Pechlivanoglou, Lusine Abrahamyan, Linda MacKeigan, Lisa Dolovich, Giulia P Consiglio, Valeria E Rac, Jiandong Shin, Paul Grootendorst, Elizabeth A Bojarski, Suzanne M Cadarette, Murray Krahn. (Canada)
- 85. Incidence of Medication Errors in the Peri-Operative Period: A Retrospective Study [156]**  
Sarah Khayyat, Sara Qureshi, Li Wei. (Saudi Arabia)
- 86. Hypothyroidism and Thyroid Hormone Use in Older Adults in Lazio, Italy [157]**  
Ursula Kirchmayer, Flavia Mayer, Raffaele Antonelli Incalzi, Mario Barbagallo, Giuseppe Paolisso, Gianpaolo Ceda, Marina Davoli. (Italy)
- 87. Prevalence and Risk Factors for Adverse Drug Reactions in Older Adults in the Acute Care Setting [158]**  
Tariq M Alhawassi, Ines Krass, Lisa G Pont. (Australia)
- 88. Adherence To Evidence-Based Pharmacological Therapies in Patients With COPD: A Multilevel Analysis of Patient, General Practitioner and Hospital of Discharge [159]**  
Martina Ventura, Mirko Di Martino, Danilo Fusco, Nera Agabiti, Giovanna Cappai, Marina Davoli. (Italy)
- 89. Clinical Provider Experiences With Medication Discontinuation [160]**  
Amy Linsky, Steven R Simon, Kelly Stolzmann, Mark Meterko. (United States)
- 90. Non-Compliance With Guideline on NSAID Use and Gastroprotection in Hospitalized Surgical Patients Who Are Prescribed NSAIDs [161]**  
Naoual Chaouit, Michael HJ Verhofstad, Esther MM van Lieshout, Patricia MLA van den Bemt. (Netherlands)
- 91. Hypertension Management and Control in Older Persons on Admission To an Acute Care Setting [162]**  
Tariq M Alhawassi, Ines Krass, Lisa G Pont. (Australia)
- 92. Study of Drug Utilization Pattern of Antidiabetic Agents: Analysis on the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) [163]**  
Roberta Carvalho de Figueiredo, Thaís Resende Batista, Raiany Thaimeny Nery. (Brazil)
- 93. Results of the European Science Foundation Exploratory Workshop on Quality and Safety of Pharmacotherapy in Old Age: A Focus on Potentially Inappropriate Medication (PIM) Lists [164]**  
Majda Azermai, Monique Elseviers, Robert Vander Stichele, On Behalf of the European Science Foundation Exploratory Workshop Members. (Belgium)
- 94. Evaluation of a Rapid Implementation Quality Improvement Program for Medicine Security [165]**  
Alice V Gilbert, Michael Roberts, Des Williams, Andrew Leigh Gilbert. (Australia)
- 95. A Multinational, Drug Utilisation Study To Investigate the Use of Dexmedetomidine (Dexdor®) in Clinical Practice in the EU [166]**  
Susana Perez-Gutthann, Mary Weatherall, Chris Garratt, Pasi Pohjanjousi, Riku Aantaa, Giorgio Conti, Michael Lewis, Nicholas Moore. (Spain)
- 96. An Academic Detailing Program To Reduce Antipsychotic Medication Use in Nursing Homes [167]**  
Eimir Hurley, Connie DiCocco, Michael Fischer, Niteesh Choudhry, Jerry Avorn. (United States)
- 97. Availability of Essential Medicines for Children in Armenia [168]**  
Irina Kazaryan, Lusine Vardanyan. (Armenia)
- 98. Real-World Analysis of Taxane Use in the First-Line Setting and Prior Comorbidities Among Female Metastatic Triple-Negative Breast Cancer Patients [169]**  
Shih-Wen Lin, Dixa Thakrar, Joseph Simpson, Roel Funke, Stephen Chui. (United States)
- 99. Withdrawn By Author**
- 100. Questionable Care: Use of Memantine Hydrochloride and Cholinesterase Inhibitors in Patients With Advanced Dementia at the End of Life Who Were Enrolled in Hospice [171]**  
Jacob N Hunnicutt, Jennifer Tjia, Kate L Lapane. (United States)
- 101. Withdrawn By Author**
- 102. Withdrawn By Author**
- 103. Withdrawn By Author**
- 104. Agreement Between Self-Reported Medication from Patient Questionnaires With Physician Information: Results from a Long-Term Cohort With Coronary Heart Disease [175]**  
Dietrich Rothenbacher, Andrea Jaensch, Ute Mons, Lutz Breitling, Dhayana Dallmeier, Harry Hahmann, Hermann Brenner. (Germany)
- 105. Concordance Among Anticholinergic Burden Scales [176]**  
Jennifer G Naples, Zachary A Marcum, Subashan Perera, Shelly L Gray, Anne B Newman, Eleanor M Simonsick, Kristine Yaffe, Ronald I Shorr, Joseph T Hanlon. (United States)
- 106. An Assessment of the Basic Medication Safety Practices in Sudan [177]**  
Mansour A Mahmoud, Shihabeddin Siddig, Alnada Mohamed, Hisham Aljadhey. (Malaysia)
- 107. Applicability of a Systematic Tool To Reduce Inappropriate Prescribing in Adults With an Intellectual Disability: A Pilot Study [178]**  
Rianne J Zaal, Susan Ebbers, Mirka Borms, Bart de Koning, Patricia MLA van den Bemt, Heleen M Evenhuis. (Netherlands)
- 108. Medications Prescribed and Stopped at Hospital Discharge and Filled Medications in the Community: Medication Discrepancies 30-Days Post Hospital Discharge [179]**  
Dania L Weir, Aude Motulsky, Maria-Teresa Moraga, Robyn Tamblin. (Canada)

- 109. Completeness of Medications Prescriptions: Prescription Errors Study in Hail Region (PeSHR) [180]**  
Ali F Altebenawi, Mubarek Alrashedi, Thamir M Alshammari, Mohamad Aljofan. (Saudi Arabia)
- 110. Prevalence of Potentially Inappropriate Medication Prescribing Among Older Adults in Emergency Department in Chile [181]**  
Marcela Jirón, Luis Herrada, Alex Rojas, Andrés Lueiza, Elena Vega, Erwin Buckel, Hernán Acuña, José Luis Santelices, Renato Maynard, Ricardo Quezada. (Chile)
- 111. Potentially Inappropriate Medication Among Chilean Older Inpatients: Comparison Between a 2012 Beers Criteria and STOPP [182]**  
Marcela Jirón, Mariangel Tapia, Tamara Sandoval, Daniel Palma, Sebastián Orellana, Leslie Escobar, Isabel Huala, Elena Vega. (Chile)
- 112. Factors Associated With Medication Errors in Hospitalized Patients in Chile [183]**  
Ann-Loren Smith, Inés Ruiz, Marcela Jirón. (Chile)
- 113. Effect of No Technological Interventions for Reducing Medication Error [184]**  
Ann-Loren Smith, Inés Ruiz, Tamara Yañez, Mónica Catalán, Marcela Jirón. (Chile)
- 114. Incidence of Intravenous Medication Errors in a Chinese Hospital [185]**  
Qian Ding, Kenneth Barker, Elizabeth Flynn, Ming Chang. (United States)
- 115. Prevalence and Determinants of Potentially Inappropriate Medication Prescribing Among Older US Adults According To STOPP Criteria [186]**  
Marcela Jirón, Virginia Pate, Laura C Hanson, Michele Jonsson Funk, Til Stürmer. (Chile)
- 116. Drug Utilization and Characteristics of New Users of Prucalopride in a UK Primary Care Setting [187]**  
Ana Ruigómez, Luis-Alberto García-Rodríguez. (Spain)
- 117. Patterns of Use of Incretin-Based Therapies in Europe and USA [188]**  
Ingrid Leal, Cormac Sammon, Gwen MC Masclee, Giovanni Corrao, Giorgia De Berardis, Irene Bezemer, Miguel Gil, Elisa Martin, Anita McGrogan, Niklas Schmedt, John D Seeger, Gianluca Trifiro, Serena Pecchioli, Cristina Varas-Lorenzo, Mark M Smits, Peter Rijnbeek, Miriam CJM Sturkenboom, Silvana Romio. (Netherlands)
- 118. Trends of Use of Non-Insulin Blood Glucose Lowering Drugs in Europe and USA [189]**  
Ingrid Leal, Cormac Sammon, Gwen MC Masclee, Lorenza Scotti, Giorgia De Berardis, Irene Bezemer, Miguel Gil, Elisa Martin, Anita McGrogan, Niklas Schmedt, John D Seeger, Gianluca Trifiro, Serena Pecchioli, Cristina Varas-Lorenzo, Mark M Smits, Peter Rijnbeek, Miriam CJM Sturkenboom, Silvana Romio. (Netherlands)
- 119. Survey on Management of GERD: Clinical Experience With Esomeprazole and Levosulpiride [190]**  
Mayuresh Fegade, Chetan Mehndiratta. (India)
- 120. 11-Year of Outpatient Antibiotic Utilization in Portugal – Utilization Pattern and Regional Comparison Between 2004-2014 [191]**  
Marta V Gomes, Carla Torre, José Guerreiro, Paulo Nogueira, Cristina Furtado. (Portugal)
- 121. Prevalence of Prescription and Dosage of Antibiotics in Outpatients from Mexico City: Pilot Study [192]**  
Ramiro Sánchez-Huesca, Jesús-Oswaldo García-Ávila, Claudia Lerma. (Mexico)
- 122. Survey To Understand Role of Angiotensin Receptor Blockers (ARBs) in the Management of Hypertension [193]**  
Mayuresh Fegade, Chetan Mehndiratta. (India)
- 123. Prescription Profile of Cefpodoxime Proxetil in Patients With Various Infections [194]**  
Mayuresh Fegade, Chetan Mehndiratta, Jejoje KaranKumar. (India)
- 127. Geographic Variations in Use of Cancer Targeted Therapies in Taiwan [206]**  
Jason C Hsu, Yea-Huei Kao Yang, Jin-Ding Huang, Christine Y Lu. (Taiwan)
- 128. Utilization and Trends of Molecularly Targeted Therapies in Cancer Treatment: A 2006-2010 NAMCS Analysis [207]**  
Donna R Rivera, Kelly Filipiski, Andrew N Freedman. (United States)
- 129. Impact of Cancer Diagnosis and Treatment on Glycaemic Control Among Individuals With Colorectal Cancer Using Glucose Lowering Drugs [208]**  
Marjolein Zanders, Myrthe van Herk-Sukel, Ron Herings, Lonneke van de Poll-Franse, Harm Haak. (Netherlands)
- 130. Real World Treatment Pattern Trends in Patients With Multiple Myeloma in the US [209]**  
Xue Song, Ze Cong, Kathleen Wilson. (United States)
- 131. Pattern of Chemotherapy Dose Delay and Dose Reduction [210]**  
Hairong Xu, Chun Chao, Lanfang Xu, Kimberly Cannavale, Olivia Sattayapiwat, John H Page, Roberto Rodriguez, Leila Family. (United States)
- 132. Patterns of Antiplatelet Use in Patients With Myocardial Infarction and Subsequent Acute Coronary Syndrome Events [211]**  
Alfi Yasmina, Anthonius de Boer, Olaf H Klungel, Patrick C Souverein. (Netherlands)
- 133. Statins Prescription Rates in a Population-Based Cohort of Amyotrophic Lateral Sclerosis: Comparison With the General Population [212]**  
Francesca Palese, Paolo Battiston Giacomelli, Silvia Ussai, Manuela Giangreco, Lorenzo Verriello, Fabio Barbone, Giancarlo Logroscino, Federica E Pisa. (Italy)
- 134. The Temporal Trend of Concomitant Prescription of Contraindicated Drugs in Dronedarone Users [213]**  
Chuntao Wu, Andrew Koren, Jane Thammakhoun, Hayet Kechemir, Stephanie Tcherny-Lessenot, Stephen Lin, Juhaeri Juhaeri. (United States)
- 135. Impact of New Oral Anticoagulants (NOACs) on Therapy of Patients With Japanese Patients: Descriptive Study Using Commercially Available Database [214]**  
Kiyoshi Kubota, Nobuhiro Ooba, Yukari Kamijima, Kuniyasu Sato, Daisuke Koide. (Japan)

## Drug Utilization Research Health Services Research

- 124. Treatment Patterns and Characteristics of Post-Menopausal Women With HR+/HER2- Metastatic Breast Cancer Receiving Everolimus [203]**  
Francis Vekeman, Yanni Hao, Wendy Y Cheng, Jonathan Fortier, Marie-Noëlle Robitaille, Mei Sheng Duh. (Canada)
- 125. Nationwide Time Trend Analysis of Cancer Targeted Therapies in Taiwan (2009-2016) [204]**  
Jason C Hsu, Yea-Huei Kao Yang, Jin-Ding Huang, Christine Y Lu. (Taiwan)
- 126. Which Types of Cancer Account for the Highest Use of Targeted Therapies in Taiwan? [205]**  
Jason C Hsu, Yea-Huei Kao Yang, Jin-Ding Huang, Christine Y Lu. (Taiwan)



- 136. Use of Overactive Bladder Medications in the Adult Population of the UK: A Cohort Study in the Clinical Practice Research Datalink [215]**  
Andrea V Margulis, Lisa J McQuay, Susana Perez-Gutthann, James A Kaye, Alejandro Arana. (Spain)
- 137. Use of Oral Non-Steroidal Anti-Inflammatory Drugs in People With Asthma [216]**  
Daniel R Morales, Peter T Donnan, Bruce Guthrie. (United Kingdom)
- 138. Use of Antipsychotics (AP) in Mental Health Secondary Care Setting Vs Primary Care [217]**  
Deborah Layton, Vicki Osborne, Miranda Davies, Ian Ratcliffe, Sarah Clarke, Saad AW Shakir, Joe Reilly, Tony Hale. (United Kingdom)
- 139. Sex Difference in Antidepressant Use in Brain Injury Rehabilitation Centres [218]**  
Veronica Campagnol, Silvia Ussai, Giorgia Cosano, Manuela Giangreco, Tullio Giorgini, Emanuele Biasutti, Fabio Barbone, Federica E Pisa. (Italy)
- 140. Trends in Prescribing Patterns for Cabergoline in 4 European Countries [219]**  
Cynthia de Luise, René Schade, Gianluca Trifirò, Lars Pederson, Ron Herings, Miriam Sturkenboom. (United States)
- 141. Drug Utilisation (DU) Study of Seroquel® Extended Release (XR) Prescribed By Psychiatrists as Treatment for Major Depressive Disorder (MDD) in Selected Countries in the European Union (EU) [220]**  
Robert S Brody, Charlie L Liss, Wray Heather, Anneli Thureson, Leigh Jefferies. (United States)
- 142. Risk of Injury With Sedative Hypnotic Use in an Over-65 Population [221]**  
Sanket Shah, Julieta Scalo, Karen Rascati. (United States)
- 143. National Trends in Adult Bipolar Disorder Subtypes and Prescribed Psychotropic Medications [222]**  
Thiyagu Rajakannan, Dinci Pennap, Daniel J Safer, Julie M Zito. (United States)
- 144. Patterns of Prescription Refill and Pregabalin: A Five-Year Prospective Cohort Study on High Consumption [223]**  
Micaela Tjäderborn, Carola Bardage, Staffan Hägg, Elisabet Nikolic, Anna K Jönsson. (Sweden)
- 145. Use of Varenicline in a Canadian Province: A Population-Based Study [224]**  
Noor Breik, Shelley Derksen, Silvia Alessi-Severini. (Canada)
- 146. Psychopharmacological Treatment Patterns in Bipolar Disorder – A Nationwide Register-Based Study [225]**  
Louise Bjørklund, Henriette Thisted, Ole Mors, Søren D Østergaard, Christiane Gasse. (Denmark)
- 147. Pattern Mining of Drug Prescriptions Suggests Complications from Chronic Opioid Use [226]**  
Yen Low, Tanya Podchiyska, Nigam Shah, Anna Lembke. (United States)
- 148. Prescribing Patterns of Proton Pump Inhibitors in Patients With NSAID Use – A Comparison Between Switzerland and the UK in Primary Care [227]**  
Fabienne AM Biétry, Oliver Reich, Susan S Jick, Christoph R Meier. (Switzerland)
- 149. Determining Exposure of Newly Initiated Antipsychotic Medication in a Cohort of Elderly Dementia Patients [228]**  
Kimberly A Fernandes, Mina Tadrous, Diana Martins, Zhan Yao, Samantha Singh, Nathan Herrmann, Muhammed Mamdani, David Juurlink, Tara Gomes. (Canada)
- 150. Drug Switches in Antiretroviral Regimens: Results of a 5-Year Historical Cohort [229]**  
Cristiane A Menezes de Pádua, Leticia P Braga, Débora C Hilário, Miriam M Lima Souza, Lorenza N Campos Dezanet. (Brazil)
- 151. Dose and Duration of Use Among Commercially Insured Adults Prescribed Immediate-Release (IR) or Extended-Release (ER) Oxycodone [230]**  
Angela DeVeaugh-Geiss, Paul Coplan, Aditi Kadakia. (United States)
- 152. Medicare Part D's Impact on Pain Management in Dual-Eligible Nursing Home Residents With Cancer: An Interrupted Time-Series Study [231]**  
Camilla B Pimentel, Kate L Lapane, Allison B Rosen, Jerry H Gurwitz, Becky A Briesacher. (United States)
- 153. The Potential Impact of the Leucovorin Shortage on U.S. Medicaid Utilization and Spending from 2008 To 2013 [232]**  
Ying Xia, Boyang Bian, Christina ML Kelton, Jeff J Guo. (United States)
- 154. Utilization and Spending Trends for Diuretics in the U.S. Medicaid Program: 1991 - 2011 [233]**  
Amarsinh M Desai, Jeff J Guo, Christina ML Kelton, Pamela C Heaton, Teresa M Cavanaugh. (United States)
- 155. Type 2 Diabetes Treatment Patterns Across Europe [234]**  
Edith M Heintjes, Jetty A Overbeek, Patrick Blin, Gillian C Hall, Francesco Lapi, Daniel Prieto Alhambra, Irene D Bezemer. (Netherlands)
- 156. Estimating the Impact of a Breast Cancer Diagnosis on Antidepressant Adherence [235]**  
Yi-Ting Chou, Aaron N Winn, Donald L Rosenstein, Stacie B Dusetzina. (United States)
- 157. Trends in the Utilization of Warfarin and the New Oral Anticoagulants in Atrial Fibrillation Patients [236]**  
Abdullah Abdulaziz Alalwan, Stacy A Voils, Abraham Hartzema. (United States)
- 158. Utilization and Predictors of Psychotropic Polypharmacy in Adult Patients With Attention-Deficit/Hyperactivity Disorder [237]**  
Wei Liu, Xinyue Liu, Paul Kubilis, Yan Li, Yanmin Zhu, Almut G Winterstein. (United States)
- 159. Withdrawn By Author**
- 160. Withdrawn By Author**
- 161. Dispensing of Non-Tamper-Deterrent Brands of Oxycodone Close To the Canadian USA Border [240]**  
Tara Gomes, David Henry, Mariam Mukati, Michael Paterson. (Canada)
- 162. Prevalence of Switching from Brand To Generic Asthma Medications in the Netherlands [241]**  
Marjolein Engelkes, Nico C van Blijderveen, Katia MC Verhamme, Jetty A Overbeek, Josine G Kuiper, Ron CM Herings, Miriam CJM Sturkenboom, Johan C de Jongste, Hettie M Janssens. (Netherlands)
- 163. Withdrawn By Author**
- 164. Using Group-Based Trajectory Models To Characterize Longitudinal Patterns of Spending Phenotypes and Predict High-Cost Patients Using Medication Use and Comorbidity Characteristics [243]**  
Julie C Lauffenburger, Jessica M Franklin, Alexis A Krumme, William H Shrank, Olga S Matlin, Claire M Spettell, Gregory Brill, Niteesh K Choudhry. (United States)
- 165. Diagnosis and Management of Premenstrual Syndrome in UK General Practice: A Study Using the Health Improvement Network [244]**  
Cormac J Sammon, Irwin Nazareth, Irene Petersen. (United Kingdom)
- 166. Therapeutic Class Differences in Generic Usage [245]**  
Jodi B Segal, Matthew Daubresse, Chia-Ying Lee, Mischka Moechtar, Sarah Duchter, Wenlei Jiang, Robert Romanelli. (United States)



- 167. Analgesic Use in a Norwegian General Population: Change Over Time and High-Risk Use. A Repeated Cross-Sectional Study: The Tromsø Study [246]**  
Per-Jostein Samuelsen, Lars Størdal, Ulla Dorte Mathisen, Anne Elise Eggen. (Norway)
- 168. HIV Treatment Strategies in Europe (EU): Adoption of Single Tablet Regimen (STR) [247]**  
Siva Narayanan, Camelia M Graham, Sarah Brown, Samantha Fernando. (United States)
- 169. Polypharmacy Among Older Individuals With Diabetes in Quebec, Canada [248]**  
Caroline Sirois, Marie-Eve Gagnon, Céline Plante, Marc Simard, Isabelle Larocque. (Canada)
- 170. Withdrawn By Author**
- 171. Trends in Asthma-Related Pharmacy Fills [250]**  
Karen E Wells, Haejin Kim, Suzanne Havstad, Kimberley J Woodcroft. (United States)
- 172. Utilization, Price, and Spending Trends for Fluoroquinolones in the US Medicaid Program: 1991-2013 [251]**  
Xiaomeng Yue, Jeff J Guo, Ying Xia, Ziyad S Almalki, Patricia R Wgle. (United States)
- 173. Trends of Systemic Antibiotics (AB) Consumption in the Community in Russian Federation (RF) [252]**  
Ivan Zaharenkov, Polina Antoshkina, Svetlana Rachina, Julia Belkova. (Russian Federation)
- 174. Use of Antidepressives and the Economic Crisis in Portugal [253]**  
Claudia Furtado. (Spain)
- 175. Trends in Use of Erythropoiesis-Stimulating Agents and Blood Transfusions in US Hemodialysis Patients With Cancer [254]**  
Anne M Butler, Abhijit V Kshirsagar, Andrew F Olshan, Matthew E Nielsen, Stephanie B Wheeler, M Alan Brookhart. (United States)
- 176. Drug Utilization in Rheumatoid Arthritis from a Large Japanese Hospital Administrative Database [255]**  
Bruce Crawford, Joseph Kim. (Japan)
- 177. New Oral Anticoagulants in Clinical Practice: Trends in Prescribing Patterns and Health Spending [256]**  
Claudia Furtado. (Spain)
- 178. Urban-Rural Differences in the Uptake of New Formulations of Osteoporosis Drugs [257]**  
Racquel Jandoc, Muhammad Mamdani, Linda E Lévesque, Suzanne M Cadarette. (Canada)
- 179. Attitudes in Statins Use in Greece [258]**  
Paraskevi Papaioannidou, Achilleas Ntaralas. (Greece)
- 180. Drug Use Among Elderly in the Year Before Colon Cancer Diagnosis Versus Matched Cancer-Free Controls [259]**  
Felice N van Erning, Marjolein MJ Zanders, Myrthe PP van Herk-Sukel, Josine G Kuiper, Valery EPP Lemmens. (The Netherlands)
- 181. Prevalence of Low Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults [260]**  
Joshua D Brown, Nathan J Pauly. (United States)
- 182. Gaps in Ethical Policies for the Conduct of Drug Utilization Studies To Assess the Effectiveness of Risk Minimization Interventions [261]**  
Caroline Tremblay, Alia Yousif, Aurore Bergamasco, Yola Moride. (Canada)
- 183. Prescriptions Errors in a Random Sample of Egyptian Community Pharmacies of the City of Alexandria [262]**  
Omnia AbdelRahman, Aida Reda, Nessrin Elnimr, Adel Abou-Ali. (Egypt)
- 184. Assessing the Completeness of Data Included on a Random Sample of Medical Prescriptions Dispensed at Local Pharmacies in the City of Alexandria, Egypt [263]**  
Omnia AbdelRahman, Aida Reda, Nessrin Elnimr, Adel Abou-Ali. (Egypt)
- 185. Trends in the Medical Consumption of Strong Opioid Analgesics in Taiwan During Years 2007 To 2011 [264]**  
Li-Fen Kuo, Wen-Ing Tsay. (Taiwan)
- 186. The Burden of Cardiovascular Disease and the Impact of Anti-Diabetic Medication on Incident Cardiovascular Disease in Patients With Type 2 Diabetes: Findings from U.S. National Surveys [265]**  
Longjian Liu, Hui Liu. (United States)
- 187. Antipsychotic (AP) Use in Older Adults With Dementia: Results from a Post-Authorisation Safety Study (PASS) [266]**  
Deborah Layton, Miranda Davies, Vicki Osborne, Saad AW Shakir. (United Kingdom)
- 188. Preadmission Prescriptions of Antidepressants and Prognosis After Colorectal Cancer Surgery [267]**  
Kathrine D Lycke, Christian F Christiansen, Mette Nørgaard. (Denmark)
- 189. Survey on Management of Severe Intensive Care Unit (ICU) Infections: Clinical Experience With Colistin Methane Sulfonate (CMS) [268]**  
Chetan Mehndiratta, Pradip Gore, Mayuresh Fegade. (India)
- 190. Survey on Management of Severe Intensive Care Unit (ICU) Infections: Clinical Experience With Imipenem+Cilastatin [269]**  
Chetan Mehndiratta, Pradip Gore, Mayuresh Fegade. (India)
- 191. Prescription Event Monitoring of Doripenem Therapy in Management of Serious Infections [270]**  
Chetan Mehndiratta, Pradip Gore, Jejee KaranKumar. (India)
- 192. Effects of Sex and Alcohol Use on Antiretroviral Therapy Outcomes in Botswana [271]**  
Robert Gross, Scarlett L Bellamy, Bakgaki Ratshaa, Xiaoyan Han, Andrew P Steenhoff, Mosepele Mosepele, Gregory P Bisson. (United States)
- 193. Systemic Treatment of Metachronous Metastases After Curative Treatment of Breast Cancer [272]**  
Josephina G Kuiper, Myrthe PP van Herk-Sukel, Yvette RBM van Gestel, Adri C Voogd, Valery EPP Lemmens, Sabine Siesling. (Netherlands)
- 194. Generic and Essential Medicines Towards a More Efficient Use of Resources in the Prevention and Treatment of Cardiovascular Diseases in Portugal [273]**  
Helena Gama, Carla Torre, Jose Pedro Guerreiro, Maria João Lima, Ana Azevedo, Suzete Costa, Nuno Lunet. (Portugal)
- 195. Patients' Awareness of Bioequivalence Study Methods Supporting Generic Venlafaxine Extended Release (ER) Tablet Approval [274]**  
Bilal Khokhar, Yujin Park, Francoise Pradel, Francis Palumbo, Zippora Kiptanui, Sarah Dutcher, Wenlei Jiang, Ilene Zuckerman. (United States)
- 196. Prescribing Pattern of Anti-Epileptic and Concomitant Drugs in Children With Epilepsy in India [275]**  
Anil Dasari, Dipika Bhansal, Chandrika Azad. (India)
- 197. Socio-Demographic and Geographic Variations in the Utilization of Hormone Therapy in Older Breast Cancer Women With Medicare Part-D Coverage [276]**  
Xin Wang, Xianglin Du. (United States)
- 198. Polypharmacy and Multiple Indications Among Adults Prescribed Antidepressants [277]**  
Jenna Wong, Aude Motulsky, Robyn Tamblyn. (Canada)
- 199. Role of Residential Segregation in Disparity Research: A Case Example of ADHD Diagnosis and Treatment [278]**  
Dinci Pennap, Mehmet Burcu, Julie M Zito. (United States)



- 200. Socioeconomic Differential in One-Year Survival After Hospitalization for Ischemic Stroke: The Effect of Acute and Post-Acute Care-Pathways [279]**  
Valeria Belleudi, Paolo Sciattella, Nera Agabiti, Mirko Di Martino, Riccardo Di Domenicantonio, Marina Davoli, Danilo Fusco. (Italy)
- 201. Drug Utilization Study of Asthma Medications in the U.S. Medicare Beneficiaries [280]**  
Ayad K Ali. (United States)
- 202. Misclassification of Indication When Measuring Indacaterol Use in a US Administrative Claims Database [281]**  
Scott C Quinlan, Rajeev K Amar, Raymond Schlienger, Stephan Lanes, Crystal N Holick. (United States)
- 203. Prescribed Opioid Use and Potential Misuse in Australia (2006 To 2013) [282]**  
Bianca Blanch, Nicholas Buckley, Preeyaporn Srasuebkul, Melisa Litchfield and Sallie-Anne Pearson. (Australia)
- 204. Quality of Community Pharmacy Care in the Netherlands: Changes in Dispensing Outcome Scores Across Five Years [283]**  
Martina Teichert, Tim Scheonmakers, Nico Kijlstra, Berend Mosk, Marcel Bouvy, Frans van de Vaart, Peter de Smet, Michel Wensing. (Netherlands)
- 205. Effect of a Certified Quality Management System on Dispensing Outcome Quality Indicators in Community Pharmacies [284]**  
Martina Teichert, Tim Schoenmakers, Nico Kijlstra, Berend Mosk, Marcel Bouvy, Frans van de Vaart, Peter de Smet, Michel Wensing. (Netherlands)
- 206. Translation and Cross-Cultural Adaptation of the Brief Illness Perception Questionnaire, the Beliefs About Medicines Questionnaire and the Morisky Medication Adherence Scale Into Vietnamese [285]**  
Thang Nguyen, Thao H Nguyen, Suol T Pham, Hoang TK Cao, Khanh K Le, Hoa TK Pham, Phong T Pham, Dung N Quach, Dao TT Tran, Tam T Pham, Katja Taxis. (Viet Nam)
- 207. Access To Drug Benefit Plans Among Canadian Cancer Survivors [286]**  
Lawson Eng, Devon Alton, Tom Yoannidis, Robin Milne, Samantha Sarabia, Zahra Merali, Liam Murphy, M Catherine Brown, Ashlee Vennettilli, Meredith E Giuliani, Wei Xu, Geoffrey Liu. (Canada)
- 208. Affordability of Medicines in Armenia [287]**  
Irina Kazaryan, Anahit Sevikyan, Margarit Melikyan, Anahit Amirkhanyan. (Armenia)
- 209. Drug Utilization: Pattern and Influence on the Quality of Life of Patients Under Care at Public Health Centers in Brazil [288]**  
Katia Rodrigues Silva, Micheline Rosa Silveira, Celline Cardoso Almeida-Brasil, Luana Faria Cruz, Lais Lessa Pantuzza, Mariana Guimarães Lima, Maria das Graças Braga Ceccato. (Brazil)
- 210. Health Literacy Skills and Correct Use of Medicines in the Netherlands: A Study in Community Pharmacies [289]**  
Ellen S Koster, Daphne Philbert, Marcel L Bouvy. (Netherlands)
- 211. An Educational Intervention To Improve the Knowledge and Practice of Pharmacovigilance Among Healthcare Professionals in Private Hospitals in Lagos State Nigeria [290]**  
Chioma S Ejekam, Vivian O Chuka-Ebene, Ibrahim A Oreagba, SO Olayemi, AJ Adewumi. (Nigeria)
- 212. Clinical Manifestations and Treatment Patterns of Systemic Lupus Erythematosus [291]**  
Sreedharan Nair, Sowmya Annavarapu, Vijayanarayana Kunhikatta, Girish Thunga. (India)
- 213. Prevalence and Predictors of Medication Non-Adherence in Patients With Mental Disorders: A Cross-Sectional Study [292]**  
Gurumurthy Parthasarathi, Jisha Jojo, Madhan Ramesh, Krishna Undela, Dushad Ram. (India)
- 214. Baseline Antidiabetic Drug Patterns in Patients Initiating Treatment for Diabetes [293]**  
Donnie P Funch, Li Zhou, Atheline Major-Pedersen, Helge Gydesen, David D Dore. (United States)
- 215. Multiple Imputation (MI) for Missing Outcome Data in a Medical Chart Review Study [294]**  
Xiaojuan Li, Violeta Hennessey, Fei Xue. (United States)
- 216. Applying the Ready Reckoner (RRec) Tool for Assessing Antipsychotic (AP) Prescribing Within Post-Authorisation Safety Studies (PASS) [295]**  
Deborah Layton. (United Kingdom)
- 217. Drug Utilization Study (DUS) Methodology: Applications and Challenges [296]**  
Dara Stein, Kristin A Hanson. (Canada)
- 218. Automated Extraction of VTE Events from Narrative Radiology Reports in Electronic Health Records: A Validation Study [297]**  
Zhe Tian, Simon Sun, Tewodros Eguale, Christian Rochefort. (Canada)
- 219. Physicians' Acceptance of Pharmacists' Interventions in a Dutch University Hospital [298]**  
Rianne J Zaai, Edwin W den Haak, Arnold G Vulto, Patricia MLA van den Bemt. (Netherlands)
- 220. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Medicare Specialty Drug Users [299]**  
Stacie B Dusetzina, Nancy L Keating. (United States)
- 221. Treatment Patterns and Outcomes of Patients Diagnosed With Ovarian Cancer in the Netherlands: A Registry Study [300]**  
Eline Houben, Heleen GM van Haalen, Wouter Sparreboom, Jetty A Overbeek, Nicole Ezendam, Hannie JMA Pijnenborg, Myrthe PP van Herk-Sukel. (Netherlands)
- 222. Predictors of Gastrointestinal Bleeding Among Patients With Atrial Fibrillation Initiating Dabigatran and Subsequent Patterns of Use [301]**  
Julie C Lauffenburger, Denise H Rhoney, Joel F Farley, Anil K Gehi, Gang Fang. (United States)
- 223. Monitoring of Mortality Associated To New Oral Anticoagulants vs Warfarin in Atrial Fibrillation [302]**  
Flavia Mayer, Ursula Kirchmayer, Nera Agabiti, Giovanna Cappai, Danilo Fusco, Marina Davoli. (Italy)
- 224. The Risk of Urinary Tract Infections With the Use of Dextromethorphan in Different Indications. Results from a Systematic Review and Meta-Analysis of Randomised Clinical Trials [303]**  
Luis G Velez-Nandayapa, Laura M DeVore. (Switzerland)
- 225. Ocular Beta-Blockers in People With Asthma and Glaucoma [304]**  
Daniel R Morales, Brian J Lipworth, Cathy Jackson, Bruce Guthrie. (United Kingdom)
- 226. Can Reporters of a Medicines Incident Accurately Reflect the Clinical Risk? [305]**  
Alice V Gilbert, Michael Roberts, Des Williams, Andrew L Gilbert. (Australia)
- 227. Pharmacovigilance Practices for Better Healthcare Services: Knowledge, Awareness and Practices of Healthcare Professionals (HCPs) Toward Pharmacovigilance in Malaysia [306]**  
Muhammad Shahid Iqbal, Mohd Baidi Bahari, Muhammad Zahid Iqbal, Muhammad Waseem Iqbal. (Malaysia)

- 228. Adverse Drug Reactions (ADRs) Reporting Among Community Health Extension Workers (CHEWs) in Oyo State, Nigeria: An Assessment of Attitude and Practice [307]**  
 Waheed A Adedeji, Fatai A Fehintola. (Nigeria)

## Spotlight Session-Vaccines

- 229. New Methodology for Enhanced Safety Surveillance of Nasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) Using Participant Questionnaire Feedback: Interim Results [308]**  
 Rhian McNaughton, Elizabeth Lynn, Vicki Osborne, Saad Shakir, Abigail Coughtrie. (United Kingdom)
- 230. What Explains the Different Rates of Human Papillomavirus Vaccination Among Adolescent Males and Females in the United States? [309]**  
 Yoonyoung Choi, Efe Eworuke, Richard Segal. (United States)
- 231. Safety of a Novel Meningococcal Group B Vaccine Used in Response To Two Outbreaks in the US [310]**  
 Jonathan Duffy, Peter Johnsen, Mary Ferris, Mary Miller, Kevin Leighton, Mark McGilvray, Lucy McNamara, Lucy Breakwell, Yon Yu, Tina Bhavsar, Elizabeth Briere, Manisha Patel. (United States)
- 232. Immunocompromising Medications and Conditions Among Patients With Severe Streptococcus pneumoniae Infections [311]**  
 Jacob B Morton, Haley J Morrill, Aisling R Caffrey, Kerry L LaPlante. (United States)
- 233. Near “Real-Time” Vaccine Safety Surveillance Using Electronic Health Records – A Systematic Review of Statistical Methods [312]**  
 Andreia H Leite, Nick J Andrews, Sara L Thomas. (United Kingdom)
- 234. Key Features of Vaccine Reports in VigiBase [313]**  
 Lovisa Sandberg, Jonas Fransson, Kristina Juhlin, Kristina Star, Rebecca Chandler. (Sweden)
- 235. Risk of Anaphylaxis Following Vaccination in Children and Adults [314]**  
 Michael M McNeil, Eric Weintraub, Jonathan Duffy, Lakshmi Sukumaran, Steven J Jacobsen, Nicola P Klein, Simon J Hambidge, Grace M Lee, Lisa A Jackson, Stephanie A Irving, Jennifer P King, Elyse O Kharbanda, Robert A Bednarczyk, Frank DeStefano. (United States)

- 236. Incidence of Outcomes Relevant To Vaccine Safety Monitoring in a Large Commercially Insured Population [315]**  
 Daina B Esposito, Lina Titievsky, Jennifer CL Hawes, Rosalind C Hollingsworth, Daniel A Scott, Crystal N Holick, Stephan Lanes. (United States)

## Vaccines

- 237. Use of the High-Dose Influenza Vaccine Among Commercially Insured Patients in the United States, 2010-2012 [316]**  
 Leah J McGrath, M Alan Brookhart. (United States)
- 238. Effectiveness of Influenza Vaccination for Children in Japan [317]**  
 Natsumi Shibata, Hisashi Urushihara. (Japan)
- 239. Active Monitoring of Local Inflammations Within a Cohort of Patients Vaccinated With Influenza Vaccine [318]**  
 Leontine HW van Balveren, Agnes C Kant, Linda VDH Härmark. (Netherlands)
- 240. Effectiveness of Seasonal Influenza Vaccines Against Influenza A (H1N1) Infection in Post-Pandemic Seasons: A Systematic Review [319]**  
 Songul Bozat-Emre, Natalie Casaciang, Hasantha C Sinnock, Xibiao Ye, Salaheddin M Mahmud. (Canada)
- 241. Influenza Vaccine Utilization: A Comparison Between Urban and Rural Counties in Florida [320]**  
 Abdullah Abdulaziz Alalwan, Xiaohui Xu, Abraham Hartzema. (United States)
- 242. Reduction of Influenza Disease Cost With Suboptimal Vaccination [321]**  
 Nicole M Bailey, Andrew Wilson, Yongmei Li, Aaron Kamau. (United States)
- 243. Post-Licensure Surveillance of Quadrivalent Live Attenuated Influenza Vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014 [322]**  
 Penina Haber, Pedro L Moro, Maria Cano, Paige Lewis, Brock Stewart, Tom T Shimabukuro. (United States)
- 244. Safety of Seasonal Influenza Vaccines in Pregnancy in the Vaccine Adverse Event Reporting System, 2010 - 2014 [323]**  
 Pedro L Moro, Paige Lewis, Janet Cragan, Naomi Tepper. (United States)
- 245. Pattern of Quadrivalent Human Papillomavirus Vaccine (HPV4) Use Among Insured Males in the United States: 2009 - 2013 [324]**  
 Kandace L Amend, Bruce Turnbull, Michael Doherty, Mark Marsico, Christine Velicer, Patricia Saddier, John Seeger. (United States)

- 246. Factors Predicting Human Papillomavirus Vaccination Intention and Uptake: A Meta-Analysis and Systematic Review [325]**  
 Andrew R Wilson, Mia Hashibe, Lisa H Gren, Chang-Chung Chou, Anna T Gardener, Jessica Greenwood, Brian R Jackson, Rosemary She, Deanna Kepka, Nicole Bailey, Marlene J Egger. (United States)
- 247. Validation of Current Procedural Terminology Codes for Rotavirus Vaccination in Two Commercially-Insured US Populations [326]**  
 Veena Hoffman, Nicholas J Everage, Scott Quinlan, Kathleen Skerry, Daina Esposito, Nicolas Praet, Dominique Rosillon, Crystal N Holick, David D Dore. (United States)
- 248. Intussusception After Rotarix Vaccines Adverse Event Reporting System(VAERS), 04/2008-12/2014 [327]**  
 Penina Haber, Umesh D Parashar, Eric S Weintraub, Michael J Haber, Frank DeStefano. (United States)
- 249. Clinical and Demographic Characteristics of an Expanded Target Population for 13-Valent Pneumococcal Conjugate Vaccine (Pneumovax 13, PCV13) [328]**  
 Lina Titievsky, Daina B Esposito, Jennifer CL Hawes, Robert Maroko, Rosalind C Hollingsworth, Crystal N Holick, Stephan Lanes. (United States)
- 250. Knowledge, Attitude, and Practice of Healthcare Professionals Toward Hepatitis B Vaccine and Disease [329]**  
 Hisham Alshammari, Metab Alenazi, Mohammad Almuslim, Mohamad Aljofan, Thamer Alshammari. (Saudi Arabia)
- 251. Current Practices and Regulations in European Countries for Data Privacy and Ethics for the Use of Secondary Data: An ADVANCE Initiative [330]**  
 Helene Denis, Alena Khromava, Harshana Liyanage, Jorgen Bauwens, Lieke Van der Aa, Patrick Mahy, Filipa Ferreira, Alessandro Spina, Germano Ferreira, Miia Artama, Kari Natunen, Nynke Rots, Klara Berencsi, Miriam Sturkenboom, Simon de Lusignan. (Canada)
- 252. The ADVANCE Code of Conduct: A Tool for Vaccine Benefit-Risk Monitoring in Europe [331]**  
 Xavier Kurz, Vincent Bauchau, Jorgen Bauwens, Phillip Bryan, Stephen Glismann, Mirna Robert-Du Ry van Beest Holle, Raphaelae Roten, Miriam Sturkenboom, Lieke van der Aa, Jane Whelan. (United Kingdom)
- 253. Assessment of Sex-Specific Differences in Adverse Event Following Immunization Reporting in Ontario, Canada [332]**  
 Tara M Harris, Kenny Wong, Jill Fediurek, Shelley L Deeks. (Canada)



- 254. The Assessment of Characteristics of Adverse Events Following Immunization in Japanese Adverse Drug Event Report Database and Vaccine Adverse Event Reporting System for Signal Detection [333]**  
 Makoto Miyazaki, Akihito Shito, Minoru Shimodera. (Japan)
- 255. Is the Case-Population Approach Useful for Vaccine Safety Surveillance? [334]**  
 H el ene Th eophile, Antoine Pariente, Nicholas Moore, Bernard B egaud. (France)
- 256. The Development of an In-House Signal Mining and Management Tool for GSK Vaccine Spontaneous Reports [335]**  
 Lionel Van Holle, Pascale Schrauben. (Belgium)
- 257. Screening Vaccine Spontaneous Reports Linked With Hierarchical Manufacturing Data: A Proof-Of-Concept of Manufacturing Safety Signal Detection [336]**  
 Olivia J Mahaux, Lionel F Van Holle. (Belgium)
- 258. The Incidence of Childhood and Adolescent Seizures in the UK from 1999 To 2011; a Retrospective Cohort Study Using the Clinical Practice Research Datalink [337]**  
 Cormac J Sammon, Rachel A Charlton, Julia Snowball, John G Weil. (United Kingdom)
- 259. Pharmacoepidemiology in the Vaccine Industry: GSK Vaccines' Example of a Multidisciplinary Response To the Changing Regulatory Environment [338]**  
 Catherine Cohet, Corinne Willame, Fran ois Haguinet, Dominique Luyts, Vincent Bauchau, Germano LC Ferreira, Dominique Rosillon, Laurence Baril. (Belgium)
- 260. Landscape Analysis of Existing Models of Public-Private Interactions in a Public Health Environment: An ADVANCE Initiative [339]**  
 Laurence Torcel-Pagnon, Tin Tin Myint Htar, Lisen Arnheim Dahlstr om, Fran ois Simondon, Vincent Bauchau, Xavier Kurz. (France)
- 261. Safety and Tolerability Evaluation of the Use of Montanide ISATM 51 as Vaccine Adjuvant: A Systematic Review [340]**  
 Eva van Doorn, Heng Liu, Anke Huckriede, Eelko Hak. (Netherlands)
- 262. Assessing Bias in Administrative Database Studies of Vaccine Completion Due To Exclusion of Subjects With Incomplete Follow-Up [341]**  
 Scott C Quinlan, T Christopher Mast, Sander Greenland, Crystal N Holick, Stephan Lanes. (United States)

## Spotlight Session Molecular Epidemiology Biomarkers/ Pharmacogenetics

- 263. Tumor Subtypes Among Breast Cancer Patients With Diabetes [342]**  
 Heleen K Bronsveld, Vibeke Jensen, Pernille Vahl, Marieke L de Bruin, Sten Cornelissen, Joyce Sanders, Peter Vestergaard, Marjanka K Schmidt. (Netherlands)
- 264. Preliminary Results on the Impact of Genetic Factors on Gastrointestinal Bleeding in a Prospective Cohort of New Warfarin Users [343]**  
 Stephanie Dumas, Sylvie Perreault, Robert C ot e, Payman Shahabi, Ian Mongrain, Marie-Jos ee Gaulin, Sylvie Provost, Jean-Claude Tardif, Marie-Pierre Dub e. (Canada)
- 265. Decision Analysis Model for Genetic Testing Prior To Antidepressant Treatment [344]**  
 Jacob T Painter, Bradley C Martin, Chenghui Li, Amit Bodhani, Jeffrey M Pyne. (United States)
- 266. Association Between Genetic Polymorphisms of Drug-Metabolizing Enzymes and Transporters and Anti-Tuberculosis Drug-Induced Liver Injury in a Chinese Population [345]**  
 Ru Chen, Jing Wang, Shaowen Tang, Yuan Zhang, Xiaozhen Lv, Siyan Zhan. (China)
- 267. Prevalence and Characteristics of Non-Small Cell Lung Cancer (NSCLC) Patients Harboring Oncogenic Drivers [346]**  
 Dixa B Thakrar, Ceri Hirst. (United Kingdom)
- 268. A National Survey of Pharmacists' Roles in Clinical Pharmacogenomics: Assessment of Predictors [347]**  
 Emily Schwartz, Amalia M Issa. (United States)



**Spotlight Session-Medicines in Pregnancy**

1. **Association Between Exposure To Acid-Suppressing Drugs During Pregnancy and Asthma in Childhood [428]**  
Lucia Cea Soriano, Sonia Hernández-Díaz, Saga Johansson, Péter Nagy, Luis A García-Rodríguez. (Spain)
2. **Oral Fluconazole in Pregnancy and Risk of Fetal Death [429]**  
Ditte Mølgaard-Nielsen, Henrik Svanström, Mads Melbye, Anders Hviid, Björn Pasternak. (Denmark)
3. **Maternal Use of Specific Selective Serotonin-Reuptake Inhibitors in Early Pregnancy and the Risk of Birth Defects [430]**  
Jennifer N Lind, Jennita Reefhuis, Jan M Friedman, Carol Louik, Tiffany Riehle-Colarusso, Margaret A Honein. (United States)
4. **Maternal Use of Varenicline and Risk of Congenital Malformations [431]**  
Morten Olsen, Kenneth R Petronis, Trine Frøsløv, Lars Pedersen, Vera Ehrenstein, Jingping Mo, Fredrik Granath, Helle Kieler, Henrik T Sørensen. (Denmark)
5. **The Teratogenic Risk of Antiepileptic Drugs in Pregnancy [432]**  
Shuk-Li Collings, Irwin Nazareth, Mary Thompson, Irene Petersen. (United Kingdom)
6. **Patterns of Anti-Epileptic Drug (AED) Use During Pregnancy in the Mini-Sentinel Database (MSDD) Among Women Delivering a Liveborn Infant [433]**  
Marilyn R Pitts, Katrina Mott, Marsha E Reichman, Carrie Ceresa, Susan E Andrade, Caren Kieswetter, Sengwee Toh, Monika Houstoun, Katherine Haffenreffer. (United States)
7. **Antidepressant, Especially SSRI Use, During Pregnancy and the Risk of Autism Spectrum Disorder: A Meta-Analysis [434]**  
Takoua Boukhris, Flory Muanda-Tsobo, Anick Bérard. (Canada)
8. **Asthma Medicine Prescribing Before, During and After Pregnancy: A Study in 7 European Regions [435]**  
Rachel Charlton, Anna Pierini, Kari Klungsøyr, Amanda Neville, Sue Jordan, Lolkje de Jong-van den Berg, Daniel Thayer, H Jens Bos, Aurora Puccini, Anna Hansen, Rosa Gini, Anders Engeland, Anne-Marie Nybo Andersen, Helen Dolk, Ester Garne. (United Kingdom)

**Medicines in Pregnancy**

9. **Insulin Analogues in Pregnancy and Specific Congenital Anomalies; a Literature Review [436]**  
Josta de Jong, Ester Garne, Ewa Wender-Ozegowska, Margery Morgan, Lolkje TW de Jong-van den Berg, Hao Wang. (Netherlands)
10. **Use of Insulin Analogs in Pregestational Diabetes and Risk of Congenital Anomalies [437]**  
Hao Wang, Ewa Wender-Ozegowska, Ester Garne, Margery Morgan, Maria Loane, Anna Materna-Kirylyuk, Awi Wiesel, Sue Jordan, Miriam Gatt, Guy Thys, Vera Nelen, Marian Bakker, Hermien de Walle, Lolkje de Jong-van den Berg. (Netherlands)
11. **Patterns of Antidiabetic Agent Use During Pregnancy Among Women Delivering a Liveborn Infant in the Mini-Sentinel Database (MSDD) [438]**  
Katrina Mott, Marsha E Reichman, Darren Toh, Monika Houstoun, Marilyn Pitts, Caren Kieswetter, Carrie Ceresa, Katherine Haffenreffer, Susan E Andrade. (United States)
12. **Risk of Preterm Delivery Among Live Births Exposed To Anti-Diabetic Agents During the First Trimester of Pregnancy [439]**  
Caitlin A Knox, Christian Hampp, Babette Brumback, Xiaohui Xu, Richard Segal, Almut G Winterstein. (United States)
13. **Risk of Preeclampsia Among Live Births Exposed To Anti-Diabetic Agents During the First Trimester of Pregnancy [440]**  
Caitlin A Knox, Christian Hampp, Babette Brumback, Xiaohui Xu, Richard Segal, Almut G Winterstein. (United States)
14. **Risk of Cesarean Section Delivery Among Live Births Exposed To Anti-Diabetic Agents During the First Trimester of Pregnancy [441]**  
Caitlin A Knox, Christian Hampp, Babette Brumback, Xiaohui Xu, Richard Segal, Almut G Winterstein. (United States)
15. **Sulfonamide Use During the First Trimester of Pregnancy and Risk of Selected Congenital Anomalies Among Live Births [442]**  
Craig Hansen, Susan E Andrade, Heather Freiman, Sascha Dublin, Katie Haffenreffer, William O Cooper, T Craig Cheetham, Darren Toh, De-Kun Li, Marsha A Raebel, Jennifer L Kuntz, Nancy Perrin, A Gabriela Rosales, Shelley Carter, Pamela A Pawloski, Elizabeth M Maloney, David J Graham, Leyla Sahin, Pamela E Scott, John Yap, Robert Davis. (United States)
16. **HAART Use During Pregnancy and the Risk of Major Congenital Malformations [443]**  
Anick Bérard, Odile Sheehy, Sasha Bernatsky, Marc Boucher. (Canada)
17. **Quality of Reporting of Malaria Trials During Pregnancy and Its Impact on the Effectiveness of Antimalarial Drug [444]**  
Flory Tsobo Muanda, Anick Bérard. (Canada)
18. **Women's Values and Preferences: Decisions Making About Thromboprophylaxis in Pregnancy [445]**  
Luciane C Lopes, Shannon M Bates, Pablo Alonso-Coello, Mark Eckman, Ignacio Neumann, Elie A Akl, Amparo Santamaria, Anne F Jacobsen, Yuqing Zhang, Kari A Tikkinen, Shanil Ebrahim, Sarah D McDonald, Gordon H Guyatt. (Brazil)
19. **Use of Antihypertensive Drugs in Pregnancy. A Cross-Sectional Study in the Lazio Region, Italy [446]**  
Martina Ventura, Ursula Kirchmayer, Serena Donati, Alice Maraschini, Alessandra Marani, Marta Buoncristiano, Sabrina Senatore, Flavia Mayer, Marina Davoli. (Italy)
20. **Pregnancies and Pregnancy Outcomes During Isotretinoin Treatment in Four Canadian Provinces [447]**  
David Henry, Colin Dormuth, Brandy Winquist, Shawn Bugden, Robert Platt. (Canada)
21. **Intranasal Triamcinolone Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes [448]**  
Anick Bérard, Odile Sheehy, Marie-Laure Kurzinger, Juhaeri Juhaeri. (Canada)
22. **Calcium Channel Blockers To Prevent Preterm Labor: A Drug Utilization Study in Two French Databases [449]**  
Justine Benevent, Anna-belle Beau, Béatrice Guyard-Boileau, Caroline Delarue-Hurault, Isabelle Lacroix, Jean-Louis Montastruc, Christine Damase-Michel. (France)
23. **Risk Factors Associated With Early Intrauterine Device Insertion After Delivery [450]**  
Efe Eworuke, David G Moeny. (United States)
24. **Periconceptional Benzodiazepine Use and the Risk for Birth Defects: Data from the National Birth Defects Prevention Study [451]**  
Sarah Tinker, Jennita Reefhuis, Cheryl Broussard, Suzanne Gilboa, Rebecca Bitsko, Martha Werler, Allen Mitchell. (United States)
25. **Psychotropic Medications in Combination Prior To Pregnancy: A UK Population Based Study [452]**  
Rachel L McCrea, Irwin Nazareth, David PJ Osborn, Stephen JW Evans, Irene Petersen. (United Kingdom)



26. **Use of Folic Acid and Antidepressants During Pregnancy and Child Language Development [453]**  
Marte Handal, Svetlana Skurtveit, Christine Roth, Sonia Hernandez-Diaz, Randi Selmer. (Norway)
27. **Selective Serotonin Reuptake Inhibitor Use in First Trimester Pregnancy and Risk of Congenital Anomalies: A EUROMediCAT Case-Malformed Control Study in 12 Countries [454]**  
B Boyle, M Loane, M Bakker, MC Addor, L Arriola, E Garne, M Gatt, S Jordan, B Khoshnood, K Klungsoyr, V Nelen, A Neville, M O'Mahoney, A Pierini, A Rissman, D Tucker, A Wiesel, H Dolk. (United Kingdom)
28. **5-Year Experience With the Cymbalta Pregnancy Registry: A Prospective Observational Study To Assess Duloxetine Exposure During Pregnancy [455]**  
Hu Li, Mark Bangs, Jennifer Zimmer, Dawn Dyer, Sheila Miller. (United States)
29. **Antipsychotics in Pregnancy: Comparative Cohort Studies of Women Treated Before and During Pregnancy [456]**  
Irene Petersen, Rachel L McCrear, Cormac J Sammon, Stephen JW Evans, David Osborn, Phil J Cowen, Irwin Nazareth. (United Kingdom)
30. **Use of Topiramate in Relation To the Risk of Orofacial Clefts [457]**  
Hao Wang, Maria Loane, Joan Morris, Ester Garne, Vera Nelen, Babak Khoshnood, Anke Rißmann, Awi Wiesel, Mary O'Mahony, Anna Pierini, Amanda Neville, Miriam Gatt, Hermien de Walle, Marie-Claude Addor, David Tucker, Kari Klungsoyr, Anna Latos-Bielenska, Jan Mejnartowicz, Christine Verellen-Dumoulin, Bérénice Doray, Larraitz Arriola, Ingeborg Barisic, Elisa Calzolari, Diana Wellesley, Helen Dolk, Lolkje de Jong-van den Berg. (The Netherlands)
31. **Prenatal Triptan Exposure and Psychomotor Changes in 18 and 36 Month Old Norwegian Children [458]**  
Mollie Wood, Kate Lapane, Jean Frazier, Nordeng Hedvig. (United States)
32. **Is Exposure To Benzodiazepine During Pregnancy Increase the Risk of Spontaneous Abortion? [459]**  
Odile Sheehy, Anick Bérard. (Canada)
33. **Prenatal Acetaminophen Exposure and Cortical Thickness in Typically-Developing Children [460]**  
Mollie Wood, David Kennedy, Steven Hodge, Jean Frazier. (United States)
34. **Exposure To Prescription Opioid Analgesics In-Utero and the Risk of Neonatal Abstinence Syndrome: A Population-Based Cohort Study [461]**  
Rishi J Desai, Krista F Huybrechts, Sonia Hernandez-Diaz, Elisabetta Patorno, Brian T Bateman. (United States)
35. **SNRI, Bupropion and Mirtazapine Use During Pregnancy and the Risk of PPHN [462]**  
Anick Bérard, Odile Sheehy, Sasha Bernatsky, Michal Abrahamowitz. (Canada)
36. **Detection Bias in the Prenatal Diagnosis of Malformations Among SSRI Exposed Women [463]**  
Anna M Modest, Marth M Werler, Carla Van Bennekom, Allen A Mitchell. (United States)
37. **Neonatal Drug Withdrawal Syndrome: Cross-Country Comparison of Recorded Hospital Admissions in England, USA, Western Australia and Ontario, Canada [464]**  
Hilary R Davies, Ruth Gilbert, Irene Petersen, Irwin Nazareth, Arturo Gonzalez-Izquierdo. (United Kingdom)
38. **The Impact of Different Case Ascertainment Definitions on the Prevalence of Major Congenital Malformations and Their Association With Asthma During Pregnancy [465]**  
Sherif Eltonsy, Amelie Forget, Lucie Blais. (Canada)
39. **Asthma Medication During Pregnancy: A Cohort Study in EFEMERIS Database [466]**  
Anna-belle Beau, Alain Didier, Isabelle Lacroix, Caroline Delarue-Hurault, Jean-Louis Montastruc, Christine Damase-Michel. (France)
40. **The Use of Antiasthmatic Medications During Pregnancy and the Risk of Gestational Diabetes [467]**  
Veronique Baribeau, Marie-France Beauchesne, Evelyne Rey, Amelie Forget, Lucie Blais. (Canada)
41. **Association Between Folic Acid Supplementation and Neural Tube Defects Among High Risk Pregnancies [468]**  
Corey M Benedum, Samantha E Parker, Allen A Mitchell, Martha M Werler. (United States)
42. **Factors Associated With Achieving Success for Pregnancy Registries [469]**  
Deborah Covington, Kristin Veley, Ann Mallard. (United States)
43. **First Data on Participation Rates of a National Pregnancy Drug Register in the Netherlands [470]**Saskia Vorstenbosch, Agnes Kant (Netherlands)
44. **Direct-To-Patient Research: The Future of Pharmacovigilance? [471]**  
Nancy A Dreyer, Shahrul Mt. Isa, Jonathan L Richardson, Maja Laursen, A Priscilla Zetstra-van der Woude, Anna Jamry-Dziurla, Valerie Hliva, Alison Bourke, Stella Blackburn. (United States)
45. **The Epidemiology of Ebstein's Anomaly in Europe: A Registry-Based Study With Special Emphasis on Medication Exposure [472]**  
Breidge Boyle, Ester Garne, Maria Loane, Marie-Claude Addor, Larraitz Arriola, Clara Cavero-Carbonell, Hermien EK deWall, Miriam Gatt, Nathalie Lelong, Catherine Lynch, Vera Nelen, Amanda J Neville, Mary O'Mahony, Anna Pierini, Anke Rissmann, David Tucker, Natalia Zymak-Zakutnia, Helen Dolk. (United Kingdom)
46. **Medication Use Among Pregnant Women Enrolled in the United States Medicaid Program [473]**  
Kristin Palmsten, Sonia Hernández-Díaz, Christina D Chambers, Helen Mogun, Sophia Lai, Todd P Gilmer, Krista F Huybrechts. (United States)
47. **Medications Prescription in Pregnancy: Is There an Association With Sociodemographic Features? [474]**  
Francesca Sammartano, Silvia Ussai, Liza Vecchi Brumatti, Anica Casetta, Federica E Pisa, Fabio Barbone. (Italy)
48. **Systematic Review of Pregnancy Exposure Registries: Fetal/Infant Outcomes, Target Sample Size, and Comparators [475]**  
Kate Gelperin, Hoda Hammad, Steven Bird, Christian Hampf, Kira Leishear, Leyla Sahin, Lockwood Taylor. (United States)
49. **A Multidisciplinary Structured Approach for Interpreting and Integrating Medication Exposure and Pregnancy Outcomes Information [476]**  
Keele E Wurst, Sara A Ephross, Patrick Wier, Greta A Bushnell, Alice D White. (United States)
50. **Performance of an Algorithm for Identifying Pregnancy Outcomes in Commercial Health Plan Claims Data [477]**  
Wendy J Carman, Neil A Accortt, Li Zhou, Lauren Sanders, Mary S Anthony, Cheryl Enger. (United States)
51. **Performance of an Algorithm for Determining Dates of Conception and Pregnancy Termination Dates Using Commercial Health Plan Claims Data [478]**  
Wendy J Carman, Neil A Accortt, Li Zhou, Lauren A Sanders, Mary S Anthony, Cheryl Enger. (United States)

- 52. Prevalence and Associated Factors With Use of Medication During Pregnancy By Risk Class [479]**  
Djanilson Barbosa Santos, Bruna Cunha Girardi, Lais Alves de Lima Prisco, Wilanne Pinheiro de Oliveira Alves, Michele de Jesus Cavalcante. (Brazil)
- 53. Optimizing the Value of Pregnancy Reports in a Drug Safety Database [480]**  
Amanda Golembesky, Dirk De Cuyper, Laura Shaughnessy, Maureen Cooney, Kristel Luijters, Marie Teil. (United States)
- 54. Obstetric Complications Following Fertility Treatment – Disentangling the Role of Multiple Gestation [481]**  
Anna S Oberg, Tyler J VanderWeele, Catarina Almqvist, Sonia Hernandez-Diaz. (United States)

## Spotlight Session-Pediatrics

- 55. Asthma Medication Use Before and After the Onset of Type 1 Diabetes in Children and Adolescents: A Population-Based Cohort Study [482]**  
Fariba Ahmadizar, Anke-Hilse Maitland-van der Zee, Anthonius de Boer, Patrick Souverein, Hubertus Arets. (The Netherlands)
- 56. Antibiotic Exposure and the Development of Pediatric Psoriasis: A Population-Based Case-Control Study [483]**  
Daniel B Horton, Frank I Scott, Kevin Haynes, Mary E Putt, Carlos D Rose, James D Lewis, Brian L Strom. (United States)
- 57. The Impact of Antibiotic Exposures Early in Life on Childhood Obesity [484]**  
Frank I Scott, Daniel B Horton, Ronac Mamtani, Dale Y Lee, Kevin Haynes, James D Lewis. (United States)
- 58. The Extent of Off-Label Use of Psychotropic Drugs for Danish Children and Adolescents: A Nationwide Study [485]**  
Eva Skovslund Nielsen, Maja Hellfritsch, Mette Nørgaard, Torben Laursen. (Denmark)
- 59. State-Level Variation of Psychotropic Drug Utilization in Children With ADHD in the United States Using Multiple Disparity Measures [486]**  
Xinyue Liu, Paul Kubilis, Regina Bussing, Almut G Winterstein. (United States)
- 60. Medication Errors Among Paediatric In-Patients at a Rural Referral Hospital in Kenya [487]**  
Christabel N Khaemba, Christabel N Khaemba, Eric M Guantai, Margaret O Oluka, Kipruto A Sinei. (Kenya)

- 61. Psychiatric Healthcare Utilization and Related Costs in Newly Diagnosed Individuals With Autism Spectrum Disorder (ASD) in Quebec (Canada) [488]**  
Caroline Croteau, Laurent Mottron, Jean-Eric Tarride, Marc Dorais, Sylvie Perreault. (Canada)
- 62. Stratification, Hypothesis Testing, and Clinical Trial Simulation in Pediatric Drug Development [489]**  
Ann W McMahon, M Dianne Murphy. (United States)

## Pediatrics

- 63. Cardiovascular Medication Use and Cardiovascular Disease in Children and Adolescents With Type 1 Diabetes [490]**  
Fariba Ahmadizar, Soulmaz Fazeli Farsani, Patrick Souverein, Anthonius de Boer, Anke Hilse Maitland-van der Zee. (Netherlands)
- 64. Increased Use of Oral Anti-Diabetic Medications in Dutch Children Mainly Driven By (Off-Label) Metformin Use [491]**  
Soulmaz Fazeli Farsani, Patrick C Souverein, Jetty A Overbeek, Marja M van der Vorst, Catherijne A Knibbe, Ron M Herings, Anthonius de Boer, Aukje K Mantel-Teeuwisse. (Netherlands)
- 65. Metformin Prescriptions as a Proxy for Pediatric Type 2 Diabetes Burden [492]**  
Ann M McNeill, Tongtong Wang, Yong Chen, Ravi R Shankar, Michael Sanderak. (United States)
- 66. Antibiotic Prescribing for Children in General Practice and Adherence To Treatment Guidelines [493]**  
Verica Ivanovska, Karin Hek, Aukje Mantel Teeuwisse, Bert Leufkens, Liset van Dijk. (Macedonia, The Former Yugoslav Republic of)
- 67. Adherence To Index Therapy as a Predictor of Treatment Augmentation in Children and Adolescents Newly Initialized on Metformin Monotherapy [494]**  
Mona Cai, Til Stuermer, Cynthia J Girman, Michael Kappelman, Nina Jain, Alan Brookhart. (United States)
- 68. Association Between Antipsychotics and Risk of Epilepsy in Patients With Autism Spectrum Disorder in Taiwan [495]**  
Chien-Chou Su, Ching-Lan Cheng, Yen-Kuang Yang, Yea-Huei Kao Yang. (Taiwan)
- 69. Initial Prescription Medication for Children With Anxiety: Concordance With Evidence [496]**  
Greta A Bushnell, Stacie B Dusetzina, Bradley N Gaynes, Scott N Compton, Alice D White, Til Stürmer. (United States)

- 70. Psychotropic Medication Use Prior To Initiation of Antipsychotics in Foster Care Youth: Are All New Users Equal? [497]**  
Wendy Camelo Castillo, Ming-Hui Tai, James F Gardner, Susan dosReis. (United States)
- 71. The Use of Psychotropic Medications in Autism Spectrum Disorder: The Parents' Perspective [498]**  
Danielle Boucher, Hubert Gascon, Caroline Sirois, Maude Garant. (Canada)
- 72. Modeling the Complexity and Continuity of Psychotropic Use Among Youth as an Indicator of Illness Severity [499]**  
Susan dosReis, Wendy Camelo Castillo, James Gardner, Ming-Hui Tai. (United States)
- 73. The Association Between Atopic Diseases and Childhood Attention-Deficit/Hyperactivity Disorder: A Retrospective Matched Case-Control Study [500]**  
Jurjen van der Schans, Janine C Pleiter, Tjalling W de Vries, Catherina CM Schuiling-Veninga, Jens HJ Bos, Pieter J Hoekstra, Eelko Hak. (Netherlands)
- 74. High Incidence of Oral Corticosteroids Prescriptions in Young Children With Asthma [501]**  
Ali Arabkhaezali, Susanne JH Vijverberg, Cornelis K van der Ent, Jan Raaijmakers, Anke-Hilse Maitland-van der Zee. (Netherlands)
- 75. Comparative Safety of Antimuscarinics in the United States Pediatric Population, 2000-2012 [502]**  
Alan C Kinlaw, Jennifer M Wu, Mitchell M Conover, Michele Jonsson Funk. (United States)
- 76. Parental Exposure To Folic Acid Antagonists Are Associated With Childhood Cancer [503]**  
Yu-Hsuan Joni Shao, Ming-Tsang Chuang, Kitaw Demissie. (Taiwan)
- 77. Access To Oral Paediatric Medicines in Ghana: An Unmet Need [504]**  
Daniel Ankrah, Joseph Turkson, Edith Boateng, Frank Amegavie, Elizabeth Bruce. (Ghana)
- 78. Use of Epidemiology Data To Inform Pediatric Clinical Trials [505]**  
Laura E Wallace, Stacy Baldrige. (United States)
- 79. The Risk of Malignancy Among Biologic-Naïve Pediatric Psoriasis Patients: A Retrospective Cohort Study in a US Claims Database [506]**  
Yun Gu, Beth L Nordstrom. (United States)



**80. Factors Associated With Hospital Admissions Through the Emergency Department for Pediatric Patients With Acute Asthma [507]**  
Wei Wang, Haesuk Park. (United States)

**81. Drug Utilization Study in Neonates of a Public Hospital in Brazil: Off-Label, Unlicensed, Potentially Harmful Drugs and Harmful Excipients [508]**  
Djanilson Barbosa Ssntos, Alcidésio Sales de Souza Júnior, Helena Lutésia Luna Coelho. (Brazil)

**82. Performance of Signal Detection Algorithms in the Paediatric Dataset of the Publicly-Available US FDA Adverse Event Reporting System (FAERS) [509]**  
Osemeke Osokogu, Caitlin Dodd, Daniel Weibel, Erik van Mulligen, Florentia Kaguelidou, Miriam Sturkenboom. (Netherlands)

## Spotlight Session- Medical Devices

**83. Characterization of Patients With End-Stage Heart Failure Secondary To Anthracycline Cardiac Toxicity [510]**  
Garry R Thomas, Michael A McDonald, Heather J Ross, Diego H Delgado, Billia Filio, Thavendiranathan Paaladinesh. (Canada)

**84. NIS/AHRQ-Derived Epidemiologic Evidence on Modifying Effects of Sex and Race on Arthroplasty-Related Outcomes [511]**  
Yelizaveta Torosyan, Tigran Karapetyan, Nilsa Loyo-Berrios, Danica Marinac-Dabic. (United States)

**85. Predictors of Early (6-Month) Revision and All-Cause Mortality Following Hip Arthroplasty: A Population-Based Cohort Study [512]**  
Albert Roso, Cristian Tebé, Mireia Espallargues, Daniel Prieto-Alhambra, PRESS-UP Study Investigators. (United Kingdom)

**86. National Trends and Cost Related To the Use of Minimally Invasive Device Technology in Urology [513]**  
Bilal Chughtai, Jialin Mao, Abby Isaacs, Richard Lee, Alexis Te, Steven Kaplan, Peter Schlegel, Art Sedrakyan. (United States)

**87. National Trends in Utilization and In-Hospital Outcomes of Mechanical vs. Bioprosthetic Aortic Valve Replacements [514]**  
Abby Isaacs, Jeffrey Shuhaiber, Arash Salemi, O Wayne Isom, Art Sedrakyan. (United States)

**88. Comparison of Open, Laparoscopic, and Robotic Colectomy in a National Database: Outcomes and Trends Related To Hospital Volume [515]**  
Heather Yeo, Abby Isaacs, Jeffrey Milsom, Art Sedrakyan. (United States)

**89. Relationships Between Total Hip Replacement Characteristics and Its Survivorship at Three Years in 100 191 Patients: A Population-Based Study [516]**  
Sandrine Colas, Cédric Collin, Philippe Piriou, Mahmoud Zureik. (France)

**90. How Risky Is Morcellation? Population-Based Estimates of Prevalence of Uterine Sarcoma Among Leiomyomata Patients Undergoing Surgical Treatment [517]**  
Jialin Mao, Samantha Pfeifer, Xi E Zheng, Peter Schlegel, Art Sedrakyan. (United States)

## Medical Devices

**91. Effect of Femoral Head Size on the Rate of Revision Surgeries Among Metal-On-Metal Total Hip Replacements: A Propensity Score Matched Cohort Study from the Veterans Health Administration [518]**  
Katherine Etter, Art Sedrakyan, Lee E Rubin, Linda Resnik, Ira Wilson, David D Dore. (United States)

**92. Opioid Use as an Early Indication of Total Knee Arthroplasty Failure [519]**  
Maria CS Inacio, Robert S Namba, Nicole L Pratt, Stephen E Graves, Elizabeth E Roughead, Craig T Cheetham, Elizabeth W Paxton. (Australia)

**93. Effect of Femoral Head Size in Non-Metal-On-Metal Devices on Surgical Revision Rates in Total Hip Replacements: A Propensity Score Matched Cohort from the Veterans Health Administration [520]**  
Katherine Etter, Art Sedrakyan, Lee E Rubin, Linda Resnik, Ira Wilson, David D Dore. (United States)

**94. Effect of Bearing Surface Material on Surgical Revision Rates in Total Hip Replacements: A Propensity Score Matched Cohort from the Veterans Health Administration [521]**  
Katherine Etter, Art Sedrakyan, Lee E Rubin, Linda Resnik, Ira Wilson, David D Dore. (United States)

**95. Clipping and Coiling of Unruptured Intracranial Aneurysms (UIA) Among Medicare Beneficiaries, 2000-2010 [522]**  
Jessica J Jalbert, Abby J Isaacs, Hooman Kamel, Art Sedrakyan. (United States)

**96. Extracorporeal Membrane Oxygenation (ECMO) Use Among Children and Adults in the United States, 2009-2012 [523]**  
Sarah R Hoffman, Erika Avila Tang, John C Laschinger. (United States)

**97. The Effect of Age on Re-Intervention for Sling Implants in Stress Urinary Incontinence [524]**  
Bilal Chughtai, Jessica Buck, Jialin Mao, Richard Lee, Alexis Te, Steven Kaplan, Art Sedrakyan. (United States)

**98. Spontaneous Reports for Toothbrushes: An Exemplar of Postmarket Vigilance for Low-Risk Devices [525]**  
Mary E Ritchey, Lisa Dunlap, Kelly Solinsky, Michael Steinbuch. (United States)

**99. A Quality Weighted Pooled Analysis of Single Proportions: A Case Study of Infections in Modular Endoprosthesis Implant [526]**  
Grace Wangge, Siti RF Saldi, Meutia A Kumaheri, Yogi Prabowo, Sudigdo Sastroasmoro, Achmad F Kamal. (Indonesia)

**100. Increased Sensitivity and Negative Predictive Value With the Sysmex UF-1000i™ Urine Particle Analyzer Reduces the Need for Empirical Antibiotic Therapy [527]**  
Meghan Riley, Patrick Erdman, Keri Donaldson. (United States)

**101. Accuracy of Optional ICD-9-CM Bearing Surface Codes for Total Hip Replacement in the Veterans Health Administration [528]**  
Katherine Etter, David D Dore. (United States)

## Safety End Point Studies

**102. Cardiovascular Risks Associated With Dipeptidyl–Peptidase 4 Inhibitors: A Cohort Study [529]**  
Maki Komamine, Chieko Ishiguro, Yoshiaki Uyama, Emiko Kondo. (Japan)

**103. Domperidone, Cytochrome P450 3A4 Isoenzyme Inhibitors and Ventricular Arrhythmia: A Nationwide Case-Crossover Study [530]**  
Hung-Lin Chen, Pi-Hui Chao, Jia-Jhen Chen, Fei-Yuan Hsiao. (Taiwan)

**104. Systematic Review With Meta-Analysis: The Association Between the Use of Calcium Channel Blockers and Gastrointestinal Bleeding [531]**  
Ying He, Esther W Chan, Wai K Leung, Shweta Anand, Ian CK Wong. (China)

**105. Metformin Exposure in Head and Neck Cancer Patients: Is There an Association With Improved Survival? [532]**  
Matthew Alcusky, Scott Keith, Tom Karagiannis, Carol Rabinowitz, Daniel Louis, Vittorio Maio. (United States)

- 106. The Role of Differential Work-Up in the Association Between Pioglitazone and Bladder Cancer [533]**  
Elizabeth M Garry, John B Buse, Virginia Pate, Til Stürmer. (United States)
- 107. Thiazolidinediones and Parkinson's Disease: A Cohort Study [534]**  
John G Connolly, Katsiaryna Bykov, Joshua J Gagne. (United States)
- 108. Comparative Risk of Acute Liver Injury Associated With Oral Azole Antifungal Drugs [535]**  
Vincent Lo Re III, Dena M Carbonari, James D Lewis, Kimberly A Forde, David S Goldberg, Rajender Reddy, Kevin Haynes, Jason Roy, Daohang Sha, Amy R Marks, Jennifer L Schneider, Brian L Strom, Douglas A Corley. (United States)
- 109. Fluoroquinolones Use and Development of Retinal Detachment: A Systematic Review and Meta-Analysis [536]**  
Carlos Alves, Ana Penedones, Diogo Mendes, Francisco Batel Marques. (Portugal)
- 110. Use of Fluoroquinolones Is Associated With Increased Risk for Nontraumatic Spontaneous Pneumothorax - A Population-Based Study in a National Representative Cohort [537]**  
Chien-Chang Lee, Meng-tse Gabriel Lee, Tse-Chih Chou, Yi-Hsien Lin, Shyr-Chyr Chen. (Taiwan)
- 111. Rates of Anaphylaxis With Moxifloxacin: Verification of Case Status [538]**  
Najat J Ziyadeh, Kiliana Suzart-Woischnik, Frank Kruesmann, Pierre Arvis, N Franklin Adkinson, Jr, Werner J Pichler, Gillian M Shepherd, John D Seeger. (United States)
- 112. Clinical Outcomes Among Patients Who Are Prescribed Antibiotics With Vs. Without Point-Of-Care Testing for Infection: A Danish Nationwide Population-Based Cohort Study [539]**  
Mette Søgaard, Johnny Kahlert, Reimar W Thomsen, Flemming Bro, Henrik T Sørensen. (Denmark)
- 113. The Safety of Pegylated Interferon  $\alpha$ -2a and  $\alpha$ -2b Combined With Ribavirin in Patients With Chronic Hepatitis C Based on the Japanese Interferon Database [540]**  
Izumi Sato, Yohei Kawasaki, Takumi Imai, Sachiko Tanaka, Hiroshi Yamada, Koji Kawakami, Naohiko Masaki. (Japan)
- 114. Androgen Deprivation Therapy Use and the Risk of Venous Thromboembolism [541]**  
Adi J Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. (Canada)
- 115. Androgen Deprivation Therapy and the Incidence of Autoimmune Diseases in Patients With Prostate Cancer [542]**  
Adi J Klil-Drori, Koray Tascilar, Hui Yin, Armen Aprikian, Laurent Azoulay. (Canada)
- 116. Effectiveness and Safety of Cetuximab as 1st-Line Treatment in the Elderly With Metastatic Colorectal Cancer from the ERBUS Cohort [543]**  
Annie Fourrier-Réglat, Pernelle Noize, Magali Rouyer, Denis Smith, Eric François, Alain Monnereau, Aurélie Balestra, Jérémy Jové, Régis Lassalle, Nicholas Moore. (France)
- 117. Risk of Venous Thromboembolism in Cancer Patients Treated With Epoetins or Blood Transfusions [544]**  
Antonios Douros, Kathrin Jobski, Bianca Kollhorst, Tania Schink, Edeltraut Garbe. (Germany)
- 118. Safety of Low Molecular Weight Heparin Compared To Unfractionated Heparin in Hemodialysis: A Systematic Review and Meta-Analysis [545]**  
Hind Harrak, Émilie René, Naoual Elftouh, Jean-Philippe Lafrance. (Canada)
- 119. Drug Associated Angioedema: Effect Modification By Race [546]**  
Marsha E Reichman, Michael Wernecke, John Yap, Yoganand Chillarige, Jiemin Liao, Stephine Keeton, Margie Goulding, Katrina Mott, Jeffrey A Kelman, David J Graham. (United States)
- 120. Long-Term Use of Calcium Channel Blockers, Beta-Blockers, Angiotensin-Receptor Blockade and Risk of Breast Cancer in Women Aged 55 Years or Older: A Nation-Wide Study [547]**  
Chia-Hsui Chang, Li-Chiu Wu, Chien-Hsieh Chiang, Jou-Wei Lin, Mei-Shu Lai. (Taiwan)
- 121. Bleeding Risks Are High in Elderly Persons Who Use Vitamin K Antagonists Combined With Platelet Aggregation Inhibitors [548]**  
Nienke van Rein, Uffe Heide-Jørgensen, Willem M Lijfering, Lars Pedersen, Olaf M Dekkers, Henrik T Sørensen, Suzanne C Cannegieter. (Netherlands)
- 122. Assessing Clinical Outcome of Aspirin Containing Magnesium Stearate for Acute Coronary Syndrome [549]**  
Kelly Huang, Chin-lan Cheng, Jinding Huang, Yea-Huei Kao Yang. (Taiwan)
- 123. Epidemiologic Study on the Risk of Developing Depression in Association With use of Beta-Blockers or Other Cardiovascular Drugs [550]**  
Delia C Bornand, Susan S Jick, Christoph R Meier. (Switzerland)
- 124. Lipophilic Statins and the Risk of Suicide: A Population Based Study [551]**  
Jessica LS Leen, Erin M MacDonald, Simon Hollands, Muhammad M Mamdani, J Michael Paterson, David N Juurlink. (Canada)
- 125. Use of Nicorandil Is Associated With Increased Risk for Gastrointestinal Ulceration and Perforation - A Nationally Representative Population-Based Study [552]**  
Meng-tse Gabriel Lee, Shih-Hao Lee, Yueh-Sheng Chen, Xia-Dong Xia, Shy-Shin Chang, Chien-Chang Lee. (Taiwan)
- 126. Use of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Risk of Ileus Among a Type 2 Diabetes Mellitus (T2DM) Population: A Retrospective Cohort Study in Japan [553]**  
Dimitri Bennett, Shreya Davé, Motonobu Sakaguchi, Chia-Hsien Chang, Paul Dolin. (United States)
- 127. Safety Experience in New Oral Anticoagulant Use in Patients With Non-Valvular Atrial Fibrillation - Data from One-Year Post Launch [554]**  
Han-Yao Huang, Hugh Kawabata. (United States)
- 128. Statin-Related Muscle Problems: Prevalence and Therapeutic Response [555]**  
Donald R Miller, Kyung Lee, Adam Rose, Varsha Vimalananda, Cindy L Christiansen. (United States)
- 129. Preadmission Diuretic Use Is Associated With 30-Day and 1-Year Mortality in Patients With Hyponatremia [556]**  
Louise Holland-Bill, Christian F Christiansen, Sinna P Ulrichsen, Troels Ring, Jens Otto L Jørgensen, Henrik T Sørensen. (Denmark)
- 130. Cataract Risk After Exposure To Angiotensin-Converting-Enzyme Inhibitors: A Case-Control Analysis [557]**  
Claudia Becker, Susan S Jick, Christoph R Meier. (Switzerland)
- 131. Cardiovascular Drugs and Erectile Dysfunction – A Symmetry Analysis [558]**  
Lotte Rasmussen, Jesper Hallas, Kenneth Grønkjær Madsen, Anton Pottegård. (Denmark)
- 132. Pattern of Risks of Systemic Lupus Erythematosus Among Statin Users: A Population-Based Retrospective Cohort Study [559]**  
Hilda J De Jong, Tjeerd P Van Staa, Arief Lalmohamed, Rob J Vandebriel, Henk Van Loveren, Frank De Vries, Olaf H Klungel, Jan Willem Cohen Tervaert. (Canada)



- 133. Risk of Skin Ulcerations Associated With Oral Nicorandil Therapy- A Population-Based Study [560]**  
Chien-Chang Lee, Hsin-Yi Lin, Meng-tse Gabriel Lee, Shih-Hao Lee, Sie-Huei Lee, Shy-Shin Chang, Hsiung-Wen Vennia Chang, Shyr-Chyr Chen. (Taiwan)
- 134. Effect of Non-Technological Interventions on Medication Errors in Cardiology [561]**  
Mariana Molina, Carolina Lobos, Pia Cárcamo, Marcela Jirón. (Chile)
- 135. Safety of Aspirin for Cardiovascular Disease in China: A Systematic Review and Meta-Analysis [562]**  
Lin Zhuo, Yinchu Cheng, Yang Zhang. (China)
- 136. The Effect of Antiarrhythmics on QT Variability in a Population-Based Cohort of Middle-Aged and Elderly Persons [563]**  
Marten E van den Berg, Maartje N Niemeijer, Bruno H Stricker, Mark Eijgelsheim, Jan A Kors, Peter R Rijnbeek. (Netherlands)
- 137. Epidemiological Evidence on Associations Between Statin Use and Lymphoid Malignancy Incidence Risk and Survival [564]**  
Xibiao Ye, Ayat Mneina, James Johnston, Salaheddin Mahmud. (Canada)
- 138. The Association of Hormone Therapy and Incident Gout: Population-Based Case-Control Study [565]**  
Saskia G Bruderer, Michael Bodmer, Susan S Jick, Christoph R Meier. (Switzerland)
- 139. Cardiovascular Disease Risk and Androgen Deprivation Therapy in Patients With Localized Prostate Cancer [566]**  
Reina Haque, Xiaoqing Xu, Marianne Ulcickas Yood, Andrea E Cassidy-Bushrow, Stephen K Van Den Eeden, Arnold L Potosky. (United States)
- 140. Risk of Fracture Following Bisphosphonate Drug Holiday [567]**  
Jennifer L Kuntz, John L Adams, Marsha A Raebel, Beth T Tang, Vinutha Vijayadeva, Elizabeth A McGlynn, Wendolyn S Gozansky, Annette L Adams. (United States)
- 141. Type II Diabetes Mellitus, Antidiabetic Drugs, and Statins and the Risk of Developing Osteoarthritis in Non-Weight Bearing Joints [568]**  
Noel Frey, Julia Spoendlin, Thomas Huegle, Susan S Jick, Christoph R Meier. (Switzerland)
- 142. Comparative Risk of Venous Thromboembolism Among Elderly Users of Antipsychotic Drugs [569]**  
Niklas Schmedt, Bianca Kollhorst, Kathrin Jobski, Tania Schink, Edeltraut Garbe. (Germany)
- 143. Antidepressant Medication Use and Its Association With Cardiovascular Disease [570]**  
Richard A Hansen, Yulia Khodneva, Stephen Glasser, Jingjing Qian, Nicole Redmond, Monika M Safford. (United States)
- 144. Transient Risk of Breakthrough Seizures Associated With Phenytoin Refilling [571]**  
Mengdong He, Jodi Segal. (United States)
- 145. Benzodiazepine Use Is Not Associated With an Increased Risk of Alzheimer's Disease or Vascular Dementia [572]**  
Patrick Imfeld, Michael Bodmer, Susan S Jick, Christoph R Meier. (Switzerland)
- 146. Association of Antipsychotic Use With Extrapyramidal Symptoms: Data Mining of the Japanese National Receipt Database [573]**  
Kouichi Hosomi. (Japan)
- 147. Risk Evaluation of Drug-Induced Parkinsonism Associated With Antipsychotics Based on Two Different Study Designs [574]**  
Chieko Ishiguro, Kazuhiro Kajiyama, Yoshiaki Uyama, Emiko Kondo. (Japan)
- 148. Risk of Seizures Associated With Antipsychotic Drug Use - A Nested Case-Control Analysis [575]**  
Marlene Bloechliger, Stephan Rueegg, Susan S Jick, Christoph R Meier, Michael Bodmer. (Switzerland)
- 149. Comparative Risk of Death Among Elderly Users of Antipsychotic Drugs [576]**  
Niklas Schmedt, Bianca Kollhorst, Kathrin Jobski, Tania Schink, Edeltraut Garbe. (Germany)
- 150. All-Cause Mortality Among Elderly Users of Antidepressant Drugs in Germany [577]**  
Bianca Kollhorst, Kathrin Jobski, Niklas Schmedt, Tania Schink, Edeltraut Garbe. (Germany)
- 151. Use of Antipsychotics and the Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies [578]**  
Wan-Ting Hsu, Jason Wang, Yi-Han Sheu, Che-Wei Su, Sheng-Chi Tung, Chien-Chang Lee. (Taiwan)
- 152. Risk of Medication Use for Heat-Related Hospital Admissions - A Matched Case Control Study [579]**  
Ying Zhang, Monika Nitschke, Antoinette Krackowizer, Peng Bi. (Australia)
- 153. Use of Antipsychotics and the Risk of Pneumonia: A Systematic Review and Meta-Analysis of Observational Studies [580]**  
Chien-Chang Lee, Wan-Ting Hsu, John W Jackson, Jason Wang, Albert Yuh-Chyuan Shan, Wei Kian Chua. (Taiwan)
- 154. Comparative Safety of Typical and Atypical Antipsychotics After Cardiac Surgery [581]**  
Dae Kim, Elisabetta Patomo, Yoonyoung Park, Krista Huybrechts, Raisa Levin, Brian Bateman. (United States)
- 155. Observational Assessment of Safety in Seroquel (OASIS) – Rates & Patterns of Common Events Observed in Users of Quetiapine Extended-Release (Seroquel XL®) and Immediate Release (IR) [582]**  
Deborah Layton, Sarah Clarke, Ian Ratcliffe, Saad AW Shakir, Tony Hale. (United Kingdom)
- 156. Suicide Risk and Side Effects from Antipsychotics in Schizophrenia: A Nested Case-Control Study [583]**  
Johan Reutfors, Shahram Bahmanyar, Lena Brandt, Eric Clapham, Erik G Jönsson, Robert Bodén, Anders Ekblom, Urban Ösby. (Sweden)
- 157. The Potential Risk of Upper Gastrointestinal Bleeding Associated With Use of Selective Serotonin Reuptake Inhibitors in Older Adults [584]**  
Eunsun Noh, Brian J Quilliam. (United States)
- 158. Anticholinergic Medication Use and Risk of Community-Acquired Pneumonia in Older Adults [585]**  
Kathleen J Paul, Rod L Walker, Sascha Dublin. (United States)
- 159. Effects of Second-Generation Antidepressants on Cognitive Function: A Systematic Review and Meta-Analysis [586]**  
Shalak Gunjal, Satabdi Chatterjee, Helena VonVille, Patricia Dolan Mullen, Hua Chen, Rajender Aparasu. (United States)
- 160. The Impact of Intravitreal Drugs on Rates of Post-Injection Endophthalmitis [587]**  
Brian L VanderBeek, Sarah Bonaffini, Liyuan Ma. (United States)
- 161. Low Dose Aspirin, Non-Steroidal Anti-Inflammatory Drugs, Selective COX-2 Inhibitor Prescriptions & Breast Cancer Recurrence: A Danish Population-Based Cohort Study [588]**  
Deirdre Cronin-Fenton, Uffe Heide-Jørgensen, Thomas P Ahern, Timothy L Lash, Peer Christiansen, Bent Ejlersten, Henrik T Sørensen. (Denmark)

- 162. Ethnic and Regional Differences in Neutrophil Counts and Neutropenia Reporting in Two International Clinical Trials of Rifapentine and Rifampicin for Tuberculosis Treatment [589]**  
Ruth N Moro, John L Johnson, Chi-Chiu Leung, Kwok-Chiu Chang, Neil Martinson, Andrey Borisov, Stefan V Goldberg. (United States)
- 163. The Role of Allopurinol and Febuxostat in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis [590]**  
Maja Mockenhaupt, Peggy Sekula, Jean-Claude Roujeau. (Germany)
- 164. Drugs and Ventricular Repolarization in a General Population: The Rotterdam Study [591]**  
Maartje N Niemeijer, Marten E van den Berg, Oscar H Franco, Albert Hofman, Jan A Kors, Bruno H Stricker, Mark Eijgelsheim, Peter R Rijnbeek. (Netherlands)
- 165. Risk of Hospital Admission for Liver Injury in Users of NSAIDs and Non-Overdose Paracetamol (EPIHAM) [592]**  
Ezgi Gulmez, Régis Lassalle, Jérémy Jové, Guillaume Caridade, Adeline Grolleau, Nicholas Moore. (France)
- 166. Heterogeneity on Case Definition and Diagnostic Method of Lipodystrophy Among HIV-Infected Patients on Antiretroviral Therapy [593]**  
Lorena GC Lana, Daniela RG Junqueira, Edson Perini, Cristiane A Menezes de Padua, Letícia Penna Braga. (Brazil)
- 167. Initiative To Improve Recruitment To a Streamlined Safety Study By Providing Study Information in a More Accessible Format [594]**  
Robert Flynn, Claudine Jennings, Wendy Saywood, Isla Mackenzie, Evelyn Findlay, Kay Walker, George Nuki, Ian Ford, Thomas MacDonald. (United Kingdom)
- 168. Observations of Progressive Multifocal Leukoencephalopathy (PML) in Patients With Systemic Lupus Erythematosus (SLE): Systematic Literature Review [595]**  
Amanda Eudy, Cassidy Henegar, Vineetkumar Kumar, Dimitri Bennett, Barbara Haight, Eric Lewis, Deanna Hill. (United States)
- 170. Effect of Antimalaria Prophylaxis With Sulfadoxine-Pyrimethamine on Pregnancy Outcomes [597]**  
Nneka U Igboeli, Chibunna J Mbaeri, Cletus N Aguwa. (Nigeria)
- 171. Outcomes of Facility-Level Use of Ferumoxytol Versus Other Intravenous Iron Formulations in Incident Hemodialysis Patients [598]**  
Medha Airy, Sreedhar Mandayam, Aya A Mitani, Tara I Chang, M Alan Brookhart, Benjamin A Goldstein, Wolfgang C Winkelmayr. (United States)
- 172. Comparative Effectiveness and Safety of SSRI Treatment With or Without Concomitant Use of Statins: A Population-Based Study [599]**  
Ole Köhler, Christiane Gasse, Ole Mors, Andrew Nierenberg, Liselotte Petersen, Søren Dinesen Østergaard. (Denmark)
- 173. Effectiveness of Medication in Preventing Psychiatric Hospitalization in Bipolar Disorder - A Swedish Register Based Study [600]**  
Erik Joas, Aina Karanti, Paul Lichtenstein, Mikael Landén. (Sweden)
- 174. Effects of Reformulating OxyContin on Opioid Abuse in 6 National US Abuse Surveillance Systems [601]**  
Paul M Coplan, Howard D Chilcoat. (United States)
- 175. Metformin Plus Insulin Versus Metformin Plus Sulfonylurea and the Associated Risk of Hypoglycemia [602]**  
Christianne L Roumie, JeaYoung Min, Robert A Greevy, Carlos Grijalva, Adriana M Hung, Xulei Liu, Marie R Griffin. (United States)
- 176. Associations Between Lithium and Suicide and Nonsuicide Death Among Veterans Health Administration Patients [603]**  
Eric G Smith, Karen L Austin, Hyungjin M Kim, Susan V Eisen, Amy M Kilbourne, Donald R Miller, Kara Zivin, Claire Hannemann, Brian Sauer, Marcia Valenstein. (United States)
- 177. Differential Postpartum Surveillance for Type 2 Diabetes in Women Treated With Glyburide Versus Insulin for Gestational Diabetes [604]**  
Suzanne N Landi, Wendy Camelo Castillo, Kim Boggess, Mitchell M Conover, Michele Jonsson Funk. (United States)
- 178. Long-Term Effectiveness of Entecavir Among Hepatitis B Patients in Taiwan [605]**  
Yi-Chun Yeh, Chun-Jen Liu, Pei-Jer Chen, Mei-Shu Lai. (Taiwan)
- 179. Short Term Effect on Hemoglobinemia in Epoetin Users: No Difference Between Biosimilar and Originator [606]**  
Ylenia Ingrassiotta, Francesco Giorgianni, Andrea Fontana, Jenny Bolcato, Roberta Pirolo, Alessandro Chinellato, Achille Patrizio Caputi, Gianluca Trifirò. (Italy)
- 180. Comparative Effects of Antihypertensive Medications on Colorectal Cancer Risk [607]**  
Phyo T Htoo, Til Stürmer, Michele J Funk, Virginia Pate, Jennifer L Lund. (United States)
- 181. Effectiveness of Aldosterone Antagonist Therapy Among Survivors of Acute ST-Elevation Myocardial Infarction - A Nationwide Nested Case-Control Study [608]**  
Hsu-Wen Chou, Chao-Lun Lai, Kin-Wei Arnold Chan, Mei-Shu Lai. (Taiwan)
- 182. Association of Treatment With Carvedilol, Bisoprolol and Metoprolol on the Risk of Mortality and Hospital Admission Among Older Adults With Heart Failure [609]**  
Perreault Sylvie, De Denus Simon, White Michel, Guay-White Brian, Bouvier Michel, Dorais Marc, Dubé Marie-Pierre. (Canada)
- 183. Comparison of Methods To Estimate Cardiovascular Event Rates Over Time in a Diabetic Population on High Intensity Statin Therapy [610]**  
Mark Danese, Benjamin Taylor, Villa Guillermo, Lothgren Mickael. (United States)
- 184. Impact of Fibrates on the Cardiovascular Events in Patients With Acute Coronary Syndrome Underwent Percutaneous Transluminal Coronary Angioplasty: A Population-Based Cohort Study in Taiwan [611]**  
Jui Wang, Zhen-Fang Lin. (Taiwan)
- 185. Comparative Effectiveness of Carotid Artery Stenting (CAS) and Carotid Endarterectomy (CEA) Among Medicare Beneficiaries Treated in Routine Clinical Practice [612]**  
Jessica J Jalbert, Louis L Nguyen, Marie D Gerhard-Herman, Hiraku Kumamaru, Lauren A Williams, Chih-Ying Chen, Jun Liu, Andrew T Rothman, Michael R Jaff, John D Seeger, Herbert D Aronow, Joseph A Johnston, Thomas G Brott, Christopher J White, Soko Setoguchi. (United States)
- 186. Unintended Pregnancies in Users of Different Combined Oral Contraceptives – Final Results from the INAS-SCORE Study [613]**  
Kristina Bardenheuer, Juergen Dinger, Christian Franke, Christine Hagemann, Sabine Möhner. (Germany)

## Comparative Effectiveness Research (CER)

### Spotlight Session Comparative Effectiveness Research (CER)

- 169. Risk of Hypoglycemia Associated With Sulfonylurea and Insulin or Insulin Monotherapy [596]**  
Jea Young Min, Marie R Griffin, Carlos G Grijalva, Robert A Greevy, Adriana M Hung, Xulei Liu, Christianne L Roumie. (United States)

- 178. Long-Term Effectiveness of Entecavir Among Hepatitis B Patients in Taiwan [605]**  
Yi-Chun Yeh, Chun-Jen Liu, Pei-Jer Chen, Mei-Shu Lai. (Taiwan)



- 187. Withdrawn By Author**
- 188. Similarities Regarding Diagnostic Workup Utilization in Two Data Systems [614]**  
Xiaojuan Li, Yong Chen, Julie Chandler, Cynthia J Girman, Til Stürmer. (United States)
- 189. Impact of Urate Level on Cardiovascular Risk in Allopurinol Treated Patients. A Nested Case Control Study [615]**  
Kasper Søltøft Larsen, Anton Pottegård, Hanne M Lindegaard, Jesper Hallas. (Denmark)
- 190. Efficacy of Osteoporosis Pharmacotherapies in Preventing Fractures Among Chronic Oral Glucocorticoids Users: A Network Meta-Analysis [616]**  
M Amine Amiche, Jordan M Albaum, Mina Tadrous, Petros Pechlivanoglou, Jonathan D Adachi, Linda E Lévesque, Suzanne M Cadarette. (Canada)
- 191. Selective Serotonin Reuptake Inhibitors (SSRIs) and Colorectal Cancer (CRC) [617]**  
Monica E D'Arcy, Til Stürmer, Michele Jonsson-Funk, John Baron, Robert S Sandler, Virginia Pate, Anne Marie Meyer, Melissa A Troester, Jennifer L Lund. (United States)
- 192. Antidepressants (AD) and Colorectal Cancer (CRC) [618]**  
Monica E D'Arcy, Til Stürmer, Michele Jonsson Funk, Robert S Sandler, John A Baron, Pate Virginia, Anne Marie Meyer, Melissa A Troester, Jennifer L Lund. (United States)
- 193. Use of Different Formulations Rivastigmine and Risk of Cardiovascular Adverse Events [619]**  
Edward Chia-Cheng Lai, Monera B Wong, Isao Iwata, Yinghong Zhang, Cheng-Yang Hsieh, Yea-Huei Kao Yang, Soko Setoguchi. (Taiwan)
- 194. Comparison of Short-Term Versus Long-Term Outcomes of West Syndrome Treatment [620]**  
Marina E Farnosova, Tatiana F Zharikova, Rimma G Gamirova. (Russian Federation)
- 195. Stimulant Treatment and Risk of Traffic Accidents Requiring Acute Care in Adults With Attention Deficit Hyperactivity Disorder [621]**  
Daina B Esposito, Gaurav Deshpande, Crystal N Holick, Stephan Lanes. (United States)
- 196. Comparative Risk of Glaucoma in Patients With Epilepsy Receiving Antiepileptic Drugs [622]**  
Wan-Ju Annabelle Lee, Chia-Cheng Edward Lai, Yea-Huei Kao Yang. (Taiwan)
- 197. Prescription Opioid Use and Mortality Risk in Hemodialysis Patients [623]**  
Maurice A Brookhart, Diane Reams, Anne Butler, Magdalene Assimon, Jennifer Flythe, Abhijit Kshirsagar. (United States)
- 198. Protective Effects of Statins in Staphylococcus aureus Bacteremia [624]**  
Eunsun Noh, Aisling R Caffrey, Kerry L LaPlante. (United States)
- 199. Comparing Patient-Centered Outcomes After Uterus-Conserving Procedures for Uterine Fibroids Using a Linked Electronic Medical Record (EMR)-Claims Database [625]**  
Kristina M Franke, Aaron B Mendelsohn, Emma Brinkley, Priscilla Velentgas, Tongsheng Wang, Evan R Myers, Kathy Lang. (United States)
- 200. Diabetes Treatment Intensification and Associated Changes in HbA1c and Body Mass Index [626]**  
Christianne L Roumie, Robert A Greevy, Carlos G Grijalva, Adriana M Hung, Xulei Liu, Marie R Griffin. (United States)
- 201. The Use of Low Molecular Weight Heparin and Pneumatic Compression Devices for Deep Vein Thrombosis Prophylaxis in Major Trauma Patients: A Comparative Effectiveness Analysis [627]**  
Abdullah Alahmari, Ziyad Almalki, Guo Jeff. (United States)
- 202. Comparing Inverse Probability Weighting, Stabilized IPW and Entropy Balance Methods To Generalize Observational Cohorts To a Population [628]**  
Raymond A Harvey, Jennifer D Hayden, Pravin S Kamble, Joanna C Huang, Jonathan R Bouchard. (United States)
- 203. Improving Utility of Electronic Health Data for Clinical Research: The Need for Harmonization [629]**  
Michelle Leavy, Michael Barboza, Estefania Rodriguez, Sarah Rosenblum, Lisa Green. (United States)
- 204. In Balance You Say? How We Assess Baseline Comparability in Comparative Effectiveness Research [630]**  
Jin-Liern Hong, Richard Wyss, Til Stürmer, Cynthia J Girman. (United States)
- 205. Best Methods To Get Your Comparative Effectiveness Paper Cited: How GRACE Helps [631]**  
Nancy A Dreyer, Allison Bryant, Priscilla Velentgas, Zhaohui Su. (United States)
- 206. Registry of Patient Registries (RoPR): Pilot Results and Lessons Learned for Registering Observational Studies [632]**  
Michelle Leavy, Daniel Campion, Thomas Taylor, Jannette Karl. (United States)
- Burden of Disease Epidemiology of Illness**
- 207. Epidemiology of Lactic Acidosis in Type 2 Diabetes Patients Treated With Metformin in Japan [633]**  
Chia-Hsien Chang, Motonobu Sakaguchi. (Japan)
- 208. Change in Prevalence and Distribution of Diabetes Mellitus Type I and Type II Over Time in the Netherlands [634]**  
Jetty A Overbeek, Fernie JA Penning-van Beest, Eric CJ van Dongen, Ron MC Herings. (Netherlands)
- 209. Time To Onset and Duration of Induction Therapy and Associated Factors Among Newly Diagnosed Multiple Myeloma Patients [635]**  
Akeem A Yusuf, Tanya Bovitz, Tom Matlon, Winifred Werther, Diana Felici, Maya Mahue, Kenneth Bridges, Yi Peng. (United States)
- 210. Prevalence and Characteristics of Patients With Low Level of Low-Density Lipoprotein Cholesterol in Denmark [636]**  
Sigrún AJ Schmidt, Uffe Heide-Jørgensen, Angelika D Manthripragada, Vera Ehrenstein. (Denmark)
- 211. Comparison of Diagnostic Accuracy of IASP Grading System and ID Pain Questionnaire in Patients With Confirmed Neuropathic Component and Chronic Low Back Pain [637]**  
Kapil Gudala, Dipika Bansal, Babita Ghai. (India)
- 212. Cross-Cultural Adaptation and Validation of the Hindi Version of the Pain Catastrophizing Scale [638]**  
Sreenu Lavudiya, Kapil Gudala, Dipika Bansal, Babita Ghai. (India)
- 213. Trends and Outcome of Acute Poisoning in a Tertiary Care Hospital of Eastern India: A Prospective Observational Study [639]**  
Suparna Chatterjee, Vivek Verma, Avijit Hazra. (India)
- 214. A Multi-State Model for Investigating the Effects of Multiple Medication Use and Drug Burden Index on Transitions in Cognitive Function and Death in Community-Dwelling Older Men: The CHAMP Cohort [640]**  
Kris M Jansen, Danijela Gnjidic, Sarah N Hilmer, Jenni Iiomaki, David Le Couteur, Fiona M Blyth, Vasi Naganathan, Robert G Cumming, J Simon Bell. (Australia)
- 215. Age of Initiation of Opioid Abuse Overall and By Route of Administration Among Opioid Abusers in Rural Kentucky [641]**  
Angela DeVeauugh-Geiss, Jennifer Havens, Carl Leukefeld, Paul Coplan, Howard Chilcoat. (United States)

- 216. Clinical Outcomes and Predictors in Patients With Biofilm Producing Methicillin-Resistant Staphylococcus aureus (MRSA) [642]**  
Diane M Gomes, Aisling R Caffrey, Megan K Luther, Kerry L LaPlante. (United States)
- 217. The Association of Thyroid Disorders and Incident Gout: Population-Based Case-Control Study [643]**  
Saskia G Bruderer, Susan S Jick, Christoph R Meier, Michael Bodmer. (Switzerland)
- 218. Incidence and Prevalence of COPD By GOLD 2013 Classification in the Netherlands [644]**  
Jetty A Overbeek, Elsa J van den Berg, Fernie JA Penning-van Beest, Mona Khalid, Richard Dekhuijzen, Ron MC Herings. (Netherlands)
- 219. Characteristics of Patients Enrolled in a Cancer Care Quality Program: A Linked Pharmacoepidemiology Resource in the HealthCore Research Environment [645]**  
Kevin Haynes, Crystal Hollick, Nandini Selvam, Vincent J Willey, Ralph Quimbo, Ozgur Tunceli, Michael R Mack, Jennifer Malin. (United States)
- 220. Iron Deficiency, Anemia and Colorectal Cancer [646]**  
Cornelia Schneider, Michael Bodmer, Susan S Jick, Christoph R Meier. (Switzerland)
- 221. Outcomes in Patients With Stable Coronary Artery Disease Post Myocardial Infarction: the HORUS Cohort Study in the French Health Insurance and Hospital-Discharge Database [647]**  
Patrick Blin, Caroline Dureau-Pournin, Régis Lassalle, Jérémy Jové, Florence Thomas-Delecourt, Cécile Droz-Perroteau, Nicolas Danchin, Nicholas Moore. (France)
- 222. Risk of Myocardial Infarction in Patients With Increased Level of Lipoprotein (A) - Retrospective Analysis of an Us Insurance Claims Database and NHANES III [648]**  
Tzuyung D Kou, Anura Deshmukh, Andres Gomez. (United States)
- 223. Subgroups of Depression in the Sequenced Treatment Alternatives To Relieve Depression (STAR\*D) Study: A Latent Class Analysis [649]**  
Christine M Ulbricht, Anthony J Rothschild, Kate L Lapane. (United States)
- 224. Body Mass Index and Risk of Dementia in a Cohort Study of Two Million People in UK Primary Care Database [650]**  
Nawab Qizilbash, John Gregson, Michelle E Johnson, Neil Pearce, Ian Douglas, Kevin Wing, Stephen JW Evans, Stuart J Pocock. (United Kingdom)
- 225. The Prevalence of Sjögren's Syndrome in United States Health Insurance Claims [651]**  
Susan A Hall, Maneesh Juneja, Lisa Vinikoor, Cristina Musselli, Nathalie Franchimont. (United States)
- 226. Factors Associated With Primary and Secondary Diagnosis of Clostridium Difficile Infection [652]**  
Robert McConeghy, Cynthia Willey, Aisling Caffrey. (United States)
- 227. Incidence of Pulmonary Embolism Among Postmenopausal (PM) Women With ER+/HER2- Breast Cancer [653]**  
Xiaofeng Zhou, Cynthia de Luise, Rongjun Shen, Andrew Bate, Nicolle Gatto. (United States)
- 228. Minimally Important Differences for Patient-Reported Outcomes Measurement Information System (Promis) Fatigue and Pain Interference Scores [654]**  
Jennifer Beaumont, James F Fries, Jeffrey R Curtis, David Cella, Hui Feng Yun. (United States)
- 229. Attention Deficit Hyperactivity Disorder (ADHD) and Socioeconomic Status in Children and Adolescents in the UK [655]**  
Adrian J Hire, Darren M Ashcroft, David A Springate, Doug Steinke. (United Kingdom)
- 230. Does FEV1 Change Predict Hospital Admission and All-Cause Mortality in Patients With Chronic Obstructive Pulmonary Disease (COPD)? [656]**  
Robert W Flynn, Thomas M MacDonald, Adrian Hapca, Isla S Mackenzie, Li Wei, Steve V Morant, Stuart Schembri. (United Kingdom)
- 231. Correlates of Patient Delay in the Initiation of Treatment Among New-Smear Positive TB Patients in Rural Health Settings in the Philippines [657]**  
Imelda G Pena. (Philippines)
- 232. Breast Cancer Subtype and Survival in a Population-Based Cohort of Patients from California [658]**  
Christina A Clarke, Scarlett Lin-Gomez, Li Tao, Lisa Moy, Juan Yang, Lisa I Wang, Mary S Beattie, Jennifer Eng-Wong, Melissa Brammer, Laura Chu. (United States)
- 233. Cardiovascular and Renal Morbidity in Gout Patients in Germany, United Kingdom, United States, and France [659]**  
Fredrik Nyberg, Javier Nuevo, Laura Horne, Robert Morlock, Chris Storgard, Lalitha Aiyer, Dionne M Hines, Xavier Ansalobehere, Pierre Chevalier. (Sweden)
- 234. Trends in Healthcare Utilization and Cost of Epilepsy Across Ages 0-90 [660]**  
Chintan Dave, Abraham Hartzema. (United States)
- 235. Non-Medical Use of Benzodiazepines and Opioids: An Online National Survey in the United Kingdom [661]**  
Jody L Green, Andrea C Besharat, Erin M Goodman, Becki Bucher-Bartelson, David M Wood, Paul I Dargan. (United States)
- 236. Primary Sclerosing Cholangitis in the UK Clinical Practice Research Datalink (CPRD GOLD) [662]**  
Huifang Liang, Jennifer H Lin, Jesse Shick, Sudhakar Manne, Punam Bharania, Paul Dolin. (United States)
- 237. Mitigating the Paucity-of-Data Problem for Target Population Sizing: Exploring a Model-Based Approach for Advanced Gastroenteropancreatic Neuroendocrine Tumors [663]**  
Alia Yousif, Aurore Bergamasco, Caroline Tremblay, Anne-Marie Castilloux, Jérôme Dinet, Gabrielle Nayroles, Sylvie Gabriel, Yola Moride. (Canada)
- 238. Prevalence of Attention Deficit Hyperactivity Disorder in Publicly Insured Adults [664]**  
Yanmin Zhu, Wei Liu, Yan Li, Almut G Winterstein. (United States)
- 239. Association Between Lifestyle and Quality of Life in Healthy Postgraduate Students of India [665]**  
Shallu Sharma, Deepika Bansal. (India)

## Spotlight Session-AsPEN

- 240. Suboptimal Management of Patients With Non-Valvular Atrial Fibrillation: Real-World Clinical Setting [666]**  
Wallis CY Lau, Esther W Chan, Ian CK Wong. (China)
- 241. Effect of Antiplatelet Agents Combined With Cilostazol on Cardio-Cerebrovascular Events and Bleeding Risk in Acute Coronary Syndrome Patients [667]**  
Xue-Mei Jin, Ye-Jee Kim, Bo Ram Yang, Nam-Kyong Choi, Joongyub Lee, Mi-Sook Kim, Ju-Young Shin, Jong-Mi Seong, Yoosoo Chang, Byung-Joo Park. (Republic of Korea)
- 242. Persistence To Oral Anticoagulant Therapy in Japanese Atrial Fibrillation Patients [668]**  
Hiraku Kumamaru, Chisa Matsumoto, Soko Setoguchi. (United States)
- 243. Persistence of Dabigatran Versus Warfarin Therapy in Patients With Non-Valvular Atrial Fibrillation in the Real-World Clinical Practice [669]**  
Wallis CY Lau, Esther W Chan, Ian CK Wong. (China)



**244. Increasing Atomoxetine and Decreasing Methylphenidate Use for Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD) in Korea [670]**  
Ju-Young Shin, Sun Mi Shin, Shin Haeng Lee, Han Na Shin. (Republic of Korea)

**245. Validity of a Claims-Based Stroke Severity Index for Hospitalized Acute Ischemic Stroke Patients [671]**  
Cheng-Yang Hsieh, Sheng-Feng Sung, Huey-Juan Lin, Yu-Wei Chen, Chih-Hung Chen, Yea-Huei Kao Yang, Ya-Han Hu. (Taiwan)

**246. Myocardial Infarction Associated With Current Use of Helicobacter Pylori Eradication Regimen Containing Clarithromycin: Self-Controlled Case Series [672]**  
Angel YS Wong, Adrian Root, Ian Douglas, Celine Chui, Esther W Chan, Yonas Ghebremichael-Weldeselassie, Liam Smeeth, Ian CK Wong. (China)

**247. Withdrawn By Author**

## AsPEN

**248. The Gender Differences in the Short-Term and Long-Term Treatment Outcomes in Taiwan Rheumatoid Arthritis Patients [674]**  
Tzu-Chieh Lin, Yea-Huei Kao Yang, Swu-Jane Lin. (Taiwan)

**249. Comparison of High-Potency Statin Monotherapy and Statin Plus Ezetimibe Combination Therapy for Reducing Cardio-Cerebrovascular Disease Risk [675]**  
Bo Ram Yang, Joongyub Lee, Nam-Kyong Choi, Ju-Young Shin, Yoosoo Chang, Hong-Ji Song, KyungEun Youn, Xue-Mei Jin, Mi-Sook Kim, Ye-Jee Kim, Jong-Mi Seong, Byung-Joo Park. (Republic of Korea)

**250. Risk of Peptic Ulcer Among Antidepressants Users With or Without Concurrent Use of Non-Steroidal Anti-Inflammatory Drugs: Nationwide Propensity Score Matched Study [676]**  
Ju-Young Shin, Mi-Ju Park, Shin Haeng Lee, So-Hyun Choi, Byung-Joo Park. (Republic of Korea)

**251. Prescribing Patterns of Antidepressants for the Elderly Depressive Patients in Korea [677]**  
Kyoung-eun Kwon, Ju-Young Shin, Ye-Jee Kim, Nam-Kyong Choi, Joongyub Lee, Byung-Joo Park. (Republic of Korea)

**252. Geographic Variation and Type of Medical Service in the Prescribing Pattern of Zolpidem Use in Korea [678]**  
Hyo-Ju Park, Ju-Young Shin, Han-Na Shin. (Republic of Korea)

**253. A Survey on Self-Medication With Antibiotics and Over the Counter Drugs Among Undergraduate Medical Students in Yogyakarta, Indonesia [679]**  
Sharonjit Sandhu. (Indonesia)

**254. Survey on Self-Medication of Vitamin and Supplement Among Medical Undergraduate Students in Yogyakarta, Indonesia [680]**  
Yana Suryani. (Indonesia)

**255. Myocardial Infarction and Cardiac Death Associated With Current Use of Clarithromycin: Cohort Study [681]**  
Angel YS Wong, Adrian Root, Ian Douglas, Celine Chui, Esther W Chan, Liam Smeeth, Ian CK Wong. (China)

**256. Association Between an Excess Risk of Anaphylaxis and Concomitant Use of Benzylpenicillin and Herba Houltuyniae Injection, Retrospective Analysis of a Spontaneous Reporting System [682]**  
Haona Li, Jianxiang Deng, Yiexiang Zhang, He Sun. (China)

**257. The Association Between Oral Fluoroquinolones and Seizures: A Hong Kong and United Kingdom Population-Based Self-Controlled Case Series Study [683]**  
Celine SL Chui, Esther W Chan, Angel YS Wong, Adrian Root, Ian J Douglas, Ian CK Wong. (China)

**258. Cardiotoxicity of Adjuvant Trastuzumab in Taiwan Breast Cancer Patients: A Population-Based Study [684]**  
Hsu-Chih Chien, Yea-Huei Kao Yang, Jane PF Bai. (Taiwan)

**259. Withdrawn By Author**

**260. An Indian Study on Assessment of the Suitability of Pharmacotherapy in Elderly Patients and Its Enhancement [686]**  
Mandavi Kashyap, Mangu Rohit, Vinay Kapur, Sanjay D'Cruz, Atul Sachdev, Pramil Tiwari. (Malaysia)

**261. Type 2 Diabetes Among Adults in Bangladesh: A Population Based Study [687]**  
Muhammad AB Chowdhury, Md Jamal Uddin, Hafiz MRU Khan, Md Rabiul Haque. (United States)

**262. Risk Factors of Hypertension Among Adults in Bangladesh: Evidence from a National Cross Sectional Survey [688]**  
Muhammad A.B. Chowdhury, Md. Jamal Uddin, Boubakari Ibrahimou, Md. Rabiul Haque, Oren Dale Williams. (United States)

END SESSION B

## Pharmacovigilance

1. **Pharmacovigilance Knowledge and Practices Amongst Health Care Professionals; a Regional Survey [768]**  
Maria Rizvi, Mehreen Abbas. (Pakistan)
2. **Prospective Evaluation of vigiRank for First-Pass Screening in Real-World Signal Detection [769]**  
Ola Caster, Lovisa Sandberg, Kristina Juhlin, Sarah Watson, G Niklas Norén. (Sweden)
3. **Evaluation of EU Post-Authorization Safety Studies Using EU-RMP / European Public Assessment Reports: Analysis, Trends, and Implications [770]**  
David Neasham, Sarah Baradaran, Corina Chalkiadaki, Ravi Sadasivan, Beth L Nordstrom, Matthew W Reynolds. (United Kingdom)
4. **Comparison of Events in Spontaneous Adverse Event Reports To Events Discussed Within Context of Drug Use on Facebook and Twitter [771]**  
Gregory Powell, Heidi Bell, Harold Rodriguez, Michele Thomas, Jeffery Painter, Cath Harvey, James Blowers, Nabarun Dasgupta. (United States)
5. **Bias in Spontaneous Reporting of Adverse Drug Reactions in Japan [772]**  
Shinichi Matsuda, Kotonari Aoki, Takuya Kawamata, Tetsuji Kimotsuki, Takumi Kobayashi, Hiroshi Kuriki, Terumi Nakayama, Seigo Okugawa, Yoshihiko Sugimura, Minami Tomita, Yoichiro Takahashi. (Japan)
6. **Experiences With a Computer-Assisted Database Screening Tool at the Netherlands Pharmacovigilance Centre Lareb [773]**  
Florence van Hunsel, Corine Ekhart. (Netherlands)
7. **The Role of Registries in European Post-Marketing Surveillance: A Retrospective Analysis of Centrally Approved Products During 2005-2013 [774]**  
Jacoline Bouvy, Xavier Kurz, Kevin Blake, Giampiero Mazzaglia, Jim Slattery, Corinne de Vries, Marie L De Bruin, Peter Arlett. (United Kingdom)
8. **Framework for Impact Assessment of Regulatory Science: Application To the PROTECT Project [775]**  
Xavier Kurz, Peter Arlett, Jim Slattery, Kevin Blake, Corinne de Vries. (United Kingdom)
9. **Impact of Scheduled Post-Marketing Safety Summary Analyses on Regulatory Actions [776]**  
Shohko Sekine, Ellen E Pinnow, Rebecca Kurtzig, Eileen Wu, Hall Marni, Gerald Dal Pan. (Japan)
10. **Utility of Social Listening in Pharmacovigilance for Groups of Special Interest: Product Complaints, Pregnancy, Pediatric, and the Elderly [777]**  
Heidi G Bell, Laurie S Anderson, Nancy A Yuen, Bridget Ruane, Harry Seifert, Gregory E Powell. (United States)
11. **A Statistical Method for Estimating the Prevalence of Adverse Drug Reactions in Hospitalized Patients Using Laboratory Results from Electronic Health Records [778]**  
Dukyong Yoon, Man Young Park, Eun Kyoung Ahn, Soo Yeon Cho, Dahye Shin, Jihyun Kim, Hojun Park, George Hripcsak, Rae Woong Park. (Republic of Korea)
12. **Active Surveillance of Adverse Drug Reactions Using Administrative Databases [779]**  
Ella T Nkhoma, Kyna Gooden, Jennifer Wood, Brian Dreyfus, Heather Mazakas, Andres Gomez. (United States)
13. **The Impact of the New Pharmacovigilance Legislation on the Applications and Files Submitted to the Department of Adverse Drug Reactions of the National Organisation for Medicines in Greece (EOF) [780]**  
Eirini Apostolidou, George Aislaitner, Leonidas Klironomos, Agni Kapou, Dimitrios Kouvelas. (Greece)
14. **Comparison of Safety Signal Detection Algorithms Used in Data Mining With Regard To Masking Bias [781]**  
David J Nimke, Vaishali K Patadia. (United States)
15. **Consumption Adjusted Reporting Rates of Adverse Drug Reactions in Norway [782]**  
Kristian Svendsen. (Norway)
16. **Sentinel Site Active Surveillance for First-Line Antiretroviral Medicines in Namibia [783]**  
Marita Mann, Assegid Mengistu, Johannes Gaeseb, Evans Sagwa, Greatjoy Mazibuko, Andy Stergachis. (United States)
17. **Pharmacovigilance Data from Systematic Patient Reported Outcome (PRO) Tools Versus Usual Clinician Interactions: Are Cancer Patients Reporting Toxicity Data To Their Health Care Providers? [784]**  
Joseph N Samuel, Tian Qi Wang, Andrea Perez-Cosio, M Catherine Brown, Ashlee Vennettilli, Nicholas Cheng, Gusharan Gill, Mindy Liang, Doris Howell, Wei Xu, Jack Seki, Geoffrey Liu. (Canada)
18. **Studying Cancer as an Adverse Outcome from Nononcological Therapies: Review of the Food and Drug Administration's Postmarketing Commitment Database [785]**  
Kirk D Midkiff, David H Harris, Alicia W Gilsenan, Elizabeth B Andrews. (United States)
19. **Pharmacovigilance of Psychotropic Medicines in a Developing Country—A Prospective Surveillance [786]**  
Ramesh Madhan, Jisha Lucca, Parthasarathi Gurumurthy. (India)
20. **Impact of Adverse Drug Reactions on Daily Living of Patients on Anti-Psychotic Medications [787]**  
Ramesh Madhan, Jisha Lucca, Parthasarathi Gurumurthy, Himanshu Patel. (India)
21. **Prospective Safety Monitoring of Drug-Drug Interactions: A Case Study of Warfarin and Selective Serotonin-Reuptake Inhibitors [788]**  
Krista F Huybrechts, Macarius M Donneyong, Moa Park, Joshua J Gagne, Sebastian Schneeweiss, Shirley Wang. (United States)
22. **Rhabdomyolysis Could Be a Consequence of the Interaction Between Clonazepam and Other Antiepileptic Medications: A Pharmacovigilance Assessment [789]**  
Ayad K Ali, Mahyar Etminan. (United States)
23. **Inverse Association Between Antiepileptic Drugs and Cancers; Data Mining of Large Medical Databases [790]**  
Mitsutaka Takada, Mai Fujimoto, Migiwa Kanou, Kouichi Hosomi. (Japan)
24. **397 Patterns in Spontaneous Adverse Event Reporting Among Branded and Generic Antiepileptic Drugs [791]**  
Justin Bohn, Cindy Kortepeter, Monica Muñoz, Kelley Simms, Susan Montenegro, Gerald Dal Pan. (United States)
25. **Psychotropic Drug-Drug Interactions in Three Most Commonly Used Drug Information Databases [792]**  
Xinyue Liu, Marie Barnicoat, Regina Bussing, Almut G Winterstein. (United States)
26. **Polypharmacy in Spontaneous Reports of Over-the-Counter (OTC) Products: Skin Care [793]**  
Mary E Ritchey, Leslie Rylander, Michael Steinbuch. (United States)
27. **Comparison of Inhibitors of Dipeptidylpeptidase 4 (DDP-4 Inhibitors or Gliptins) Marketed By Indian Companies With the Original SmPC from Innovator Companies [794]**  
Nilima P Justice, Pipasha N Biswas. (United States)



- 28. **Allergic Reactions Associated With Herbal Remedies in the WHO-UMC Pharmacovigilance Database [795]**  
Jitka Pokladnikova, Ricarda Meincke, Ronald Meyboom, Stefan Russmann. (Switzerland)
- 29. **Withdrawn By Author**
- 30. **Development of a Research Network and an Infrastructure for the Nationwide Registry Study in Palliative Care in Japan [797]**  
Keisuke Ariyoshi, Tempei Miyaji, Isseki Maeda, Satoru Iwase, Takuhiro Yamaguchi. (Japan)
- 31. **Using the Earliest Available Claims Data for Influenza Vaccine Safety Surveillance in Mini-Sentinel [798]**  
W Katherine Yih, Lauren Zichittella, Sukhminder K Sandhu, Michael Nguyen, Martin Kulldorff, David V Cole, Robert Jin, Alison T Kawai, Cheryl N McMahill-Walraven, Nandini Selvam, Mano S Selvan, Grace M Lee. (United States)
- 32. **Long-Acting Bronchodilators and Risk of Adverse Cardiovascular Events in Chronic Obstructive Pulmonary Disease: A Focused Critical Review [799]**  
Sunning Tao, Erika Kirsch, Karen Yeomans, Catherine Sigler. (Canada)

**Spotlight Session-Benefit Risk Assessment, Communication and Evaluation (BRACE)**

- 33. **Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study [800]**  
Joshua J Gagne, Mehdi Najafzadeh, Niteesh K Choudhry, Katsiaryna Bykov, Kristijan H Kahler, Diane Martin, James R Rogers, Sebastian Schneeweiss. (United States)
- 34. **Benefit-Risk Analysis and Management Plan for Rare Serious Adverse Events (SAEs): Progressive Multifocal Leukoencephalopathy (PML) Case Example [801]**  
Deanna Hill, Amanda Eudy, Dimitri Bennett, Jonathon Haddad, Barbara Haight, Sarah Kavanagh, Christi Kleoudis, Eric Lewis, Susan Duke. (United States)
- 35. **Direct-To-Consumer Advertising of Medicines in Singapore: Understanding Awareness, Perception and Behavior Among the General Public [802]**  
Cheong Hian Goh, Mui-Ling Tan, Terence Tze-Yin Fong, Wai-Ping Yau. (Singapore)

- 36. **Patient Knowledge of Safe Use of ER/LA Opioid Analgesics Following Implementation of the Class-Wide REMS [803]**  
Daina B Esposito, Judith J Stephenson, M Soledad Cepeda, Paul M Coplan, Jennifer CL Hawes, Crystal N Holick, Jean-Yves Maziere, Gregory P Wedin, Stephan F Lanes. (United States)
- 37. **Impact of Risk Minimisation Measures on Citalopram Use in Two European Countries [804]**  
Inge Zomerdijk, Gianluca Trifirò, Sabine Straus, Miriam Sturkenboom. (Nepal)
- 38. **Diabetes Testing for Adults Taking Antipsychotic Drugs: Where To Target Risk Minimization Interventions [805]**  
Elaine H Morrato, Elizabeth Campagna, Sarah Brewer, Miriam Dickinson, Deborah Thomas, Richard C Lindrooth. (United States)
- 39. **Primary Care Physicians and Prescription Opioid Abuse: A National Survey [806]**  
Catherine S Hwang, Lydia W Turner, Stefan P Kruszewski, Andrew Kolodny, G Caleb Alexander. (United States)
- 40. **The Combination Tenofovir/Lamivudine (Emtricitabine) /Efavirenz (Nevirapine) Better Tolerated Than Zidovudine/ Lamivudine/Nevirapine in a Prospective Observational Study of Adverse Effects in Newly Treated Individuals in Burkina Faso [807]**  
Frank ER Zongo, Emile Ouedraogo, Souleymane Fofana, Arsène Zongo, Arsène Ouedraogo, Moussa Ouedraogo. (Canada)

**Benefit Risk Assessment, Communication and Evaluation (BRACE)**

- 41. **ECG Monitoring of Hospitalised Patients Using Domperidone, Before and After Media Attention Regarding Sudden Cardiac Death [808]**  
Selma Saaid, Matthijs L Becker, Teun van Gelder, Patricia MLA van den Bemt. (Netherlands)
- 42. **Application of Quantitative Methodologies for Benefit-Risk Assessment: Case Study With Rosiglitazone and Pioglitazone [809]**  
Diogo Mendes, Carlos Alves, Francisco Batel Marques. (Portugal)
- 43. **Benefit-Risk Assessment of Statins: A Multiple Criteria Decision Analysis [810]**  
Hsing-Chun Hsieh, Jason C Hsu, Yea-Huei Kao Yang, Christine Y Lu. (Taiwan)

- 44. **Preferences of Diabetes Patients for Lipid-Lowering Treatment: A Discrete Choice Experiment [811]**  
Dianna de Vries, Sieta T de Vries, Petra Denig. (Netherlands)
- 45. **Development of a Shared Decision-Making Tool To Assist Patients and Clinicians With Assessing the Individualized Risks and Benefits of Oral Anti-Coagulation Therapy for Atrial Fibrillation [812]**  
Karen Kaiser, Wendy Cheng, Sally Jensen, Marla Clayman, Frances Schwiep, Andrew Thappa, Anita Chawla, Jeffrey J Goldberger, Nananda Col, Jeff Schein. (United States)
- 46. **Benefit-Risk Assessment of Nonprescription Diclofenac [813]**  
Eric P Brass, Jessica Swanson, Steven M Weisman. (United States)
- 47. **Defining Risk Profiles in Special Populations -Results from a Post Authorisation Safety Study (PASS) of Seroquel XL<sup>®</sup> Conducted in Primary Care in England [814]**  
Deborah Layton, Vicki Osborne, Miranda Davies, Saad Shakir. (United Kingdom)
- 48. **U.S. Women Who Could Benefit from Tamoxifen or Raloxifene for Breast Cancer Chemoprevention in 2010 [815]**  
Andrew N Freedman, Donna R Rivera, Mitchell H Gail, Barry I Graubard. (United States)
- 49. **Qualitative Research With Primary Care Clinicians and Neurologists Regarding Drug Safety Communications [816]**  
Suzanne L West, Craig Lefebvre, Lauren A McCormack, Olivia Taylor, Paula Rausch. (United States)

- 50. **Disproportionality Analysis of Cardiac Arrhythmia Events in the FDA Adverse Event Reporting System for Buprenorphine Patch [817]**  
Nelson E Sessler, Ekaterina Walker, Paul M Coplan. (United States)
- 51. **What Can Social Media Networks Contribute To Medicines Safety Surveillance? [818]**  
Preciosa M Coloma, Benedikt Becker, Miriam CJM Sturkenboom, Erik M van Mulligen, Jan A Kors. (Netherlands)
- 52. **The Use Off-Label of Thalidomide in Brazil from 2010 To 2014 [819]**  
Nair R Souza, Francisco JR Paumgarten. (Brazil)

**53. Can Online Data Lead To the Earlier Detection of Drug-Related Adverse Events? [820]**

Mei S Duh, Pierre Cremieux, Marc Van Audenrode, Francis Vekeman, Paul Karner, Haimin Zhang, Paul Greenberg. (United States)

**54. Reasons for and Time To Antipsychotic (AP) Treatment Discontinuation: Results from a Post-Authorisation Safety Study [821]**

Deborah Layton, Vicki Osborne, Miranda Davies, Saad AW Shakir. (United Kingdom)

**55. Direct Healthcare Professional Communications – Can Their Effectiveness Be Measured? [822]**

Taco Monster, Liana Martirosyan, Peter Mol. (Netherlands)

**56. Adverse Events in Patients With Advanced Non-Small Cell Lung Cancer – Findings from IMS Oncology, a US Oncology Electronic Medical Record (EMR) System [823]**

Lei Chen, Belen San Antonio, Jonathan Lucas Swain, Lucy Mitchell, William J John, Hafida Arkoub, James A Michael, Dale Quentin Marmaduke, Yuer Yan. (United States)

**57. Pattern of Postmarket Requirements and Commitments and Fda Approval of Novel Therapeutic Agents from 2003 To 2013 [824]**

Anura Deshmukh, Andres Gomez, Tzuyung D Kou. (United States)

**Risk Management  
Risk Minimization  
Communication**

**58. An Evaluation of Clinical Practices Among UK General Practitioners in Managing Individuals Attempting To Quit Smoking With Varenicline [825]**

Muhammad Younus, Kenneth R Petronis, Xiaofeng Zhou, Harshvinder Bhullar, Michelle Johnson, Shobhna Koria, Jingping Mo. (United States)

**59. Identifying Patients for Clinical Trials By Risk Stratification: The Case of an Intervention To Reduce Post-Operative Opioid Use in Total Joint Replacement [826]**

Jennifer L Kuntz, Eric S Johnson, Amanda F Petrik, Xiuhai Yang, David H Smith. (United States)

**60. Decrease in Diagnosed Abuse, Addiction, and Opioid Poisoning Among Patients Prescribed Opioids After Introduction of OxyContin With Abuse-Deterrent Characteristics [827]**

Aditi Kadakia, Paul Coplan. (United States)

**61. Bone Pain, Skeletal-Related Events and Opioid Analgesic Use in Prostate Cancer Patients With Bone Metastases [828]**

Adriana Valderrama, Sara Eapen, Kelly A Hennessey, Casey Jones, Lonnie Wen, Joseph Germino, Mei S Duh. (United States)

**62. Evaluating the Effectiveness of the Soliris REMS Program [829]**

Alexander Cole, Camille Bedrosian, Arshadul Haque, Arshad Mujeebuddin, Amanda Wilson, Jenifer Wogen, John Price. (United States)

**63. Association Between Renin-Angiotensin System Inhibitors and Cancer Risk; Data Mining of a Spontaneous Reporting Database and a Claims Database [830]**

Mai Fujimoto, Tomoya Higuchi, Kouichi Hosomi, Mitsutaka Takada. (Japan)

**64. Instructions for Clinical and Biomarker Monitoring in the Summary of Product Characteristics (SmPC) of Psychotropic Drugs: Overview and Applicability in Clinical Practice [831]**

Mariette Nederlof, Lennart J Stoker, Toine CG Egberts, Eibert R Heerdink. (Netherlands)

**65. Assessment of Metabolic Monitoring By Physicians of Patients Treated With Quetiapine in Selected European Countries [832]**

Robert S Brody, Charlie L Liss, Heather Wray, Ramon Iovin, Carmen Michaylira, Catherine Datto, Leigh Jefferies, Anneli Thuresson. (United States)

**66. Objective Assessment of Metabolic Monitoring in Patients Treated With Seroquel IR/XR in the UK and Germany Using Electronic Medical Records (EMR) [833]**

Robert S Brody, Charlie L Liss, Heather Wray, Anushini Muthutran, Catherine Datto, Leigh Jefferies. (United States)

**67. Risk Minimization and Assessment of Olanzapine Long-Acting Injection in 21 Countries in Europe [834]**

Meghan E Jones, Holland C Detke, Rashna Chhabra-Khanna. (United States)

**68. National Trends in Treatment With Prescription Medications With Risk Evaluation and Mitigation Strategies in the United States, 2003-2010 [835]**

Rachel Harrington, Dima M Qato. (United States)

**69. Trends in the Safety of New Molecular Entities and Therapeutic Biologics Approved By the FDA (1980-2014) [836]**

Enrique Seoane-Vazquez, Rosa Rodriguez-Monquiu. (United States)

**Pharmacoeconomics  
Outcomes Research**

**70. Assessing Cost-Effectiveness of HPV Vaccines with Decision Analytic Models: What Are the Distinct Challenges of Low and Middle Income Countries? A Protocol for a Systematic Review [837]**

Obinna I Ekwunife, Andreas Gerber Grote, Christoph Mosch, James F O'Mahony, Stefan K Lhachimi. (Germany)

**71. Costs, Resource Utilization, and Treatment Patterns for Patients With Metastatic Melanoma [838]**

Edmond L Toy, Michael C Lewis, Alan K Oglesby, Mei S Duh, Francis Vekeman (Canada)

**72. Clinical and Economic Benefits of Extended Treatment With Apixaban for the Treatment and Prevention of Recurrent Venous Thromboembolism in Canada [839]**

Peter Quon, Hoa H Le, Vincent Raymond, Mondher Mtibaa, Andriy Moshyk. (United States)

**73. The QUA-VKA Study To Identify New Risk Factors for Bleeding During Treatment With Vitamin K Antagonists: Objectives and Design [840]**

Nienke van Rein, Mettine HA Bos, Willem M Lijfering, Felix JM van der Meer, Pieter H Reitsma. (Netherlands)

**74. Rivaroxaban Versus Warfarin: Effect on Healthcare Resource Utilization and Costs in Nonvalvular Atrial Fibrillation Patients [841]**

François Laliberté, Concetta Crivera, Winnie W Nelson, William H Olson, Jeffrey Schein, Guillaume Germain, Patrick Lefebvre. (Canada)

**75. Health Utilities Associated With Bleeding Control and Adverse Events in Premenopausal Women With Uterine Fibroids [842]**

Seung-Mi Lee, Insun Choi, Soyun Kim, Sung-Jin Park, Dong-churl Suh. (Republic of Korea)

**76. A Cost-Effectiveness Analysis of Opioid Substitution Therapy Upon Release in Reducing Mortality Among Prisoners With a History of Opioid Dependence [843]**

Natasa Gisev, Marian Shanahan, Don J Weatherburn, Richard P Mattick, Sarah Larney, Lucy Burns, Louisa Degenhardt. (Australia)

**77. A Cost Comparison of Split-Dose Reduced-Volume Oral Sulfate Solution (OSS) and Polyethylene Glycol With Electrolytes Solution (PEG-ELS) [844]**

Mark Cleveland, Sander Yermakov, Matthew Davis, Romaine Campbell, Lynn Huynh, Francis A Farraye, Mihran Yenikomshian. (United States)



- 78. Impact of Intensive and Maintenance Treatment of Pulmonary Tuberculosis on Respiration-Quality of Life in Indonesia [845]**  
J Atthobari, H Firmansyah, UA Mulyani, D Perwitasari. (Indonesia)
- 79. Cost Effectiveness of Melanoma Therapies [846]**  
Karissa M Johnston, Emily McPherson, Katherine Osenenko, Joanna Vergidis, Adrian Levy. (Canada)
- 80. Predictors of High Healthcare Resource Utilization and Liver Disease Progression Among Patients With Chronic Hepatitis C [847]**  
Joyce LaMori, Neeta Tandon, François Laliberté, Guillaume Germain, Dominic Pilon, Patrick Lefebvre, Avinash Prabhakar. (Canada)
- 81. Outcomes and Patterns of Health Care Usage Among Acute Ischemic Stroke Patients in Canada [848]**  
qaAnne-Marie Castilloux, K. Tore Jørgensen, F. Coste, Yola Moride. (Canada)
- 82. Patterns of Health Care Utilization Among Patients Hospitalized for Acute Ischemic Stroke (AIS) in Canada [849]**  
Anne-Marie Castilloux, K. Tore, F. Coste, Yola Moride. (Canada)
- 83. A Descriptive Analysis of a Real-World Population With Chronic Hepatitis C (CHC) Treated With Simeprevir (SMV)- And/ Or Sofosbuvir (SOF)-Based Regimens: Findings from a US Payer Database [850]**  
Jamie B Forlenza, Jonathan Fortier, François Laliberté, Patrick Lefebvre, Neeta Tandon. (Canada)
- 84. Pulmonologist Involvement and Overall Survival in Newly-Diagnosed Extensive Stage Small Cell Lung Cancer Patients [851]**  
Xinyi Ng, Janaki A Deepak, Josephine Feliciano, Amy J Davidoff. (United States)

**Spotlight Session-Adherence**

- 85. Impact of Persistence and Adherence on Mortality in Women Treated With Hormonal Breast Cancer Therapy: A Nested Case Control Study in a French Nationwide Database [852]**  
Pauline Bosco-Levy, Annie Fourier-Reglat, Simone Mathoulin-Pelissier, Nicholas Moore, Julien Bezin. (France)
- 86. Persistence and Compliance With Lipid-Lowering Drugs in Patients With Chronic Kidney Disease [853]**  
Viet Thanh Truong, Jocelyne Moisan, Edeltraut Kroger, Serge Langlois, Jean-Pierre Gregoire. (Canada)

- 87. The Adherence To Inhaled Drugs in COPD Patients: Effect on Survival [854]**  
Valeria Belleudi, Nera Agabiti, Mirko Di Martino, Silvia Cascini, Ursula Kirchmayer, Riccardo Pistelli, Danilo Fusco, Marina Davoli. (Italy)
- 88. Comparative Adherence of ICS/LABA Products in Elderly Asthma Patients [855]**  
Mina Tadrous, Diana Martins, Zhan Yao, Matthew Stanbrook, Samantha Singh, David N Juurlink, Muhammad M Mamdani, Tara Gomes. (Canada)
- 89. E-Monitoring of Asthma Therapy To Improve Compliance in Children (E-MATIC) [856]**  
Erwin C Vasbinder, Lucas MA Goossens, Hettie Janssens, Brenda CM De Winter, Liset Van Dijk, Arnold G Vulto, Maureen PMH Rutten, Patricia MLA Van den Bemt. (Netherlands)
- 90. Effects of Breast Cancer on Chronic Disease Medication Adherence in Elderly Women [857]**  
Melissa L Santorelli, Hirshfield M Kim, Michael B Steinberg, Kitaw Demissie. (United States)
- 91. Primary Non-Adherence To Antidepressants: Differences By Class [858]**  
Heather D Anderson, Gerald E Pulver, Sam L Ellis, Mykel G Walsh, John T Lynch, Robert J Valuck. (United States)
- 92. Validity of Pharmacy-Based Adherence Measures in Individuals With Type 2 Diabetes [859]**  
Arsène Zongo, Jocelyne Moisan, Jean-Pierre Grégoire, Line Guénette. (Canada)

**Adherence**

- 93. Persistence of Proton Pump Inhibitor Refills in Community Pharmacies [860]**  
Emre Yucel, Aylin Yucel, Latif Ozbay. (United States)
- 94. Liver Outcomes and Mortality Among Patients Newly-Diagnosed With Hepatitis C Virus Infection in Israel During the Period 2006-2011 [861]**  
Clara Weil, David R Walker, Varda Shalev, Mira Friedman, Gabriel Chodick. (United States)
- 95. Adherence To Interferon-Based Treatment Among Patients Newly-Diagnosed With Hepatitis C Virus in Israel During the Period 2006-2011 [862]**  
Clara Weil, David R Walker, Varda Shalev, Mira Friedman, Gabriel Chodick. (United States)

- 96. Determinants of Patient Adherence To Imatinib – A Retrospective Study in a Malaysian Teaching Hospital [863]**  
Sharmini Balashanker, Li-Chia Chen, Chelsea AM Taylor, Siew Siang Chua, Izam EM Zakaria. (Malaysia)
- 97. Development of a New Methotrexate (MTX)-Specific Adherence Tool for Use in the Management of Patients With Rheumatoid Arthritis (RA) [864]**  
Jeffrey R Curtis, Maher Aassi, Carla Dias Barbosa, Corrado Bernasconi, Michel Brethous, Benoit Arnaud. (United States)
- 98. Medication Adherence in Chronic Myeloid Leukemia and Patients' Need for Information [865]**  
Christel Boons, Lonneke Timmers, Jeroen Janssen, Jan de Jong, Eleonora Swart, Jacqueline Hugtenburg. (The Netherlands)
- 99. 470 Trajectories of Adherence To Thienopyridines After Coronary Stenting in Patients on Dialysis [866]**  
Jenny I Shen, Tara I Chang, Maria E Montez-Rath, Wolfgang C Winkelmayr. (United States)
- 100. Preliminary Analyses of Primary Adherence and Persistence To Antihypertensive Therapy in Portuguese Primary Care Units [867]**  
André F Coelho, Pedro A Caetano. (Portugal)
- 101. Use of the Guideline-Recommended Drugs After a First Acute Myocardial Infarction in the Province of Québec in the Elderly: Effect of Deprivation and Sex [868]**  
Adjo E Akator, Claudia Blais, Phillippe Gamache, Guénette Line. (Canada)

- 102. Patterns of Statin Use Following Initiation of Lipid Lowering Therapy in a Commercial Insurer's Administrative Database [869]**  
Florence T Wang, Ling Li, Laura Yochum, Ben Taylor, Robin Clifford, John D Seeger. (United States)
- 103. Factors Influencing Adherence and Persistence To Cardiovascular Medications: A Systematic Review [870]**  
Danielle M van der Laan, Petra JM Elders, Christel CLM Boons, Giel Nijpels, Jacqueline G Hugtenburg. (The Netherlands)
- 104. Factors Associated With Non-Adherence To Cardiovascular Medication: A Comparison Between Pharmacy Refill and Self-Report Methods [871]**  
Danielle M van der Laan, Petra JM Elders, Christel CLM Boons, Giel Nijpels, Jacqueline G Hugtenburg. (The Netherlands)



- 105. Primary Non-Adherence Associated With Rosuvastatin from Electronic Health Record (EHR) Prescribing Data in the United States [872]**  
Christopher G Rowan, Nikita Stempniewicz, James Flory, Tobias Gerhard, James D Lewis, John Cuddeback, Sean Hennessy. (United States)
- 106. Medication Possession Ratio Associated With Rosuvastatin from Electronic Health Record (EHR) Prescribing Data in the United States [873]**  
Christopher G Rowan, Nikita Stempniewicz, James Flory, Tobias Gerhard, James D Lewis, John Cuddeback, Sean Hennessy. (United States)
- 107. Patterns of Testosterone Persistence and Switching Among Commercially-Insured Men in the United States [874]**  
J Bradley Layton, Dongmei Li, Julie L Sharpless, Til Stürmer, M Alan Brookhart. (United States)
- 108. Gout Control Among Hypertensive Patients With Gout and the Relationship To Onset of End-Stage Renal Disease [875]**  
Sylvie Perreault, Javier Nuevo, Scott Baumgartner, Rob Morlock. (Canada)
- 109. Adherence and Persistence To Allopurinol Among Hypertensive Patients With Gout [876]**  
Sylvie Perreault, Javier Nuevo, Scott Baumgartner, Rob Morlock. (Canada)
- 110. Patient and Policy-Level Determinants of Long-Acting Injectable Antipsychotic Use After Relapse: A Nationwide Study of Schizophrenia Patients in the United States [877]**  
John W Jackson, Lisa Fulchino, James Rogers, Jennifer Polinski, David C Henderson, Sebastian Schneeweiss, Michael A Fischer. (United States)
- 111. Persistence of Stimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Longitudinal Study [878]**  
Sneha Sura, Satabdi Chatterjee, Pravin Kamble, Rajender Aparasu. (United States)
- 112. Utilization and Adherence Pattern of Generic and Brand-Name Drugs in the Treatment of Epilepsy [879]**  
Chao Chen, Ramon E Bautista, Abraham G Hartzema. (United States)
- 113. Drug Utilization and Adherence in Multiple Sclerosis Patients – A Nationwide Observational Study in Taiwan [880]**  
Chih-Ho Chou, Tzu-Chieh Lin, Ching-lan Cheng, Yea-Huei Kao Yang. (Taiwan)
- 114. Adherence To Inhaled Corticosteroids in Asthmatic Children in Dutch Primary Care [881]**  
Marjolein Engelkes, Hettie M Janssens, Johan C de Jongste, Miriam CJM Sturkenboom, Katia MC Verhamme. (Netherlands)
- 115. Longitudinal Inhaled Corticosteroid Adherence Using Multiple Methods To Calculate Medication Possession Ratios [882]**  
Patrick C Souverein, Ellen S Koster, Alexandra L Dima, Gene Colice. (Netherlands)
- 116. Multi-Dose Drug Dispensing as a Tool To Improve Medication Adherence: A Crossover Study [883]**  
Nienke van Rein, Kristel S de Geus, Suzanne C Cannegieter, Pieter H Reitsma, Felix JM van der Meer, Willem M Lijfering. (Netherlands)
- 117. The Impact of Adherence To Antidiabetic Medications on Glycaemic Control in Type 2 Diabetes Patients [884]**  
Alison K Wright, Darren M Ashcroft, Martin K Rutter, Richard Emsley, Douglas T Steinke. (United Kingdom)
- 118. Improving Adherence Measurement for Applied Pharmacoepidemiology: Estimating the Association Between Endocrine Therapy Adherence and Mortality Among Women With Breast Cancer [885]**  
Aaron N Winn, Stacie B Dusetzina. (United States)
- 119. Adherence and Persistence To Anticoagulants and Its Effect on Risk of Recurrence of Venous Thromboembolism – A Systematic Review [886]**  
Pareen Vora, Gunnar Brobert, Kiliana Suzart-Woischnik, Montse Soriano-Gabarró. (Germany)
- 120. Single Versus Multi-Tablet Fixed Dose Combination (FDC) HIV Treatment Regimens: A Systematic Literature Review and Meta-Analysis [887]**  
Siva Narayanan, Soma Nag, Camelia M Graham, Patrick G Clay. (United States)
- 121. The Impact of Pharmacist-Led Educational Interventions on Medication Adherence and Polypharmacy in Geriatric Patients in Malaysia [888]**  
Muhammad Shahid Iqbal, Muhammad Zahid Iqbal, Muhammad Waseem Iqbal, Mohd Baidi Bahari. (Malaysia)
- 122. Impact of Out-Of-Pocket Expenses on Medication Adherence in Patients Covered By Private Drug Insurance Plans [889]**  
François Després, Amélie Forget, Fatima-Zohra Kettani, Lucie Blais. (Canada)
- 123. Switching Antihypertensive Drug Class in Primary Healthcare: The Swedish Primary Care Cardiovascular Database (SPCCD) [890]**  
Miriam Qvarnström, Thomas Kahan, Helle Kieler, Lena Brandt, Jan Hasselström, Kristina Bengtsson Boström, Karin Manhem, Per Hjerpe, Björn Wettermark. (Sweden)
- 124. Health Professionals' Perceptions About Oral Anticancer Drugs Adherence and Shared Decision Making in Belgium and the Netherlands [891]**  
Mathieu Verbrugge, Lonneke Timmers, Christel CLM Boons, Bart FJ Van den Bemt, Jacqueline G Hugtenburg, Ann Van Hecke. (Netherlands)
- 125. "I Just Forget To Take It"- New Media for Asthma Self Management: Assessment of Teenagers' Preferences [892]**  
Ellen S Koster, Daphne Philbert, Tjalling W de Vries, Liset van Dijk, Marcel L Bouvy, Patrick Souverein. (Netherlands)

## Spotlight Session-Databases

- 126. Use of Electronic Health Records To Evaluate Drug Safety: Example for the Incidence of Non-Melanoma Skin Cancer in Patients With Myelofibrosis [893]**  
Alex Allepuz, Iulian Alecu, Andreas Brueckner, Norbert Hollaender, Katarina Sablinska. (Spain)
- 127. Incidence of Multiple Sclerosis in Germany [894]**  
Lasse Pachaly, Edeltraut Garbe, Dunya Bentama, Laura Khil, Klaus Berger, Niklas Schmedt. (Germany)
- 128. Validation of Claims Algorithms for Progression To Metastatic Cancer in Patients With Breast, Non-Small Cell Lung, and Colorectal Cancer [895]**  
Jason C Simeone, Beth L Nordstrom, Karen G Malley, Kathy H Fraeman, Zandra Klippel, Mark Durst, John H Page, Hairong Xu. (United States)
- 129. On the Accuracy of Using Natural Language Processing Techniques for the Surveillance of Hospital-Acquired Pneumonia [896]**  
Christian M Rochefort, Aman D Verma, Tewodros Eguale, David L Buckeridge. (Canada)
- 130. Impact of Case Definition on Disease Incidence Rates Estimated from Administrative Claims Databases [897]**  
Daina B Esposito, Lina Titievsky, Jennifer CL Hawes, Crystal N Holick, Stephan Lanes. (United States)



- 131. Getting the Right Cohort: Effect of Inclusion Criteria in Studies Using EMR and Claims [898]**  
Emma Brinkley, Christina Mack, Tongsheng Wang, Kathy Lang. (United States)
- 132. Validity of Cancer Diagnoses in General Practitioner Medical Records [899]**  
Joan Fortuny, James A Kaye, Andrea V Margulis, Estel Plana, Brian Calingaert, Susana Perez-Gutthann, Alejandro Arana. (Spain)
- 133. Development of a Risk Model for Drug-Associated Inpatient Falls [900]**  
Yoonyoung Choi, Benjamin Staley, Carl Henriksen, Paul Kubilis, Gigi Lipori, Babette Brumback, Almut G Winterstein. (United States)

**Databases**

- 134. Detection and Validation of Ototoxicity Associated With Anticancer Platinum Drugs Using a Hospital Database [901]**  
Katsuhito Hori, Ayami Kato, Junichi Kawakami. (Japan)
- 135. Impact of the Sharp Changes in the Use of Contraception in 2013 on the Risk of Pulmonary Embolism in France [902]**  
Aurore Tricotel, Cédric Collin, Mahmoud Zureik. (France)
- 136. Risk of Fractures in Patients With Diabetes Mellitus Type 2 – Results of a Database Analysis in the Primary Care Setting in Germany [903]**  
Karel Kostev, Birgit Ehlken, Franz-Werner Dippel, Wolfgang Rathmann. (Germany)
- 137. Hormonal Therapy for Breast Cancer and Diabetes Incidence Among Postmenopausal Women [904]**  
Melissa L Santorelli, Tobias Gerhard, Kitaw Demissie. (United States)
- 138. Does Aspirin Use in Myocardial Infarction Patients Increase the Risk of Neovascular Age-Related Macular Degeneration [905]**  
Wan-Ju Annabelle Lee, Ching-Lan Cheng, Yea-Huei Kao Yang. (Taiwan)
- 139. The Incremental Impact of Cardiovascular (CV) Disease on the Health-Related Quality of Life (HRQoL) of Canadians With and Without Diabetes Mellitus (DM) [906]**  
Shelagh M Szabo, Karissa M Johnston, Hugh D Tildesley, Adrian R Levy. (Canada)
- 140. Comorbid Diagnostic Categories in Myotonic Dystrophy [907]**  
Cynthia Jones, Maneesh Juneja, Anne Dille. (United States)

- 141. Anesthesia Exposure and Risk of Dementia and Alzheimer's Disease: A Prospective Study [908]**  
Erin JA Bowles, Eric B Larson, Ryan P Pong, Rod L Walker, Melissa Anderson, Onchee Yu, Shelly Gray, Paul K Crane, Sascha Dublin. (United States)
- 142. Susceptibility To Infection Before Diagnosis of Primary Chronic Immune Thrombocytopenia [909]**  
Charlotta Ekstrand, Marie Linder, Honar Cherif, Helle Kieler, Shahram Bahmanyar. (Sweden)
- 143. Non-Infectious Wound Complications After Mastectomy Result in Additional Surgical Procedures and Early Breast Implant Loss [910]**  
Katelin B Nickel, Ida K Fox, Julie A Margenthaler, Anna E Wallace, Victoria J Fraser, Margaret A Olsen. (United States)
- 144. Withdrawn By Author**
- 145. Withdrawn By Author**
- 146. Incidence and Predictors for Hospitalization Among Patients With Heart Failure in the UK Using Linked Primary Care and Hospitalization Data [913]**  
Ana Ruigómez, Alexander Michel, Mar Martín-Perez, Luis-Alberto García-Rodríguez. (Spain)
- 147. Risk for Cardiovascular Disease in Japanese Patients With Rheumatoid Arthritis: A Large-Scale Epidemiological Study Using a Healthcare Database [914]**  
Kunihiko Tanaka, Kenji Hamada, Terumi Nakayama, Akihide Atsumi, Shinichi Matsuda, Tomomi Shimura, Masatomi Nemoto. (Japan)
- 148. Demographic, Co-Morbid Conditions, and Drug Utilization of Stroke Patients in a Large US Health Insurance Claims Database [915]**  
Nicholas J Everage, Sarah Gheuens, Sandra Richman, Anne Dille, Maneesh Juneja, Madé Wenten. (United States)
- 149. Incidence of Depression in Patients With Diabetes in Quebec: A Population-Based Cohort Study [916]**  
Carlotta Lunghi, Jocelyne Moisan, Jean-Pierre Grégoire, Line Guénette. (Canada)
- 150. Challenges of Identifying Relapses Among MS Patients in a Health Plan Database [917]**  
Florence T Wang, Nan Liu, Eva Ng, Audrey Muller, Daniele D'Ambrosio, Ewa Lindenstrøm, Cheryl Enger. (United States)
- 151. NFL Injury Surveillance and Analytics: Improving Data Collection Through Use of Electronic Health Records (EHR) [918]**  
Christina D Mack, Kristina Franke, Owen McCarron, Allison Bryant, Rachel Jablonski, Michael Barboza, Nancy A Dreyer. (United States)

- 152. Feasibility Analysis of Myopic Chroidal Neovascularization (mCNV) Recording Using the THIN Database [919]**  
Zdravko P Vassilev, Maria E Sáez, Antonio González-Pérez, Luis A García-Rodríguez. (United States)
- 153. Contrasting Adverse Event Rates Among Medicare Beneficiaries With High Cardiovascular Disease Risk Taking Statins [920]**  
Paul Muntner, Shia T Kent, Robert S Rosenson, Keri L Monda, Meredith Kilgore, Hong Zhao, Angelika D Manthripragada. (United States)
- 154. Suicide Incidence in Post-Menopausal Women With Breast Cancer [921]**  
Alex Allepuz, Katarina Sablinska. (Spain)
- 155. The Burden of Gout in a Primary Care Canadian Population With Uncontrolled Urate Levels [922]**  
Dawn M Williams, Cory Cowan, Alain Gendron, Jason Goodfield, Driss Oraichi, Aren Fischer, Richard Borrelli, Neil Liu, Alison Dziarmaga. (Canada)
- 156. Effects of Methotrexate on the Risk of Myocardial Infarction Among Canadian Patients With Psoriasis and Psoriatic Arthritis [923]**  
Marie-Christyne Cyr, Robert Bissonnette, Jean Lachaine. (Canada)
- 157. Development of an Approach To Identify and Quantify Statin Intolerance Using Claims Data [924]**  
Paul Muntner, Shia T Kent, Robert S Rosenson, Keri L Monda, Lei Huang, Hong Zhao, Jeffrey R Curtis, Meredith Kilgore, Angelika D Manthripragada. (United States)
- 158. Usage Patterns of Paracetamol in France [925]**  
Mai TT Duong, Abdelilah Abouelfath, Regis Lassalle, Cecile Droz, Nicholas Moore. (France)
- 159. Comparison of Claims for Sickle Cell Disease Patients Across 3 US Health Insurance Databases [926]**  
Nancy N Maserejian, Li Li, Maneesh Juneja, William Hobbs. (United States)
- 160. Effects of a Reimbursement Restriction of Proton Pump Inhibitors Among Patients With an increased Risk of Gastric Complications [927]**  
Linda E Flinterman, Karin Hek, Joke Korevaar, Liset van Dijk. (Netherlands)
- 161. The Swedish Prescribed Drug Register in the Scientific Literature 2005-2013 – A Literature Review [928]**  
Mikael Hoffmann, Susanna Wallerstedt, Björn Wettermark. (Sweden)



- 162. Applying the Common Data Model To Analyze Multiple Claims Databases in a Study of Lymphoma Among Treated Rheumatoid Arthritis Patients [929]**  
Nicole Baker, Hugh Kawabata, Vidya Moorthy, Samy Suissa, Teresa A Simon. (United States)
- 163. Application of Marginal Structural Models To Unbalanced Longitudinal Health Data [930]**  
Edmore Chamapiwa, David Reeves, Darren Ashcroft, Evangelos Kontopantelis, David Springate. (United Kingdom)
- 164. Assessing the Agreement of Hospitalization Estimates Between Three Nationally Representative US Hospital Discharge Databases, the Nationwide Inpatient Sample (NIS), the National Hospital Discharge Survey (NHDS) and the Kid's Inpatient Database (KID) [931]**  
Abigail Doucette, Elizabeth Hedgeman, Jon Fryzek. (United States)
- 165. Standardizing Event Rates in Non-Representative Data: An Applied Example [932]**  
Mitchell M Conover, Suzanne Landi, Michele Jonsson Funk. (United States)
- 166. Leveraging Real-Time Pharmacy Data from a Managed Care Organization To Collect Patient Reported Outcomes in a Real World Setting [933]**  
Suvapun Bunniran, Brandon Suehs, Cralen Davis, Claudia Uribe, Daniel Ng, Thomas Yuran, Maria Vassilakis, Matt Zajack, Hugh Lee. (United States)
- 167. Relevant Automated Healthcare Databases To Perform Studies in Oncology: Easy To Find? [934]**  
Stephan Linden, Fatemeh Asadzadeh Vostakolaei, Dorothee B Bartels, Patrice Verpillat. (Germany)
- 168. Validity of Cancer Diagnosis in UK Primary Care Databases: Comparison of Observed and Expected Cancer Incidence Rates [935]**  
Michael Rañopa, Ian Douglas, Tjeerd van Staa, Liam Smeeth, Krishnan Bhaskaran. (United Kingdom)
- 169. A Study on Treatment and Characteristics of Prostate Cancer Patients Using Real-World Data [936]**  
Jamilette Miranda, Birgitta Lilja, Björn Wettermark, Gunnar Ljunggren, Roger Henriksson. (Sweden)
- 170. Validation of Laboratory Values in a Heterogeneous Healthcare System: The US Veterans Affairs Experience [937]**  
Sanjay P Raju, Yuk-Lam Ho, Andrew Zimolzak, Beth Katcher, Valmeek Kudesia, Kelly Cho, David R Gagnon. (United States)
- 171. Identification of Device Attributes of Total Hip Replacements Via Linkage To the Veterans Health Administration's National Prosthetic Patient Database [938]**  
Katherine Etter, Art Sedrakyan, David D Dore. (United States)
- 172. Opportunities and Challenges of Using Real World Data in Oncology: Demonstrations of Truven MarketScan and IMS Oncology Electronic Medical Records Databases [939]**  
Lei Chen, Cinira Lefèvre, James A Michael, Dale Quentin Marmaduke, Jonathan Lucas Swain, Lucy Mitchell, Yu Yan. (United States)
- 173. Identifying Cases of Type 2 Diabetes from Heterogeneous Data Sources: Strategy from the EMIF Project [940]**  
Giuseppe Roberto, Ingrid Leal, Naveed Sattar, Katrina Loomis, Paul Avillach, Peter Egger, Rients van Wijngaarden, David Ansell, Sulev Reisberg, Alessandro Pasqua, Lars Pedersen, James Cunningham, Lara Tramontan, Miguel Angel Mayer, Ron Herings, Preciosa Coloma, Francesco Lapi, Miriam Sturkenboom, Johan van der Lei, Martijn Schuemie, Peter Rijnbeek, Rosa Gini. (Italy)
- 174. Refinement of a Generalized Natural Language Processing Algorithm for the Identification of Clinical Terms from Free-Text Clinical Notes [941]**  
Anthony P Nunes, Kathleen M Mortimer, Jeanne Loughlin, Florence T Wang, David D Dore. (United States)
- 175. Validation of Treatment Codes in the Danish National Patient Register [942]**  
Uffe Heide-Jørgensen, Maja Hellfritzsch, Henriette Kristoffersen, Vera Ehrenstein (Denmark)
- 176. The Use of Heatmaps for the Visualisation of Secular Trends of Data Completeness for Individual Variables: A Study Using the R Shiny Package [943]**  
Eduardo Hermosilla, Josep Maria Elorza, Manuel Medina-Peralta, Daniel Prieto-Alhambra. (United Kingdom)
- 177. Automatic Identification of Stages of Type 2 Diabetes, Hypertension, Ischaemic Heart Disease and Heart Failure from Italian General Practitioners' Electronic Medical Records: A Validation Study [944]**  
Rosa Gini, Martijn Schuemie, Giampiero Mazzaglia, Francesco Lapi, Paolo Francesconi, Alessandro Pasqua, Carmelo Montalbano, Valentina Barletta, Iacopo Cricelli, Claudio Cricelli, Mariadonata Bellentani, Miriam Sturkenboom, Niek Klazinga. (Italy)
- 178. Identifying Chronic Conditions from Data Sources With Incomplete Diagnostic Information: The Case of Italian Administrative Databases [945]**  
Rosa Gini, Martijn Schuemie, Alessandro Pasqua, Patrizio Dazzi, Emanuele Carlini, Massimo Coppola, Iacopo Cricelli, Valentina Barletta, Paolo Francesconi, Francesco Profili, Francesco Lapi, Andrea Donatini, Mario Saugo, Giulia Dal Co, Mariadonata Bellentani, Niek Klazinga, Miriam Sturkenboom. (Italy)
- 179. Evaluating CPRD GOLD Recording Sensitivity of Selected Chronic Conditions Recorded in HES Hospital Data [946]**  
Amy Matcho, Patrick Ryan. (United States)
- 180. An Audit of Patients Transferred Out of the Health Improvement Network (THIN) – A UK Primary Care Database [947]**  
Melissa Myland, David Ansell, Ahmed Nasser, Fiona Hill, Caroline J O'Leary. (United Kingdom)
- 181. The Incidence of Solid Tumors in a Healthcare Database Compared To SEER [948]**  
Chintan Dave, Jinghua He, Almut Winterstein, Abraham Hartzema. (United States)
- 182. Development of Common Data Model Using Clininformatics Datamart Database and Its Application in a Descriptive Analysis of Diabetes Population [949]**  
Ling Zhang, Lili Wang, Jusmanda Wu, Juhaeri Juhaeri, Yunxun Wang, Ali Pasha. (United States)
- 183. Comparison of Beta Coefficient Versus Risk Ratio Based Scoring System To Assign Weights To Comorbidity Score [950]**  
Hemalkumar B Mehta, Vinay Mehta, Cynthia Girman, Michael L Johnson. (United States)
- 184. The Apparent Effect of Oral Contraceptives on the Risk of Venous Thromboembolism Depends on the Length of the Look-Back Period [951]**  
Anders H Riis, Martin B Johansen, M Alan Brookhart, Til Stürmer, Henrik Størvring. (Denmark)
- 185. Addressing Confounding Through Extreme Cohort Restriction in Large Datasets: CNODES Analysis of PPIs and Pneumonia [952]**  
Dan Chateau, Kristian B Filion, Laura E Targownik, Matthew Dahl. (Canada)
- 186. Impact of the Start of Follow-Up on Estimates of Incidence Rates of Prespecified Outcomes Following Administration of 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) [953]**  
Lina Titievsky, Daina B Esposito, Jennifer CL Hawes, Crystal N Holick, Robert Maroko, Rosalind C Hollingsworth, Stephan Lanes. (United States)



- 187. Exploring Methods To Measure the Prevalence of Ménière's Disease (MD) in the US Clinformatics™ Database, 2009-2012 [954]**  
Kristen Ricchetti-Masterson, Molly L Aldridge, Nittaya Suppapanya, John Logie, Suzanne F Cook. (United States)
- 188. Hybrid Prospective Studies: Combining Existing and New Data Sources To Achieve Research Goals [955]**  
Christina D Mack, Ann Marie McNeil, Louise Parmenter, Kourtney Davis, Nancy A Dreyer. (United States)
- 189. The Risk of Cardiovascular Events With Clarithromycin: A Comparison of Self-Controlled and Propensity Score Methodologies [956]**  
Adrian A Root, Angel YS Wong, Yonas Ghebremichael-Weldeselassie, Liam Smeeth, Krishnan Bhaskaran, Stephen Evans, Ruth Brauer, Ian CK Wong, Vidya Navaratnam, Ian Douglas. (United Kingdom)
- 190. Comparing Incidence of Serious Adverse Events Between Laninamivir and Non-User of Neuraminidase Inhibitor in Influenza Patients [957]**  
Shimpei Niwa, Masato Fukushima, Kazuhito Shiosakai, Yasushi Hasebe. (Japan)
- 191. Standardised Classification Not Suitable for Spontaneous Reporting: The Example of Osteonecrosis of the Jaw [958]**  
Paul de Boissieu, Brahim Azzouz, Caroline Saint Martin, Thierry Trenque. (France)
- 192. Consequences of Drugs Withdrawal: The Examples of Pioglitazone and Dextropropoxyphene in France [959]**  
Cecile Pageot, Julien Bezin, Theo Larrousse, Francesco Salvo, Mickael Arnaud, Francoise Haramburu, Antoine Pariente. (France)
- 193. Long-Term Cancer Surveillance: Five-Year Update for the Forteo Patient Registry Surveillance Study [960]**  
David Harris, Alicia Gilsenan, Abenah Harding, Elizabeth Andrews, Nicole Kellier, Daniel Masica. (United States)
- 194. Safety Assessment and Selection Bias: Who Uses Social Media To Communicate About Medications? [961]**  
Rachael L DiSantostefano, Jeffery L Painter, Michele Thomas, Greg Powell. (United States)
- 195. A Rapid Reporting and Active Surveillance System for Adverse Drug Events Based on Electronic Medical Records: Status and Perspective [962]**  
Ying Liu, Yexiang Zhang, Yu Yang, Shengfeng Wang, Renfei Fang, Siyan Zhan, Jianxiang Deng. (China)
- 196. Minimizing Competition Bias in Signal Detection from Spontaneous Reporting Databases [963]**  
Mickael Arnaud, Francesco Salvo, Moore Nicholas, Bégau Bernard, Pariente Antoine. (France)
- 197. A Review of Databases Used for Pharmacoepidemiology in China [964]**  
Yang Zhang, Zhi Qu, Yuji Feng, Kui Huang, Xiaofeng Zhou, Siyan Zhan, Yu Yang. (China)
- 198. Detecting Early Drug Safety Signals Utilizing Data from Individual Case Safety Reports and Electronic Medical Records [965]**  
Kristina Juhlin, Alex Asiimwe, Daniel Soeria-Atmadja, Susanna Cederholm, David Ansell, I Ralph Edwards, Andrew Bate, Kristina Star, G Niklas Norén. (Sweden)
- 199. Evaluation of Internet Social Networks Using Net Scoring Tool: A Case Study in Adverse Drug Reaction Mining [966]**  
Sandrine Katsahian, Agnès Lillo Le Louet, Redhouane Abdellaoui, Nathalie Texier, Cédric Bousquet, Abdelali Boussadi, Carole Faviez, ADR Prism Study Goup. (France)
- 200. Cardiovascular Risk of Over-The-Counter Non-Steroidal Anti-Inflammatory Drugs in the French National Claims Database [967]**  
Mai TT Duong, Abdelilah Abouelfath, Regis Lassalle, Cecile Droz, Nicholas Moore. (France)
- 201. Multidimensional Indicators for Mortality Prediction in Community-Dwelling Older People in a UK Nationwide Healthcare Database: Data from the EU-Funded MPI-AGE Project [968]**  
Janet Sultana, Andrea Fontana, Francesco Giorgianni, Alberto Pilotto, Miriam Sturkenboom, Gianluca Trifiro'. (Italy)
- 202. Breast Cancer Risk With Long-Term Use of Calcium Channel Blockers or Angiotensin Converting Enzyme Inhibitors Among Postmenopausal Women [969]**  
Marsha A Raebel, Chan Zeng, Heather Spencer Feigelson, Susan Shetterly, Nikki M Carroll, Kristin Goddard, Denise M Boudreau, David H Smith, T Craig Cheetham, Heather Tavel, Stanley Xu. (United States)
- 203. Risk of Acute Myocardial Infarction During Use of Individual NSAIDs: A Nested Case-Control Study in the SOS Project [970]**  
Gwen MC Masclee, Huub Straatman, Ron Herings, Edeltraut Garbe, Tania Schink, Bianca Kollhorst, Andrea Arfe, Silvia Lucchi, Marco Villa, Jordi Castellsague, Susana Perez-Gutthann, Cristina Varas-Lorenzo, Silvana Romio, Rene Schade, Martijn J Schuemie, Vera E Valkhoff, Miriam CJM Sturkenboom. (Netherlands)
- 204. Fracture Healing Complication (FHC) in Women With Postmenopausal Osteoporosis (PMO) Exposed To Bisphosphonate (BP) Versus Other or No Osteoporosis Medication (OPM) [971]**  
Fei Xue, Yessenia Bartley, Victor Gastanaga, Chuck Wentworth. (United States)
- 205. Antidepressants and the Risk of Hip Fractures [972]**  
Tania Schink, Kathrin Jobski, Niklas Schmedt, Bianca Kollhorst, Edeltraut Garbe. (Germany)
- 206. Antipsychotics and the Risk of Hip Fractures [973]**  
Tania Schink, Niklas Schmedt, Kathrin Jobski, Bianca Kollhorst, Edeltraut Garbe. (Germany)
- 207. Risk of Major Cardiovascular Events During Second-Line Antidiabetic Treatments: A Population-Based Cohort Study [974]**  
Salwa S Zghebi, Douglas T Steinke, Martin K Rutter, Richard A Emsley, Darren M Ashcroft. (United Kingdom)
- 208. 30-year Mortality Following Coronary Artery Bypass Graft Surgery: A Nationwide Population-Based Cohort Study [975]**  
Kasper Adelborg, Erzsébet Horváth-Puhó, Morten Schmidt, Troels Munch, Lars Pedersen, Henrik Toft Sørensen. (Denmark)
- 209. What Is the Optimal Second-Line Antidiabetic Regimen To Delay the Onset of Microvascular Complications? Application of a Marginal Structural Model [976]**  
Alison K Wright, Darren M Ashcroft, Martin K Rutter, Richard Emsley, Douglas T Steinke. (United Kingdom)
- 210. Validation of Endocrine Therapy Indication To Identify Breast Cancer Chemoprevention: A Feasibility Study [977]**  
Hazel B Nichols, Kala Visvanathan, Valerie S Lee, Janise M Roh, Jean X Lee, Till Stürmer, Lawrence H Kushi. (United States)
- 211. Toward Optimizing Data Structure in Cancer Registries [978]**  
Anokhi J Kapasi, Varinder Singh, Sharmila A Kamani, Judith K Jones. (United States)
- 212. Validity of Inhospital Mortality Records in the National Health Insurance Research Database Among Patients With Acute Myocardial Infarction and Stroke Cases in Taiwan [979]**  
Ching-Lan Cheng, Cheng-Han Lee, Swu-Jane Lin, Yea-Huei Kao Yang. (Taiwan)
- 213. Development and Validation of the RxDx-Dementia Risk Index To Predict Dementia in Patients With Type 2 Diabetes and Hypertension [980]**  
Hemalkumar B Mehta, Vinay Mehta, Chu-Lin Tsai, Hua Chen, Rajender R Aparasu, Michael L Johnson. (United States)

**214. Publication of Clinical Drug Trials: An Inception Cohort Study in the Netherlands [981]**

Cornelis A van den Bogert, Patrick C Souverein, Cecile TM Brekelmans, Susan WJ Janssen, Manon van Hunnik, Gerard H Koëter, Hubertus GM Leufkens, Lex M Bouter. (Netherlands)

**215. Presence of Type 2 Diabetes Mellitus Diagnoses in Different Types of Healthcare Databases--Empirical Evidence from EHR and Claims [982]**

Zhiwen Liu, Yong Chen, Michael Senderak, Edward A Bortnichak. (United States)

**216. Treatment-Related Adverse Events Recorded in Administrative Claims Compared To Electronic Medical Records [983]**

Debra E Irwin, Helen Varker. (United States)

## Methods

**217. Improving Control for Confounding By Frailty When Estimating Influenza Vaccine Effectiveness in Older Adults [984]**

Henry T Zhang, Leah J McGrath, Richard Wyss, Alan R Ellis, Til Sturmer. (United States)

**218. Simulation Study of Analysis of an Open-Label Trial With Time-Dependent Confounders/Mediators [985]**

Heidi Moseson, Khaled Sarsour, Neil Collinson, Katie Tuckwell, Micki Klearman, Eric Vittinghoff. (United States)

**219. Using Area Over the Curve of Absolute Neutrophil Count To Estimate Severity and Duration of Chemotherapy Induced Neutropenia and Relationship With Infection Risk [986]**

Yanli Li, Zandra Klippel, Xiaolong Shih, Hong Wang, Maureen Reiner, John H Page. (United States)

**220. Reducing and Quantifying Over-Fitting in Regression Models [987]**

John Rigg, Matthew Hankins. (United Kingdom)

**221. A Novel Multi-Modal Approach To Stroke Care Quality Improvement and the Development of High-Performing Stroke Care Teams [988]**

Aaron Kamauu, Mark Loveless. (United States)

**222. The Importance of Competing Risks in Predictive Modelling of Hip Implant Survival: A Cohort Study Using Computerised Records and Registry Data [989]**

Albert Roso, Cristian Tebe, Gary Collins, Andrew Judge, M Kassim Javaid, Montse Rué, Mireia Espallargues, Daniel Prieto-Alhambra, PRESS-UP Study Investigators. (Spain)

**223. A Simulation Study To Explore Bias Generated When Conditioning on an Intermediate Variable That Is Also a Time-Varying Confounder [990]**

Yan Cheng, Marlene Egger, Wei Chen, Joanne LaFleur, Brian Sauer. (United States)

**224. Parametric Time-To-Onset (TTO) Modelling of Common ADRs in Patients Using Antidiabetic Drugs [991]**

Joep HG Scholl, Peter M van de Ven, Eugène P van Puijenbroek. (The Netherlands)

**225. Dynamic Channeling Among Initiators of a Recently Marketed Medication for Type 2 Diabetes Mellitus (T2DM) [992]**

Elisabetta Patomo, Chandrasekar Gopalakrishnan, Olesya I Zorina, Sebastian Schneeweiss, Dorothee B Bartels, Jun Liu, John D Seeger. (United States)

**226. An Evaluation of the Multinomial Propensity Score in a Simulated Drug-Drug Interaction Study [993]**

Christopher G Rowan, Warren B Bilker, Jason Roy, Sean Hennessy, James Lewis, Daniel Mines, Brian L Strom. (United States)

**227. Comparison of Calipers for Matching on the Disease Risk Score [994]**

John G Connolly, Joshua J Gagne. (United States)

**228. Non-Collapsibility and Selection Bias of Hazard Ratio [995]**

Menglan Pang, Michal Abrahamowicz, Robert W Platt. (Canada)

**229. Historical Data for Augmenting High Dimensional Covariate Selection [996]**

Hiraku Kumamaru, Joshua J Gagne, Robert J Glynn, Soko Setoguchi, Sebastian Schneeweiss. (United States)

**230. Comparison of Zero-Cell Correction Factors for the High-Dimensional Propensity Score Algorithm in Studies With Few Outcomes [997]**

Hiraku Kumamaru, Joshua J Gagne, Robert J Glynn, Wesley Eddings, Soko Setoguchi, Sebastian Schneeweiss. (United States)

**231. The ACCE Method for Estimating Unmeasured Confounding [998]**

Eric G Smith. (United States)

**232. A Method To Identify Patients Included Within Both the Clinical Practice Research Datalink (CPRD) and the Health Improvement Network (THIN) [999]**

M Elle Saine, Dena M Carbonari, Craig W Newcomb, Betina Blak, Jason Roy, Kevin Haynes, Jennifer Wood, Arlene M Gallagher, Harshvinder Bhullar, Serena Cardillo, Sean Hennessy, Brian L Strom, Vincent Lo Re III. (United States)

**233. Concordance of Hospitalizations Within the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) Among Type 2 Diabetes Mellitus Patients [1000]**

M Elle Saine, Dena M Carbonari, Craig W Newcomb, Jason A Roy, Kevin Haynes, Jennifer Wood, Arlene M Gallagher, Serena Cardillo, Sean Hennessy, Brian L Strom, Vincent Lo Re III. (United States)

**234. Differential Use of Screening Mammography in Older Women Initiating Metformin or Sulfonylureas [1001]**

Jin-Liern Hong, Louise M Henderson, Michele Jonsson Funk, Jennifer L Lund, Virginia Pate, Til Stürmer. (United States)

**235. Determination of Proxies for Obesity Status in the Clinical Practice Research Database (CPRD) [1002]**

Mona Cai, Vinay Mehta, Kimberly Brodovicz, Cynthia Girman. (United States)

**236. Application of the International Society on Thrombosis and Haemostasis (ISTH) Definition of Major Bleeds To Bleeding Events Within a Post Authorization Safety Study [1003]**

Miranda Davies, Vicki Osborne, Deborah Layton, Saad Shakir. (United Kingdom)

**237. Validity Assessment of Rosuvastatin Prescribing Data from Electronic Health Records (EHR) in the United States [1004]**

Christopher G Rowan, Nikita Stempniewicz, James Flory, Tobias Gerhard, James D Lewis, John Cuddeback, Sean Hennessy. (United States)

**238. Validation of Colorectal Cancer Diagnoses in the Health Improvement Network in the United Kingdom [1005]**

Montse Soriano-Gabarró, Lucía Cea Soriano, Luis A García Rodríguez. (Germany)

**239. Withdrawn By Author**

**240. Medical Record Validation of Algorithms for Acute Myocardial Infarction (AMI) Within a United States (US) Administrative Claims Database [1007]**

Kathleen M Mortimer, Stephen M Ezzy, Jillian T Jessup, Robert V Gately, John D Seeger. (United States)

**241. Validation of Diagnosis and Treatment Codes for Patients With Acute Lymphoblastic Leukemia (ALL) in Denmark [1008]**

Victoria M Chia, Alma B Pedersen, Thomas B Rasmussen, Aaron J Katz, Michael A Kelsh, Sally Wetten, Mette Norgaard. (United States)



- 242. Revisions To Published Algorithms for Stroke Within a United States (US) Administrative Claims Database [1009]**  
Kathleen M Mortimer, Stephen M Ezzy, Jillian T Jessup, Robert V Gately, John D Seeger. (United States)
- 243. Sensitivity of Diagnosis and Treatment Codes in the Identification of Adults With Acute Lymphoblastic Leukemia in SEER-Medicare [1010]**  
Aaron J Katz, Victoria M Chia, Mark D Danese, Jennifer Duryea, Michael A Kelsh, Deborah P Lubeck. (United States)
- 244. Small Differences Among Approaches in the Estimated Prevalence of a Very Rare Disease [1011]**  
Dana Y Teltsch, Richard Scott Swain, Don Robinson Jr., Matthew W Reynolds. (United States)
- 245. Implications for Signal Detection of Duplicated Case Reports of Stress Cardiomyopathy [1012]**  
Manfred Hauben, Maribel Salas, Peter Huber, Eric Hung. (United States)
- 246. Differential Racial and Regional Effects of Baseline Timeframe on Potential Bias in Risk Factor Assessment Using EHR Data [1013]**  
Anne Yuk-Lam Ho, Jason L Vassy, David R Gagnon, J Michael Gaziano, Jacqueline Honerlaw, Sanjay Raju, Peter WF Wilson, Kelly Cho. (United States)
- 247. Developing a Stroke Severity Index Based on Administrative Data Was Feasible Using Data Mining Techniques [1014]**  
Cheng-Yang Hsieh, Sheng-Feng Sung, Yea-Huei Kao Yang, Huey-Juan Lin, Chih-Hung Chen, Yu-Wei Chen, Ya-Han Hu. (Taiwan)
- 248. Strategies To Handle Missing Information in Predictive Modelling Using Routinely Collected Data: Differences in Identified Predictors and Model Performance [1015]**  
Albert Roso, Irene Petersen, Gary Collins, Montse Rué, Cristian Tebé, Mireia Espallargues, Daniel Prieto-Alhambra, PRESS-UP Research Group. (Spain)
- 249. Medical Record Validation of Algorithms for Ten Types of Cancer Within a United States (US) Administrative Claims Database [1016]**  
Kathleen M Mortimer, Stephen M Ezzy, Jillian T Jessup, Robert V Gately, John D Seeger. (United States)
- 250. Assessment of Residual Confounding and Selection Bias in Studies of Anti-Diabetes Medications [1017]**  
Ayad K Ali, Stephen P Motsko, Jonathan L Swain. (United States)
- 251. The Impact of Time-Window Bias on the Assessment of Long-Term Effect of Medication Adherence: The Case of Secondary Prevention After Myocardial Infarction [1018]**  
Mirko Di Martino, Ursula Kirchmayer, Nera Agabiti, Lisa Bauleo, Danilo Fusco, Carlo Alberto Perucci, Marina Davoli. (Italy)
- 252. Does the Length of the “Pre-Exposure” Window Affect the Relative Risk Estimate? A Self-Controlled Case Series Study [1019]**  
Gema Requena, Francisco J De Abajo, Consuelo Huerta, Stephen J Evans, Ian J Douglas. (United Kingdom)
- 253. The Critical Impact of Complex Cases Behavior on the Performance of Self-Controlled Case Series Method [1020]**  
Ling Zhang, Jasmanda Wu, Juhaeri Juhaeri. (United States)
- 254. Diffusion of Methodological Innovation in Pharmacoepidemiology: Self-Controlled Study Designs [1021]**  
Giulia P Consiglio, Malcolm Maclure, Lisa McCarthy, Suzanne M Cadarette. (Canada)
- 255. Does One-Size Fit All in Accounting for Immortal Time? [1022]**  
Evelyn M Flahvan, Hu Li, Claudia A Salinas, Stephen P Motsko. (United States)
- 256. Impact of Eligibility Length on Prevalence Estimates Using Automated Healthcare Claims Data [1023]**  
Yanmin Zhu, Wei Liu, Yan Li, Almut G Winterstein. (United States)
- 257. Systematic Review of Adaptive Design Clinical Trials [1024]**  
Laura Bothwell, Nazleen Khan, Aaron Kesselheim. (United States)
- 258. Comparison of Case-Only Designs With Traditional Study Designs: A Systematic Review [1025]**  
Koen B Pouwels, Bianca Mulder, Eelko Hak. (Netherlands)
- 259. Extent of Publication Bias in Observational Studies Investigating Adverse Drug Events [1026]**  
Dixa B Thakrar, Iain D Tatt, Mikkel Z Oestergaard. (United Kingdom)
- 260. Application of Indirect Treatment Comparison Method for Pooling Data from Clinical Trials for Benefit-Risk Assessment [1027]**  
Sampada K Gandhi, Lili Wang, Juhaeri Juhaeri. (United States)
- 261. Use of Natural Language Processing (NLP) To Identify Patients With Binge Eating Disorder (BED) in Optum’s Humedica Research Database [1028]**  
Kathleen M Mortimer, Baevin S Carbery, Robert V Gately, Dave D Dore. (United States)
- 262. Withdrawn By Author**
- 263. Utility of Linked Data in Controlling for Confounding By Indication: A Case of Cardiovascular CER Using Propensity Score Adjustment [1030]**  
Soko Setoguchi, Hiraku Kumamaru, Lauren Williams, Jalbert J Jessica. (United States)
- 264. Completeness of Key Variables in the Clinical Practice Research Datalink (CPRD) [1031]**  
Emily Herrett, Arlene Gallagher, Krishnan Bhaskaran, Harriet Forbes, Rohini Mathur, Tjeerd van Staa, Liam Smeeth. (United Kingdom)
- 265. Utilizing Electronic Medical Record Networks and Advanced Analytics for Identifying Patients for Clinical Trial Recruitment [1032]**  
Spencer Justin, Andrew Wilson, Nicole Bailey, Matthew Longson, Aaron Kamau. (United States)

END SESSION C

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

## MONDAY, AUGUST 24, 2015 Cont.

### Multiple Approaches To Improve Confounding Control

1		10:30 am	302	Oral
2		10:45 am	302	Oral
3		11:00 am	302	Oral
4		11:15 am	302	Oral
5		11:30 am	302	Oral
6		11:45 am	302	Oral

### Cardiovascular Treatment and Safety Outcomes

7		10:30 am	312	Oral
8		10:45 am	312	Oral
9		11:00 am	312	Oral
10		11:15 am	312	Oral
11		11:30 am	312	Oral
12		11:45 am	312	Oral

### Diabetes: Treatment and Outcomes I

13		10:30 am	311	Oral
14		10:45 am	311	Oral
15		11:00 am	311	Oral
16		11:15 am	311	Oral
17		11:30 am	311	Oral
18		11:45 am	311	Oral

### Pregnancy and Pediatrics Potpourri

19		10:30 am	210	Oral
20		10:45 am	210	Oral
21		11:00 am	210	Oral
22		11:15 am	210	Oral
23		11:30 am	210	Oral
24		11:45 am	210	Oral

### Measured Policy: Informing or Informed?

25		10:30 am	208	Oral
26		10:45 am	208	Oral
27		11:00 am	208	Oral
28		11:15 am	208	Oral
29		11:30 am	208	Oral
30		11:45 am	208	Oral

### A Boney Topic: Bisphosphonate Use and Outcomes

31		10:30 am	309	Oral
32		10:45 am	309	Oral
33		11:00 am	309	Oral
34		11:15 am	309	Oral
35		11:30 am	309	Oral
36		11:45 am	309	Oral

### Methods for Making Fair Comparisons

37		1:30 pm	302	Oral
38		1:45 pm	302	Oral
39		2:00 pm	302	Oral
40		2:15 pm	302	Oral
41		2:30 pm	302	Oral
42		2:45 pm	302	Oral

### Opioid Use and Abuse

43		1:30 pm	312	Oral
44		1:45 pm	312	Oral
45		2:00 pm	312	Oral

Pub. #	Poster #	Presentation Time	Room	Format
46		2:15 pm	312	Oral
47		2:30 pm	312	Oral
48		2:45 pm	312	Oral

### Those That Can Heal Can Harm; Those that Can Cure Can Kill

49		1:30 pm	311	Oral
50		1:45 pm	311	Oral
51		2:00 pm	311	Oral
52		2:15 pm	311	Oral
53		2:30 pm	311	Oral
54		2:45 pm	311	Oral

### Drug Use and Safety in Older People

55		1:30 pm	210	Oral
56		1:45 pm	210	Oral
57		2:00 pm	210	Oral
58		2:15 pm	210	Oral
59		2:30 pm	210	Oral
60		2:45 pm	210	Oral

### Balancing Act: Benefits, Risks, and Costs

61		1:30 pm	208	Oral
62		1:45 pm	208	Oral
63		2:00 pm	208	Oral
64		2:15 pm	208	Oral
65		2:30 pm	208	Oral
66		2:45 pm	208	Oral

### Hormone Therapy: An Equal Opportunity Risk

67		1:30 pm	309	Oral
68		1:45 pm	309	Oral
69		2:00 pm	309	Oral
70		2:15 pm	309	Oral
71		2:30 pm	Withdrawn By Author	
72		2:45 pm	309	Oral

### From Fantasy To Reality: Embedding Pragmatic Trials into Routine Clinical Care

73		5:00 pm – 6:30 pm	Ballroom A/B	Symposia
----	--	-------------------	--------------	----------

### An International Working Collaborative To Examine Global Drug Utilization: Opioid Use and Misuse

74		5:00 pm – 6:30 pm	302	Symposia
----	--	-------------------	-----	----------

### Technical and Governance Challenges in Pharmacoepidemiology Data Integration

75		5:00 pm – 6:30 pm	312	Symposia
----	--	-------------------	-----	----------

### Methods To Include Clinical Data Elements When Analyzing Observational Health Care Data Where Missing Data Are Expected

76		5:00 pm – 6:30 pm	311	Symposia
----	--	-------------------	-----	----------

### Does the Increasing Specialization of Epidemiologic Societies Ensure the Best Future for Our Profession?

77		5:00 pm – 6:30 pm	210	Symposia
----	--	-------------------	-----	----------

### Data Driven Regulatory Science

78		5:00 pm – 6:30 pm	208	Symposia
----	--	-------------------	-----	----------

### Human-Algorithm Interaction To Define Variables from Free-Text Notes in Electronic Health Records—Introduction and Examples

79		5:00 pm – 6:30 pm	309	Symposia
----	--	-------------------	-----	----------

# 31<sup>st</sup> ICPE ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
<b>MONDAY, AUGUST 24, 2015 Cont.</b>				

### Poster Session A: Spotlight Session-Biologics

80	1	8:00 am – 6:00 pm		Poster
81	2	8:00 am – 6:00 pm		Poster
82	3	8:00 am – 6:00 pm		Poster
83	4	8:00 am – 6:00 pm		Poster
84	5	8:00 am – 6:00 pm		Poster
85	6	8:00 am – 6:00 pm		Poster
86	7	8:00 am – 6:00 pm		Poster

### Poster Session A: Biologics

87	8	8:00 am – 6:00 pm		Poster
88	9	8:00 am – 6:00 pm		Poster
89	10	8:00 am – 6:00 pm		Poster
90	11	8:00 am – 6:00 pm		Poster
91	12	8:00 am – 6:00 pm		Poster

### Poster Session A: Spotlight Session-Drug Utilization Research/Health Services Research

195	13	8:00 am – 6:00 pm		Poster
196	14	8:00 am – 6:00 pm		Poster
197	15	8:00 am – 6:00 pm		Poster
198	16	8:00 am – 6:00 pm		Poster
199	17	8:00 am – 6:00 pm		Poster
200	18	8:00 am – 6:00 pm		Poster
201	19	8:00 am – 6:00 pm		Poster
202	20	8:00 am – 6:00 pm		Poster

### Poster Session A: Drug Utilization Research/Health Services Research

92	21	8:00 am – 6:00 pm		Poster
93	22	8:00 am – 6:00 pm		Poster
94	23	8:00 am – 6:00 pm		Poster
95	24	8:00 am – 6:00 pm		Poster
96	25	8:00 am – 6:00 pm	Withdrawn By Author	
97	26	8:00 am – 6:00 pm		Poster
98	27	8:00 am – 6:00 pm		Poster
99	28	8:00 am – 6:00 pm		Poster
100	29	8:00 am – 6:00 pm		Poster
101	30	8:00 am – 6:00 pm		Poster
102	31	8:00 am – 6:00 pm		Poster
103	32	8:00 am – 6:00 pm		Poster
104	33	8:00 am – 6:00 pm		Poster
105	34	8:00 am – 6:00 pm		Poster
106	35	8:00 am – 6:00 pm		Poster
107	36	8:00 am – 6:00 pm		Poster
108	37	8:00 am – 6:00 pm		Poster
109	38	8:00 am – 6:00 pm		Poster
110	39	8:00 am – 6:00 pm		Poster
111	40	8:00 am – 6:00 pm		Poster
112	41	8:00 am – 6:00 pm		Poster
113	42	8:00 am – 6:00 pm		Poster
114	43	8:00 am – 6:00 pm		Poster
115	44	8:00 am – 6:00 pm		Poster
116	45	8:00 am – 6:00 pm		Poster
117	46	8:00 am – 6:00 pm		Poster
118	47	8:00 am – 6:00 pm		Poster
119	48	8:00 am – 6:00 pm		Poster
120	49	8:00 am – 6:00 pm		Poster
121	50	8:00 am – 6:00 pm		Poster
122	51	8:00 am – 6:00 pm		Poster

Pub. #	Poster #	Presentation Time	Room	Format
123	52	8:00 am – 6:00 pm		Poster
124	53	8:00 am – 6:00 pm		Poster
125	54	8:00 am – 6:00 pm		Poster
126	55	8:00 am – 6:00 pm		Poster
127	56	8:00 am – 6:00 pm		Poster
128	57	8:00 am – 6:00 pm		Poster
129	58	8:00 am – 6:00 pm		Poster
130	59	8:00 am – 6:00 pm		Poster
131	60	8:00 am – 6:00 pm		Poster
132	61	8:00 am – 6:00 pm		Poster
133	62	8:00 am – 6:00 pm		Poster
134	63	8:00 am – 6:00 pm		Poster
135	64	8:00 am – 6:00 pm		Poster
136	65	8:00 am – 6:00 pm		Poster
137	66	8:00 am – 6:00 pm		Poster
138	67	8:00 am – 6:00 pm		Poster
139	68	8:00 am – 6:00 pm		Poster
140	69	8:00 am – 6:00 pm		Poster
141	70	8:00 am – 6:00 pm		Poster
142	71	8:00 am – 6:00 pm		Poster
143	72	8:00 am – 6:00 pm		Poster
144	73	8:00 am – 6:00 pm		Poster
145	74	8:00 am – 6:00 pm		Poster
146	75	8:00 am – 6:00 pm		Poster
147	76	8:00 am – 6:00 pm		Poster
148	77	8:00 am – 6:00 pm		Poster
149	78	8:00 am – 6:00 pm		Poster
150	79	8:00 am – 6:00 pm	Withdrawn by Author	
151	80	8:00 am – 6:00 pm		Poster
152	81	8:00 am – 6:00 pm		Poster
153	82	8:00 am – 6:00 pm		Poster
154	83	8:00 am – 6:00 pm		Poster
155	84	8:00 am – 6:00 pm		Poster
156	85	8:00 am – 6:00 pm		Poster
157	86	8:00 am – 6:00 pm		Poster
158	87	8:00 am – 6:00 pm		Poster
159	88	8:00 am – 6:00 pm		Poster
160	89	8:00 am – 6:00 pm		Poster
161	90	8:00 am – 6:00 pm		Poster
162	91	8:00 am – 6:00 pm		Poster
163	92	8:00 am – 6:00 pm		Poster
164	93	8:00 am – 6:00 pm		Poster
165	94	8:00 am – 6:00 pm		Poster
166	95	8:00 am – 6:00 pm		Poster
167	96	8:00 am – 6:00 pm		Poster
168	97	8:00 am – 6:00 pm		Poster
169	98	8:00 am – 6:00 pm		Poster
170	99	8:00 am – 6:00 pm	Withdrawn by Author	
171	100	8:00 am – 6:00 pm		Poster
172	101	8:00 am – 6:00 pm	Withdrawn by Author	
173	102	8:00 am – 6:00 pm	Withdrawn by Author	
174	103	8:00 am – 6:00 pm	Withdrawn by Author	
175	104	8:00 am – 6:00 pm		Poster
176	105	8:00 am – 6:00 pm		Poster
177	106	8:00 am – 6:00 pm		Poster
178	107	8:00 am – 6:00 pm		Poster
179	108	8:00 am – 6:00 pm		Poster
180	109	8:00 am – 6:00 pm		Poster
181	110	8:00 am – 6:00 pm		Poster
182	111	8:00 am – 6:00 pm		Poster
183	112	8:00 am – 6:00 pm		Poster
184	113	8:00 am – 6:00 pm		Poster
185	114	8:00 am – 6:00 pm		Poster

# 31<sup>st</sup> ICPE ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
<b>MONDAY, AUGUST 24 Cont.</b>				
186	115	8:00 am – 6:00 pm		Poster
187	116	8:00 am – 6:00 pm		Poster
188	117	8:00 am – 6:00 pm		Poster
189	118	8:00 am – 6:00 pm		Poster
190	119	8:00 am – 6:00 pm		Poster
191	120	8:00 am – 6:00 pm		Poster
192	121	8:00 am – 6:00 pm		Poster
193	122	8:00 am – 6:00 pm		Poster
194	123	8:00 am – 6:00 pm		Poster

## Poster Session A: Drug Utilization Research/Health Services Research

203	124	8:00 am – 6:00 pm		Poster
204	125	8:00 am – 6:00 pm		Poster
205	126	8:00 am – 6:00 pm		Poster
206	127	8:00 am – 6:00 pm		Poster
207	128	8:00 am – 6:00 pm		Poster
208	129	8:00 am – 6:00 pm		Poster
209	130	8:00 am – 6:00 pm		Poster
210	131	8:00 am – 6:00 pm		Poster
211	132	8:00 am – 6:00 pm		Poster
212	133	8:00 am – 6:00 pm		Poster
213	134	8:00 am – 6:00 pm		Poster
214	135	8:00 am – 6:00 pm		Poster
215	136	8:00 am – 6:00 pm		Poster
216	137	8:00 am – 6:00 pm		Poster
217	138	8:00 am – 6:00 pm		Poster
218	139	8:00 am – 6:00 pm		Poster
219	140	8:00 am – 6:00 pm		Poster
220	141	8:00 am – 6:00 pm		Poster
221	142	8:00 am – 6:00 pm		Poster
222	143	8:00 am – 6:00 pm		Poster
223	144	8:00 am – 6:00 pm		Poster
224	145	8:00 am – 6:00 pm		Poster
225	146	8:00 am – 6:00 pm		Poster
226	147	8:00 am – 6:00 pm		Poster
227	148	8:00 am – 6:00 pm		Poster
228	149	8:00 am – 6:00 pm		Poster
229	150	8:00 am – 6:00 pm		Poster
230	151	8:00 am – 6:00 pm		Poster
231	152	8:00 am – 6:00 pm		Poster
232	153	8:00 am – 6:00 pm		Poster
233	154	8:00 am – 6:00 pm		Poster
234	155	8:00 am – 6:00 pm		Poster
235	156	8:00 am – 6:00 pm		Poster
236	157	8:00 am – 6:00 pm		Poster
237	158	8:00 am – 6:00 pm		Poster
238	159	8:00 am – 6:00 pm	Withdrawn by Author	
239	160	8:00 am – 6:00 pm	Withdrawn by Author	
240	161	8:00 am – 6:00 pm		Poster
241	162	8:00 am – 6:00 pm		Poster
242	163	8:00 am – 6:00 pm	Withdrawn by Author	
243	164	8:00 am – 6:00 pm		Poster
244	165	8:00 am – 6:00 pm		Poster
245	166	8:00 am – 6:00 pm		Poster
246	167	8:00 am – 6:00 pm		Poster
247	168	8:00 am – 6:00 pm		Poster
248	169	8:00 am – 6:00 pm		Poster
249	170	8:00 am – 6:00 pm	Withdrawn by Author	
250	171	8:00 am – 6:00 pm		Poster
251	172	8:00 am – 6:00 pm		Poster

Pub. #	Poster #	Presentation Time	Room	Format
252	173	8:00 am – 6:00 pm		Poster
253	174	8:00 am – 6:00 pm		Poster
254	175	8:00 am – 6:00 pm		Poster
255	176	8:00 am – 6:00 pm		Poster
256	177	8:00 am – 6:00 pm		Poster
257	178	8:00 am – 6:00 pm		Poster
258	179	8:00 am – 6:00 pm		Poster
259	180	8:00 am – 6:00 pm		Poster
260	181	8:00 am – 6:00 pm		Poster
261	182	8:00 am – 6:00 pm		Poster
262	183	8:00 am – 6:00 pm		Poster
263	184	8:00 am – 6:00 pm		Poster
264	185	8:00 am – 6:00 pm		Poster
265	186	8:00 am – 6:00 pm		Poster
266	187	8:00 am – 6:00 pm		Poster
267	188	8:00 am – 6:00 pm		Poster
268	189	8:00 am – 6:00 pm		Poster
269	190	8:00 am – 6:00 pm		Poster
270	191	8:00 am – 6:00 pm		Poster
271	192	8:00 am – 6:00 pm		Poster
272	193	8:00 am – 6:00 pm		Poster
273	194	8:00 am – 6:00 pm		Poster
274	195	8:00 am – 6:00 pm		Poster
275	196	8:00 am – 6:00 pm		Poster
276	197	8:00 am – 6:00 pm		Poster
277	198	8:00 am – 6:00 pm		Poster
278	199	8:00 am – 6:00 pm		Poster
279	200	8:00 am – 6:00 pm		Poster
280	201	8:00 am – 6:00 pm		Poster
281	202	8:00 am – 6:00 pm		Poster
282	203	8:00 am – 6:00 pm		Poster
283	204	8:00 am – 6:00 pm		Poster
284	205	8:00 am – 6:00 pm		Poster
285	206	8:00 am – 6:00 pm		Poster
286	207	8:00 am – 6:00 pm		Poster
287	208	8:00 am – 6:00 pm		Poster
288	209	8:00 am – 6:00 pm		Poster
289	210	8:00 am – 6:00 pm		Poster
290	211	8:00 am – 6:00 pm		Poster
291	212	8:00 am – 6:00 pm		Poster
292	213	8:00 am – 6:00 pm		Poster
293	214	8:00 am – 6:00 pm		Poster
294	215	8:00 am – 6:00 pm		Poster
295	216	8:00 am – 6:00 pm		Poster
296	217	8:00 am – 6:00 pm		Poster
297	218	8:00 am – 6:00 pm		Poster
298	219	8:00 am – 6:00 pm		Poster
299	220	8:00 am – 6:00 pm		Poster
300	221	8:00 am – 6:00 pm		Poster
301	222	8:00 am – 6:00 pm		Poster
302	223	8:00 am – 6:00 pm		Poster
303	224	8:00 am – 6:00 pm		Poster
304	225	8:00 am – 6:00 pm		Poster
305	226	8:00 am – 6:00 pm		Poster
306	227	8:00 am – 6:00 pm		Poster
307	228	8:00 am – 6:00 pm		Poster

## Poster Session A: Spotlight Session-Vaccines

308	229	8:00 am – 6:00 pm		Poster
309	230	8:00 am – 6:00 pm		Poster
310	231	8:00 am – 6:00 pm		Poster
311	232	8:00 am – 6:00 pm		Poster
312	233	8:00 am – 6:00 pm		Poster

Pub. #	Poster #	Presentation Time	Room	Format
<b>MONDAY, AUGUST 24 Cont.</b>				
313	234	8:00 am – 6:00 pm		Poster
314	235	8:00 am – 6:00 pm		Poster
315	236	8:00 am – 6:00 pm		Poster

### Poster Session A: Vaccines

316	237	8:00 am – 6:00 pm		Poster
317	238	8:00 am – 6:00 pm		Poster
318	239	8:00 am – 6:00 pm		Poster
319	240	8:00 am – 6:00 pm		Poster
320	241	8:00 am – 6:00 pm		Poster
321	242	8:00 am – 6:00 pm		Poster
322	243	8:00 am – 6:00 pm		Poster
323	244	8:00 am – 6:00 pm		Poster
324	245	8:00 am – 6:00 pm		Poster
325	246	8:00 am – 6:00 pm		Poster
326	247	8:00 am – 6:00 pm		Poster
327	248	8:00 am – 6:00 pm		Poster
328	249	8:00 am – 6:00 pm		Poster
329	250	8:00 am – 6:00 pm		Poster
330	251	8:00 am – 6:00 pm		Poster
331	252	8:00 am – 6:00 pm		Poster
332	253	8:00 am – 6:00 pm		Poster
333	254	8:00 am – 6:00 pm		Poster
334	255	8:00 am – 6:00 pm		Poster
335	256	8:00 am – 6:00 pm		Poster
336	257	8:00 am – 6:00 pm		Poster
337	258	8:00 am – 6:00 pm		Poster
338	259	8:00 am – 6:00 pm		Poster
339	260	8:00 am – 6:00 pm		Poster
340	261	8:00 am – 6:00 pm		Poster
341	262	8:00 am – 6:00 pm		Poster

### Poster Session A: Spotlight Session-Molecular Epidemiology/ Biomarkers/Pharmacogenetics

342	263	8:00 am – 6:00 pm		Poster
343	264	8:00 am – 6:00 pm		Poster
344	265	8:00 am – 6:00 pm		Poster
345	266	8:00 am – 6:00 pm		Poster
346	267	8:00 am – 6:00 pm		Poster
347	268	8:00 am – 6:00 pm		Poster

## TUESDAY, AUGUST 25

### The Built Environment: Multiple Data Systems and Reproducibility of Research

348		8:00 am	302	Oral
349		8:15 am	302	Oral
350		8:30 am	302	Oral
351		8:45 am	302	Oral
352		9:00 am	302	Oral
353		9:15 am	302	Oral

### Nature or Nurture: Adherence or Genetic Determinance of Cardiovascular Events

354		8:00 am	312	Oral
355		8:15 am	312	Oral
356		8:30 am	312	Oral
357		8:45 am	312	Oral
358		9:00 am	312	Oral
359		9:15 am	312	Oral

Pub. #	Poster #	Presentation Time	Room	Format
<b>DUR: Beyond Drug Utilization Data</b>				
360		8:00 am	311	Oral
361		8:15 am	311	Oral
362		8:30 am	311	Oral
363		8:45 am	311	Oral
364		9:00 am	311	Oral
365		9:15 am	311	Oral

### Psychotropic Medications in Pregnancy

366		8:00 am	210	Oral
367		8:15 am	210	Oral
368		8:30 am	210	Oral
369		8:45 am	210	Oral
370		9:00 am	210	Oral
371		9:15 am	210	Oral

### Adherence: Past, Present and Future

372		8:00 am	208	Oral
373		8:15 am	208	Oral
374		8:30 am	208	Oral
375		8:45 am	208	Oral
376		9:00 am	208	Oral
377		9:15 am	208	Oral

### Rheumatoid Arthritis: Treatment and Outcomes

378		8:00 am	309	Oral
379		8:15 am	309	Oral
380		8:30 am	309	Oral
381		8:45 am	309	Oral
382		9:00 am	309	Oral
383		9:15 am	309	Oral

### The Reality of Propensity Scores at the Limit

384		1:00 pm	302	Oral
385		1:15 pm	302	Oral
386		1:30 pm	302	Oral
387		1:45 pm	302	Oral
388		2:00 pm	302	Oral
389		2:15 pm	302	Oral

### Turning into the Future of Pharmacovigilance

390		1:00 pm	312	Oral
391		1:15 pm	312	Oral
392		1:30 pm	312	Oral
393		1:45 pm	312	Oral
394		2:00 pm	312	Oral
395		2:15 pm	312	Oral

### Living with Cancer: Drugs and Outcomes

396		1:00 pm	311	Oral
397		1:15 pm	311	Oral
398		1:30 pm	311	Oral
399		1:45 pm	311	Oral
400		2:00 pm	311	Oral
401		2:15 pm	311	Oral

### Diabetes: Treatment and Outcomes II

402		1:00 pm	210	Oral
403		1:15 pm	210	Oral
404		1:30 pm	210	Oral
405		1:45 pm	210	Oral
406		2:00 pm	210	Oral
407		2:15 pm	210	Oral

Pub. #	Poster #	Presentation Time	Room	Format
<b>TUESDAY, AUGUST 25 Cont.</b>				

### Older People and Their CNS Drugs

408		1:00 pm	208	Oral
409		1:15 pm	208	Oral
410		1:30 pm	208	Oral
411		1:45 pm	208	Oral
412		2:00 pm	208	Oral
413		2:15 pm	208	Oral

### Neurodevelopmental Issues: Drugs and Outcomes

414		1:00 pm	309	Oral
415		1:15 pm	309	Oral
416		1:30 pm	309	Oral
417		1:45 pm	309	Oral
418		2:00 pm	309	Oral
419		2:15 pm	309	Oral

### Plenary Session: Edlavitch Award

420		2:30 pm	Ballroom A/B	Oral
-----	--	---------	--------------	------

### Rapid-Cycle Analytics in Pharmacoepidemiology

421		4:15 - 5:45 pm	Ballroom A/B	Symposia
-----	--	----------------	--------------	----------

### Pragmatic Randomized Trials in Practice: How Can We Overcome the Hurdles? A CER SIG-Sponsored Symposium

422		4:15 - 5:45 pm	302	Symposia
-----	--	----------------	-----	----------

### Building a Sustainable Surveillance System To Monitor the Use and Safety of Medical Products in Pregnancy

423		4:15 - 5:45 pm	312	Symposia
-----	--	----------------	-----	----------

### Historical Comparator Studies: Strengths, Limitations, and Analytical Considerations in Using Historical Pooled Clinical Data for Evaluating Efficacy and Safety of New Therapies

424		4:15 - 5:45 pm	311	Symposia
-----	--	----------------	-----	----------

### PROTECT: The Challenges and Successes

425		4:15 - 5:45 pm	210	Symposia
-----	--	----------------	-----	----------

### Challenges of Introducing New Vaccines in Resource-Limited Settings

426		4:15 - 5:45 pm	208	Symposia
-----	--	----------------	-----	----------

### Evaluating Risk Evaluation and Mitigation Strategies (REMS): Lessons Learned and Future Opportunities With a Focus on Opioid Analgesics

427		4:15 - 5:45 pm	309	Symposia
-----	--	----------------	-----	----------

### Poster Session B: Spotlight Session-Medicines in Pregnancy

428	1	8:00 am - 6:00 pm		Poster
429	2	8:00 am - 6:00 pm		Poster
430	3	8:00 am - 6:00 pm		Poster
431	4	8:00 am - 6:00 pm		Poster
432	5	8:00 am - 6:00 pm		Poster
433	6	8:00 am - 6:00 pm		Poster
434	7	8:00 am - 6:00 pm		Poster
435	8	8:00 am - 6:00 pm		Poster

### Poster Session B: Medicines in Pregnancy

436	9	8:00 am - 6:00 pm		Poster
437	10	8:00 am - 6:00 pm		Poster

Pub. #	Poster #	Presentation Time	Room	Format
438	11	8:00 am - 6:00 pm		Poster
439	12	8:00 am - 6:00 pm		Poster
440	13	8:00 am - 6:00 pm		Poster
441	14	8:00 am - 6:00 pm		Poster
442	15	8:00 am - 6:00 pm		Poster
443	16	8:00 am - 6:00 pm		Poster
444	17	8:00 am - 6:00 pm		Poster
445	18	8:00 am - 6:00 pm		Poster
446	19	8:00 am - 6:00 pm		Poster
447	20	8:00 am - 6:00 pm		Poster
448	21	8:00 am - 6:00 pm		Poster
449	22	8:00 am - 6:00 pm		Poster
450	23	8:00 am - 6:00 pm		Poster
451	24	8:00 am - 6:00 pm		Poster
452	25	8:00 am - 6:00 pm		Poster
453	26	8:00 am - 6:00 pm		Poster
454	27	8:00 am - 6:00 pm		Poster
455	28	8:00 am - 6:00 pm		Poster
456	29	8:00 am - 6:00 pm		Poster
457	30	8:00 am - 6:00 pm		Poster
458	31	8:00 am - 6:00 pm		Poster
459	32	8:00 am - 6:00 pm		Poster
460	33	8:00 am - 6:00 pm		Poster
461	34	8:00 am - 6:00 pm		Poster
462	35	8:00 am - 6:00 pm		Poster
463	36	8:00 am - 6:00 pm		Poster
464	37	8:00 am - 6:00 pm		Poster
465	38	8:00 am - 6:00 pm		Poster
466	39	8:00 am - 6:00 pm		Poster
467	40	8:00 am - 6:00 pm		Poster
468	41	8:00 am - 6:00 pm		Poster
469	42	8:00 am - 6:00 pm		Poster
470	43	8:00 am - 6:00 pm		Poster
471	44	8:00 am - 6:00 pm		Poster
472	45	8:00 am - 6:00 pm		Poster
473	46	8:00 am - 6:00 pm		Poster
474	47	8:00 am - 6:00 pm		Poster
475	48	8:00 am - 6:00 pm		Poster
476	49	8:00 am - 6:00 pm		Poster
477	50	8:00 am - 6:00 pm		Poster
478	51	8:00 am - 6:00 pm		Poster
479	52	8:00 am - 6:00 pm		Poster
480	53	8:00 am - 6:00 pm		Poster
481	54	8:00 am - 6:00 pm		Poster

### Poster Session B: Spotlight Session-Pediatrics

482	55	8:00 am - 6:00 pm		Poster
483	56	8:00 am - 6:00 pm		Poster
484	57	8:00 am - 6:00 pm		Poster
485	58	8:00 am - 6:00 pm		Poster
486	59	8:00 am - 6:00 pm		Poster
487	60	8:00 am - 6:00 pm		Poster
488	61	8:00 am - 6:00 pm		Poster
489	62	8:00 am - 6:00 pm		Poster

### Poster Session B: Pediatrics

490	63	8:00 am - 6:00 pm		Poster
491	64	8:00 am - 6:00 pm		Poster
492	65	8:00 am - 6:00 pm		Poster
493	66	8:00 am - 6:00 pm		Poster
494	67	8:00 am - 6:00 pm		Poster
495	68	8:00 am - 6:00 pm		Poster
496	69	8:00 am - 6:00 pm		Poster

# 31<sup>st</sup> ICPE ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
<b>TUESDAY, AUGUST 25 Cont.</b>				
497	70	8:00 am – 6:00 pm		Poster
498	71	8:00 am – 6:00 pm		Poster
499	72	8:00 am – 6:00 pm		Poster
500	73	8:00 am – 6:00 pm		Poster
501	74	8:00 am – 6:00 pm		Poster
502	75	8:00 am – 6:00 pm		Poster
503	76	8:00 am – 6:00 pm		Poster
504	77	8:00 am – 6:00 pm		Poster
505	78	8:00 am – 6:00 pm		Poster
506	79	8:00 am – 6:00 pm		Poster
507	80	8:00 am – 6:00 pm		Poster
508	81	8:00 am – 6:00 pm		Poster
509	82	8:00 am – 6:00 pm		Poster

## Poster Session B: Spotlight Session-Medical Devices

510	83	8:00 am – 6:00 pm		Poster
511	84	8:00 am – 6:00 pm		Poster
512	85	8:00 am – 6:00 pm		Poster
513	86	8:00 am – 6:00 pm		Poster
514	87	8:00 am – 6:00 pm		Poster
515	88	8:00 am – 6:00 pm		Poster
516	89	8:00 am – 6:00 pm		Poster
517	90	8:00 am – 6:00 pm		Poster

## Poster Session B: Medical Devices

518	91	8:00 am – 6:00 pm		Poster
519	92	8:00 am – 6:00 pm		Poster
520	93	8:00 am – 6:00 pm		Poster
521	94	8:00 am – 6:00 pm		Poster
522	95	8:00 am – 6:00 pm		Poster
523	96	8:00 am – 6:00 pm		Poster
524	97	8:00 am – 6:00 pm		Poster
525	98	8:00 am – 6:00 pm		Poster
526	99	8:00 am – 6:00 pm		Poster
527	100	8:00 am – 6:00 pm		Poster
528	101	8:00 am – 6:00 pm		Poster

## Poster Session B: Safety End Point Studies

529	102	8:00 am – 6:00 pm		Poster
530	103	8:00 am – 6:00 pm		Poster
531	104	8:00 am – 6:00 pm		Poster
532	105	8:00 am – 6:00 pm		Poster
533	106	8:00 am – 6:00 pm		Poster
534	107	8:00 am – 6:00 pm		Poster
535	108	8:00 am – 6:00 pm		Poster
536	109	8:00 am – 6:00 pm		Poster
537	110	8:00 am – 6:00 pm		Poster
538	111	8:00 am – 6:00 pm		Poster
539	112	8:00 am – 6:00 pm		Poster
540	113	8:00 am – 6:00 pm		Poster
541	114	8:00 am – 6:00 pm		Poster
542	115	8:00 am – 6:00 pm		Poster
543	116	8:00 am – 6:00 pm		Poster
544	117	8:00 am – 6:00 pm		Poster
545	118	8:00 am – 6:00 pm		Poster
546	119	8:00 am – 6:00 pm		Poster
547	120	8:00 am – 6:00 pm		Poster
548	121	8:00 am – 6:00 pm		Poster
549	122	8:00 am – 6:00 pm		Poster
550	123	8:00 am – 6:00 pm		Poster
551	124	8:00 am – 6:00 pm		Poster
552	125	8:00 am – 6:00 pm		Poster

Pub. #	Poster #	Presentation Time	Room	Format
553	126	8:00 am – 6:00 pm		Poster
554	127	8:00 am – 6:00 pm		Poster
555	128	8:00 am – 6:00 pm		Poster
556	129	8:00 am – 6:00 pm		Poster
557	130	8:00 am – 6:00 pm		Poster
558	131	8:00 am – 6:00 pm		Poster
559	132	8:00 am – 6:00 pm		Poster
560	133	8:00 am – 6:00 pm		Poster
561	134	8:00 am – 6:00 pm		Poster
562	135	8:00 am – 6:00 pm		Poster
563	136	8:00 am – 6:00 pm		Poster
564	137	8:00 am – 6:00 pm		Poster
565	138	8:00 am – 6:00 pm		Poster
566	139	8:00 am – 6:00 pm		Poster
567	140	8:00 am – 6:00 pm		Poster
568	141	8:00 am – 6:00 pm		Poster
569	142	8:00 am – 6:00 pm		Poster
570	143	8:00 am – 6:00 pm		Poster
571	144	8:00 am – 6:00 pm		Poster
572	145	8:00 am – 6:00 pm		Poster
573	146	8:00 am – 6:00 pm		Poster
574	147	8:00 am – 6:00 pm		Poster
575	148	8:00 am – 6:00 pm		Poster
576	149	8:00 am – 6:00 pm		Poster
577	150	8:00 am – 6:00 pm		Poster
578	151	8:00 am – 6:00 pm		Poster
579	152	8:00 am – 6:00 pm		Poster
580	153	8:00 am – 6:00 pm		Poster
581	154	8:00 am – 6:00 pm		Poster
582	155	8:00 am – 6:00 pm		Poster
583	156	8:00 am – 6:00 pm		Poster
584	157	8:00 am – 6:00 pm		Poster
585	158	8:00 am – 6:00 pm		Poster
586	159	8:00 am – 6:00 pm		Poster
587	160	8:00 am – 6:00 pm		Poster
588	161	8:00 am – 6:00 pm		Poster
589	162	8:00 am – 6:00 pm		Poster
590	163	8:00 am – 6:00 pm		Poster
591	164	8:00 am – 6:00 pm		Poster
592	165	8:00 am – 6:00 pm		Poster
593	166	8:00 am – 6:00 pm		Poster
594	167	8:00 am – 6:00 pm		Poster
595	168	8:00 am – 6:00 pm		Poster

## Poster Session B: Spotlight Session-Comparative Effectiveness Research (CER)

596	169	8:00 am – 6:00 pm		Poster
597	170	8:00 am – 6:00 pm		Poster
598	171	8:00 am – 6:00 pm		Poster
599	172	8:00 am – 6:00 pm		Poster
600	173	8:00 am – 6:00 pm		Poster
601	174	8:00 am – 6:00 pm		Poster
602	175	8:00 am – 6:00 pm		Poster
603	176	8:00 am – 6:00 pm		Poster

## Poster Session B: Comparative Effectiveness Research (CER)

604	177	8:00 am – 6:00 pm		Poster
605	178	8:00 am – 6:00 pm		Poster
606	179	8:00 am – 6:00 pm		Poster
607	180	8:00 am – 6:00 pm		Poster
608	181	8:00 am – 6:00 pm		Poster
609	182	8:00 am – 6:00 pm		Poster
610	183	8:00 am – 6:00 pm		Poster

# 31<sup>st</sup> ICPE ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
<b>TUESDAY, AUGUST 25 Cont.</b>				
611	184	8:00 am – 6:00 pm		Poster
612	185	8:00 am – 6:00 pm		Poster
613	186	8:00 am – 6:00 pm		Poster
614	188	8:00 am – 6:00 pm		Poster
615	189	8:00 am – 6:00 pm		Poster
616	190	8:00 am – 6:00 pm		Poster
617	191	8:00 am – 6:00 pm		Poster
618	192	8:00 am – 6:00 pm		Poster
619	193	8:00 am – 6:00 pm		Poster
620	194	8:00 am – 6:00 pm		Poster
621	195	8:00 am – 6:00 pm		Poster
622	196	8:00 am – 6:00 pm		Poster
623	197	8:00 am – 6:00 pm		Poster
624	198	8:00 am – 6:00 pm		Poster
625	199	8:00 am – 6:00 pm		Poster
626	200	8:00 am – 6:00 pm		Poster
627	201	8:00 am – 6:00 pm		Poster
628	202	8:00 am – 6:00 pm		Poster
629	203	8:00 am – 6:00 pm		Poster
630	204	8:00 am – 6:00 pm		Poster
631	205	8:00 am – 6:00 pm		Poster
632	206	8:00 am – 6:00 pm		Poster

## Poster Session B: Burden of Disease/Epidemiology of Illness

633	207	8:00 am – 6:00 pm		Poster
634	208	8:00 am – 6:00 pm		Poster
635	209	8:00 am – 6:00 pm		Poster
636	210	8:00 am – 6:00 pm		Poster
637	211	8:00 am – 6:00 pm		Poster
638	212	8:00 am – 6:00 pm		Poster
639	213	8:00 am – 6:00 pm		Poster
640	214	8:00 am – 6:00 pm		Poster
641	215	8:00 am – 6:00 pm		Poster
642	216	8:00 am – 6:00 pm		Poster
643	217	8:00 am – 6:00 pm		Poster
644	218	8:00 am – 6:00 pm		Poster
645	219	8:00 am – 6:00 pm		Poster
646	220	8:00 am – 6:00 pm		Poster
647	221	8:00 am – 6:00 pm		Poster
648	222	8:00 am – 6:00 pm		Poster
649	223	8:00 am – 6:00 pm		Poster
650	224	8:00 am – 6:00 pm		Poster
651	225	8:00 am – 6:00 pm		Poster
652	226	8:00 am – 6:00 pm		Poster
653	227	8:00 am – 6:00 pm		Poster
654	228	8:00 am – 6:00 pm		Poster
655	229	8:00 am – 6:00 pm		Poster
656	230	8:00 am – 6:00 pm		Poster
657	231	8:00 am – 6:00 pm		Poster
658	232	8:00 am – 6:00 pm		Poster
659	233	8:00 am – 6:00 pm		Poster
660	234	8:00 am – 6:00 pm		Poster
661	235	8:00 am – 6:00 pm		Poster
662	236	8:00 am – 6:00 pm		Poster
663	237	8:00 am – 6:00 pm		Poster
664	238	8:00 am – 6:00 pm		Poster
665	239	8:00 am – 6:00 pm		Poster

## Poster Session B: Spotlight Session-AsPEN

666	240	8:00 am – 6:00 pm		Poster
667	241	8:00 am – 6:00 pm		Poster
668	242	8:00 am – 6:00 pm		Poster

Pub. #	Poster #	Presentation Time	Room	Format
669	243	8:00 am – 6:00 pm		Poster
670	244	8:00 am – 6:00 pm		Poster
671	245	8:00 am – 6:00 pm		Poster
672	246	8:00 am – 6:00 pm		Poster
673	247	8:00 am – 6:00 pm	Withdrawn by Author	

## Poster Session B: AsPEN

674	248	8:00 am – 6:00 pm		Poster
675	249	8:00 am – 6:00 pm		Poster
676	250	8:00 am – 6:00 pm		Poster
677	251	8:00 am – 6:00 pm		Poster
678	252	8:00 am – 6:00 pm		Poster
679	253	8:00 am – 6:00 pm		Poster
680	254	8:00 am – 6:00 pm		Poster
681	255	8:00 am – 6:00 pm		Poster
682	256	8:00 am – 6:00 pm		Poster
683	257	8:00 am – 6:00 pm		Poster
684	258	8:00 am – 6:00 pm		Poster
685	259	8:00 am – 6:00 pm	Withdrawn by Author	
686	260	8:00 am – 6:00 pm		Poster
687	261	8:00 am – 6:00 pm		Poster
688	262	8:00 am – 6:00 pm		Poster

## WEDNESDAY, AUGUST 26

### Censoring Left to Right

689		8:30 am	302	Oral
690		8:45 am	302	Oral
691		9:00 am	302	Oral
692		9:15 am	302	Oral
693		9:30 am	302	Oral
694		9:45 am	302	Oral

### DUR: Psych!

695		8:30 am	312	Oral
696		8:45 am	312	Oral
697		9:00 am	312	Oral
698		9:15 am	312	Oral
699		9:30 am	312	Oral
700		9:45 am	312	Oral

### Maternal Disease and Pregnancy Outcomes

701		8:30 am	311	Oral
702		8:45 am	311	Oral
703		9:00 am	311	Oral
704		9:15 am	311	Oral
705		9:30 am	311	Oral
706		9:45 am	311	Oral

### Novel Anticoagulants: A Changing Paradigm

707		8:30 am	210	Oral
708		8:45 am	210	Oral
709		9:00 am	210	Oral
710		9:15 am	210	Oral
711		9:30 am	210	Oral
712		9:45 am	210	Oral

### Vaccines Around the World

713		8:30 am	208	Oral
714		8:45 am	208	Oral
715		9:00 am	208	Oral
716		9:15 am	208	Oral
717		9:30 am	208	Oral
718		9:45 am	208	Oral

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

## WEDNESDAY, AUGUST 26 Cont.

### Pharmacoepidemiology of Anti-Infectives and Steroids

719		8:30 am	309	Oral
720		8:45 am	309	Oral
721		9:00 am	309	Oral
722		9:15 am	309	Oral
723		9:30 am	309	Oral
724		9:45 am	309	Oral

### The New FDA Pregnancy Label—And How To Fill It

725		10:30 - Noon	Ballroom A/B	Symposia
-----	--	--------------	--------------	----------

### Exploring Innovative Methods To Identify Patient Subgroup Treatment Response

726		10:30 - Noon	302	Symposia
-----	--	--------------	-----	----------

### Worldwide Database Networks: Methodological Challenges for Observational Drug Effect Research

727		10:30 - Noon	312	Symposia
-----	--	--------------	-----	----------

### Protecting and Promoting Public Health Through Pharmacovigilance: Approaches for Measuring the Impact of Pharmacovigilance Systems

728		10:30 - Noon	311	Symposia
-----	--	--------------	-----	----------

### Identifying Cases in Electronic Health Care Databases: Pitfalls and Best Practices

729		10:30 - Noon	210	Symposia
-----	--	--------------	-----	----------

### Generating Real-World Safety and Effectiveness Evidence for Biosimilars: Current Issues and Methodological Considerations

730		10:30 - Noon	208	Symposia
-----	--	--------------	-----	----------

### Safety Surveillance of New Oral Anticoagulants Within the Mini-Sentinel Program – Progress, Challenges, and Future Directions

731		10:30 - Noon	731	Symposia
-----	--	--------------	-----	----------

### It's Wicked Hard To Find What You're Looking For

732		1:30 pm	302	Oral
733		1:45 pm	302	Oral
734		2:00 pm	302	Oral
735		2:15 pm	302	Oral
736		2:30 pm	302	Oral
737		2:45 pm	302	Oral

### Safety of Psychotropic Drugs

738		1:30 pm	312	Oral
739		1:45 pm	312	Oral
740		2:00 pm	312	Oral
741		2:15 pm	312	Oral
742		2:30 pm	312	Oral
743		2:45 pm	312	Oral

### Our Aging Population

744		1:30 pm	311	Oral
745		1:45 pm	311	Oral
746		2:00 pm	311	Oral
747		2:15 pm	311	Oral
748		2:30 pm	311	Oral
749		2:45 pm	311	Oral

Pub. #	Poster #	Presentation Time	Room	Format
--------	----------	-------------------	------	--------

## Complex Relations: Cancer, Diabetes, and Heart Disease

750		2:45 pm	210	Oral
751		1:45 pm	210	Oral
752		2:00 pm	210	Oral
753		2:15 pm	210	Oral
754		2:30 pm	210	Oral
755		1:30 pm	210	Oral

## Who Knows What about Risk

756		1:30 pm	208	Oral
757		1:45 pm	208	Oral
758		2:00 pm	208	Oral
759		2:15 pm	208	Oral
760		2:30 pm	208	Oral
761		2:45 pm	208	Oral

## Coming from the Gut: Gastrointestinal Pharmacoepidemiology

762		1:30 pm	309	Oral
763		1:45 pm	309	Oral
764		2:00 pm	309	Oral
765		2:15 pm	309	Oral
766		2:30 pm	309	Oral
767		2:45 pm	309	Oral

## Poster Session C: Pharmacovigilance

768	1	8:00 am – 1:45 pm		Poster
769	2	8:00 am – 1:45 pm		Poster
770	3	8:00 am – 1:45 pm		Poster
771	4	8:00 am – 1:45 pm		Poster
772	5	8:00 am – 1:45 pm		Poster
773	6	8:00 am – 1:45 pm		Poster
774	7	8:00 am – 1:45 pm		Poster
775	8	8:00 am – 1:45 pm		Poster
776	9	8:00 am – 1:45 pm		Poster
777	10	8:00 am – 1:45 pm		Poster
778	11	8:00 am – 1:45 pm		Poster
779	12	8:00 am – 1:45 pm		Poster
780	13	8:00 am – 1:45 pm		Poster
781	14	8:00 am – 1:45 pm		Poster
782	15	8:00 am – 1:45 pm		Poster
783	16	8:00 am – 1:45 pm		Poster
784	17	8:00 am – 1:45 pm		Poster
785	18	8:00 am – 1:45 pm		Poster
786	19	8:00 am – 1:45 pm		Poster
787	20	8:00 am – 1:45 pm		Poster
788	21	8:00 am – 1:45 pm		Poster
789	22	8:00 am – 1:45 pm		Poster
790	23	8:00 am – 1:45 pm		Poster
791	24	8:00 am – 1:45 pm		Poster
792	25	8:00 am – 1:45 pm		Poster
793	26	8:00 am – 1:45 pm		Poster
794	27	8:00 am – 1:45 pm		Poster
795	28	8:00 am – 1:45 pm		Poster
796	29	8:00 am – 1:45 pm		Withdrawn by Author
797	30	08:00 am – 1:45 pm		Poster
798	31	08:00 am – 1:45 pm		Poster
799	32	08:00 am – 1:45 pm		Poster

## Poster Session C: Spotlight Session-Benefit Risk Assessment, Communication and Evaluation (BRACE)

800	33	8:00 am – 1:45 pm		Poster
801	34	8:00 am – 1:45 pm		Poster

# 31<sup>st</sup> ICPE ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
<b>WEDNESDAY, AUGUST 26 Cont.</b>				
802	35	8:00 am – 1:45 pm		Poster
803	36	8:00 am – 1:45 pm		Poster
804	37	8:00 am – 1:45 pm		Poster
805	38	8:00 am – 1:45 pm		Poster
806	39	8:00 am – 1:45 pm		Poster
807	40	8:00 am – 1:45 pm		Poster

## Poster Session C: Benefit Risk Assessment, Communication and Evaluation (BRACE)

808	41	8:00 am – 1:45 pm		Poster
809	42	8:00 am – 1:45 pm		Poster
810	43	8:00 am – 1:45 pm		Poster
811	44	8:00 am – 1:45 pm		Poster
812	45	8:00 am – 1:45 pm		Poster
813	46	8:00 am – 1:45 pm		Poster
814	47	8:00 am – 1:45 pm		Poster
815	48	8:00 am – 1:45 pm		Poster
816	49	8:00 am – 1:45 pm		Poster
817	50	8:00 am – 1:45 pm		Poster
818	51	8:00 am – 1:45 pm		Poster
819	52	8:00 am – 1:45 pm		Poster
820	53	8:00 am – 1:45 pm		Poster
821	54	8:00 am – 1:45 pm		Poster
822	55	8:00 am – 1:45 pm		Poster
823	56	8:00 am – 1:45 pm		Poster
824	57	8:00 am – 1:45 pm		Poster

## Poster Session C: Risk Management/Risk Minimization/Communication

825	58	8:00 am – 1:45 pm		Poster
826	59	8:00 am – 1:45 pm		Poster
827	60	8:00 am – 1:45 pm		Poster
828	61	8:00 am – 1:45 pm		Poster
829	62	8:00 am – 1:45 pm		Poster
830	63	8:00 am – 1:45 pm		Poster
831	64	8:00 am – 1:45 pm		Poster
832	65	8:00 am – 1:45 pm		Poster
833	66	8:00 am – 1:45 pm		Poster
834	67	8:00 am – 1:45 pm		Poster
835	68	8:00 am – 1:45 pm		Poster
836	69	8:00 am – 1:45 pm		Poster

## Poster Session C: Pharmacoeconomics/Outcomes Research

837	70	8:00 am – 1:45 pm		Poster
838	71	8:00 am – 1:45 pm		Poster
839	72	8:00 am – 1:45 pm		Poster
840	73	8:00 am – 1:45 pm		Poster
841	74	8:00 am – 1:45 pm		Poster
842	75	8:00 am – 1:45 pm		Poster
843	76	8:00 am – 1:45 pm		Poster
844	77	8:00 am – 1:45 pm		Poster
845	78	8:00 am – 1:45 pm		Poster
846	79	8:00 am – 1:45 pm		Poster
847	80	8:00 am – 1:45 pm		Poster
848	81	8:00 am – 1:45 pm		Poster
849	82	8:00 am – 1:45 pm		Poster
850	83	8:00 am – 1:45 pm		Poster
851	84	8:00 am – 1:45 pm		Poster

## Poster Session C: Spotlight Session-Adherence

852	85	8:00 am – 1:45 pm		Poster
-----	----	-------------------	--	--------

Pub. #	Poster #	Presentation Time	Room	Format
853	86	8:00 am – 1:45 pm		Poster
854	87	8:00 am – 1:45 pm		Poster
855	88	8:00 am – 1:45 pm		Poster
856	89	8:00 am – 1:45 pm		Poster
857	90	8:00 am – 1:45 pm		Poster
858	91	8:00 am – 1:45 pm		Poster
859	92	8:00 am – 1:45 pm		Poster

## Poster Session C: Adherence

860	93	8:00 am – 1:45 pm		Poster
861	94	8:00 am – 1:45 pm		Poster
862	95	8:00 am – 1:45 pm		Poster
863	96	8:00 am – 1:45 pm		Poster
864	97	8:00 am – 1:45 pm		Poster
865	98	8:00 am – 1:45 pm		Poster
866	99	8:00 am – 1:45 pm		Poster
867	100	8:00 am – 1:45 pm		Poster
868	101	8:00 am – 1:45 pm		Poster
869	102	8:00 am – 1:45 pm		Poster
870	103	8:00 am – 1:45 pm		Poster
871	104	8:00 am – 1:45 pm		Poster
872	105	8:00 am – 1:45 pm		Poster
873	106	8:00 am – 1:45 pm		Poster
874	107	8:00 am – 1:45 pm		Poster
875	108	8:00 am – 1:45 pm		Poster
876	109	8:00 am – 1:45 pm		Poster
877	110	8:00 am – 1:45 pm		Poster
878	111	8:00 am – 1:45 pm		Poster
879	112	8:00 am – 1:45 pm		Poster
880	113	8:00 am – 1:45 pm		Poster
881	114	8:00 am – 1:45 pm		Poster
882	115	8:00 am – 1:45 pm		Poster
883	116	8:00 am – 1:45 pm		Poster
884	117	8:00 am – 1:45 pm		Poster
885	118	8:00 am – 1:45 pm		Poster
886	119	8:00 am – 1:45 pm		Poster
887	120	8:00 am – 1:45 pm		Poster
888	121	8:00 am – 1:45 pm		Poster
889	122	8:00 am – 1:45 pm		Poster
890	123	8:00 am – 1:45 pm		Poster
891	124	8:00 am – 1:45 pm		Poster
892	125	8:00 am – 1:45 pm		Poster

## Poster Session C: Spotlight Session-Databases

893	126	8:00 am – 1:45 pm		Poster
894	127	8:00 am – 1:45 pm		Poster
895	128	8:00 am – 1:45 pm		Poster
896	129	8:00 am – 1:45 pm		Poster
897	130	8:00 am – 1:45 pm		Poster
898	131	8:00 am – 1:45 pm		Poster
899	132	8:00 am – 1:45 pm		Poster
900	133	8:00 am – 1:45 pm		Poster

## Poster Session C: Databases

901	134	8:00 am – 1:45 pm		Poster
902	135	8:00 am – 1:45 pm		Poster
903	136	8:00 am – 1:45 pm		Poster
904	137	8:00 am – 1:45 pm		Poster
905	138	8:00 am – 1:45 pm		Poster
906	139	8:00 am – 1:45 pm		Poster
907	140	8:00 am – 1:45 pm		Poster
908	141	8:00 am – 1:45 pm		Poster
909	142	8:00 am – 1:45 pm		Poster
910	143	8:00 am – 1:45 pm		Poster

# 31<sup>st</sup> ICPE ABSTRACT INDEX

Pub. #	Poster #	Presentation Time	Room	Format
<b>WEDNESDAY, AUGUST 26 Cont.</b>				
911	144	8:00 am – 1:45 pm	Withdrawn by Author	
912	145	8:00 am – 1:45 pm	Withdrawn by Author	
913	146	8:00 am – 1:45 pm		Poster
914	147	8:00 am – 1:45 pm		Poster
915	148	8:00 am – 1:45 pm		Poster
916	149	8:00 am – 1:45 pm		Poster
917	150	8:00 am – 1:45 pm		Poster
918	151	8:00 am – 1:45 pm		Poster
919	152	8:00 am – 1:45 pm		Poster
920	153	8:00 am – 1:45 pm		Poster
921	154	8:00 am – 1:45 pm		Poster
922	155	8:00 am – 1:45 pm		Poster
923	156	8:00 am – 1:45 pm		Poster
924	157	8:00 am – 1:45 pm		Poster
925	158	8:00 am – 1:45 pm		Poster
926	159	8:00 am – 1:45 pm		Poster
927	160	8:00 am – 1:45 pm		Poster
928	161	8:00 am – 1:45 pm		Poster
929	162	8:00 am – 1:45 pm		Poster
930	163	8:00 am – 1:45 pm		Poster
931	164	8:00 am – 1:45 pm		Poster
932	165	8:00 am – 1:45 pm		Poster
933	166	8:00 am – 1:45 pm		Poster
934	167	8:00 am – 1:45 pm		Poster
935	168	8:00 am – 1:45 pm		Poster
936	169	8:00 am – 1:45 pm		Poster
937	170	8:00 am – 1:45 pm		Poster
938	171	8:00 am – 1:45 pm		Poster
939	172	8:00 am – 1:45 pm		Poster
940	173	8:00 am – 1:45 pm		Poster
941	174	8:00 am – 1:45 pm		Poster
942	175	8:00 am – 1:45 pm		Poster
943	176	8:00 am – 1:45 pm		Poster
944	177	8:00 am – 1:45 pm		Poster
945	178	8:00 am – 1:45 pm		Poster
946	179	8:00 am – 1:45 pm		Poster
947	180	8:00 am – 1:45 pm		Poster
948	181	8:00 am – 1:45 pm		Poster
949	182	8:00 am – 1:45 pm		Poster
950	183	8:00 am – 1:45 pm		Poster
951	184	8:00 am – 1:45 pm		Poster
952	185	8:00 am – 1:45 pm		Poster
953	186	8:00 am – 1:45 pm		Poster
954	187	8:00 am – 1:45 pm		Poster
955	188	8:00 am – 1:45 pm		Poster
956	189	8:00 am – 1:45 pm		Poster
957	190	8:00 am – 1:45 pm		Poster
958	191	8:00 am – 1:45 pm		Poster
959	192	8:00 am – 1:45 pm		Poster
960	193	8:00 am – 1:45 pm		Poster
961	194	8:00 am – 1:45 pm		Poster
962	195	8:00 am – 1:45 pm		Poster
963	196	8:00 am – 1:45 pm		Poster
964	197	8:00 am – 1:45 pm		Poster
965	198	8:00 am – 1:45 pm		Poster
966	199	8:00 am – 1:45 pm		Poster
967	200	8:00 am – 1:45 pm		Poster
968	201	8:00 am – 1:45 pm		Poster
969	202	8:00 am – 1:45 pm		Poster
970	203	8:00 am – 1:45 pm		Poster
971	204	8:00 am – 1:45 pm		Poster
972	205	8:00 am – 1:45 pm		Poster

Pub. #	Poster #	Presentation Time	Room	Format
973	206	8:00 am – 1:45 pm		Poster
974	207	8:00 am – 1:45 pm		Poster
975	208	8:00 am – 1:45 pm		Poster
976	209	8:00 am – 1:45 pm		Poster
977	210	8:00 am – 1:45 pm		Poster
978	211	8:00 am – 1:45 pm		Poster
979	212	8:00 am – 1:45 pm		Poster
980	213	8:00 am – 1:45 pm		Poster
981	214	8:00 am – 1:45 pm		Poster
982	215	8:00 am – 1:45 pm		Poster
983	216	8:00 am – 1:45 pm		Poster

## Poster Session C: Methods

984	217	8:00 am – 1:45 pm		Poster
985	218	8:00 am – 1:45 pm		Poster
986	219	8:00 am – 1:45 pm		Poster
987	220	8:00 am – 1:45 pm		Poster
988	221	8:00 am – 1:45 pm		Poster
989	222	8:00 am – 1:45 pm		Poster
990	223	8:00 am – 1:45 pm		Poster
991	224	8:00 am – 1:45 pm		Poster
992	225	8:00 am – 1:45 pm		Poster
993	226	8:00 am – 1:45 pm		Poster
994	227	8:00 am – 1:45 pm		Poster
995	228	8:00 am – 1:45 pm		Poster
996	229	8:00 am – 1:45 pm		Poster
997	230	8:00 am – 1:45 pm		Poster
998	231	8:00 am – 1:45 pm		Poster
999	232	8:00 am – 1:45 pm		Poster
1000	233	8:00 am – 1:45 pm		Poster
1001	234	8:00 am – 1:45 pm		Poster
1002	235	8:00 am – 1:45 pm		Poster
1003	236	8:00 am – 1:45 pm		Poster
1004	237	8:00 am – 1:45 pm		Poster
1005	238	8:00 am – 1:45 pm		Poster
1006	239	8:00 am – 1:45 pm	Withdrawn by Author	
1007	240	8:00 am – 1:45 pm		Poster
1008	241	8:00 am – 1:45 pm		Poster
1009	242	8:00 am – 1:45 pm		Poster
1010	243	8:00 am – 1:45 pm		Poster
1011	244	8:00 am – 1:45 pm		Poster
1012	245	8:00 am – 1:45 pm		Poster
1013	246	8:00 am – 1:45 pm		Poster
1014	247	8:00 am – 1:45 pm		Poster
1015	248	8:00 am – 1:45 pm		Poster
1016	249	8:00 am – 1:45 pm		Poster
1017	250	8:00 am – 1:45 pm		Poster
1018	251	8:00 am – 1:45 pm		Poster
1019	252	8:00 am – 1:45 pm		Poster
1020	253	8:00 am – 1:45 pm		Poster
1021	254	8:00 am – 1:45 pm		Poster
1022	255	8:00 am – 1:45 pm		Poster
1023	256	8:00 am – 1:45 pm		Poster
1024	257	8:00 am – 1:45 pm		Poster
1025	258	8:00 am – 1:45 pm		Poster
1026	259	8:00 am – 1:45 pm		Poster
1027	260	8:00 am – 1:45 pm		Poster
1028	261	8:00 am – 1:45 pm		Poster
1029	262	8:00 am – 1:45 pm	Withdrawn by Author	
1030	263	8:00 am – 1:45 pm		Poster
1031	264	8:00 am – 1:45 pm		Poster
1032	265	8:00 am – 1:45 pm		Poster









International Conference on  
Pharmacoepidemiology & Therapeutic Risk Management  
The Convention Center Dublin

# CALL FOR ABSTRACTS

Abstract Submission Deadline: February 17, 2016

Meeting info: [pharmacoepi.org](http://pharmacoepi.org)

## You are Invited to Submit an Abstract

ISPE invites you to submit an abstract for an oral/poster presentation, workshop or symposium at the 32<sup>nd</sup> ICPE in Dublin, Ireland. This pre-eminent conference on pharmacoepidemiology will be an invaluable scientific experience and will allow you to experience Dublin's dynamic and lively personality.

## Guidelines For Submissions

**Abstract Submission  
Deadline**  
**FEBRUARY 17, 2016**

The deadline for receipt of all abstracts is **February 17, 2016**. Please visit [pharmacoepi.org](http://pharmacoepi.org), for submission guidelines. The online submission site will be operational by mid-December 2015.

Questions about abstract submissions and technical issues should be directed to Coe Truman at [c4asupport@coetruman.com](mailto:c4asupport@coetruman.com) or by telephone +1.507.403.2305. Note, submissions will not be accepted until the online submission site is open in **December 2015**.

## Reviewing/Registration

The ISPE Scientific Program Committee will review all abstracts in **April 2016**. All submitters will be notified by email in early **June 2016**. All presenters and panelists (workshop/symposia) must register to attend the 2016 ICPE.



## Scholarships & Student Awards

**Scholarship  
Submission Deadline**  
**MARCH 1, 2016**

ISPE will award a limited number of scholarships to help defray conference expenses. Information will be posted on [pharmacoepi.org](http://pharmacoepi.org)

ISPE will grant several student awards to recognize and encourage student excellence in pharmacoepidemiology. The Scientific Program Committee oversees the selection of awards, which will be presented at the 2016 ICPE Annual Meeting of ISPE Members & Awards Ceremony.

## Sponsorships, Exhibits & Academic Showcase

ISPE offers organizations, institutions and academic programs opportunities to support the conference while sharing their products and services with attendees. A Conference Sponsorship & Exhibitor Prospectus will be posted on [pharmacoepi.org/meetings/32ICPE](http://pharmacoepi.org/meetings/32ICPE).

## Save the Dates!

**August 25-28, 2016**

The Convention Center Dublin  
Dublin, Ireland

Please visit

[pharmacoepi.org/meetings/32ICPE](http://pharmacoepi.org/meetings/32ICPE) for updated conference information.




Official Journal of the International Society for Pharmacoepidemiology

Editor-In-Chief: Professor Brian L. Strom

*Pharmacoepidemiology & Drug Safety* provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

\* Free online access for ISPE members via the society website

## Congratulations to The Ronald D. Mann Best Article of 2014 Awards Winners



Impact Factor 2.939\*

\*2014 Journal Citation Reports® (Thomson Reuters)

### First Prize

**Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany**

Jürgen Prestel, Peter Volkers, Dirk Mentzer, Helmar C. Lehmann, Hans-Peter Hartung, and Brigitte Keller-Stanislawski, for the GBS Study Group  
Volume 23, Issue 11, November 2014, Pages: 1192-1204

### Honorable Mention:

**Trimethoprim use before pregnancy and risk of congenital malformation: reanalyzed using a case crossover design and a case-time-control design**

Yuelian Sun, Chun Sen Wu and Jørn Olsen  
Volume 23, Issue 10, October 2014, Pages: 1076-1083

### Honorable Mention:

**Chronic opioid use emerging after bariatric surgery**

Marsha A. Raebel, Sophia R. Newcomer, Elizabeth A. Bayliss, Denise Boudreau, Lynn DeBar, Thomas E. Elliott, Ameena T. Ahmed, Pamala A. Pawloski, David Fisher, Sengwee Toh and William Troy Donahoo  
Volume 23, Issue 12, December 2014, Pages: 1247-1257

### Honorable mention:

**The ecology of prescription opioid abuse in the USA: geographic variation in patients' use of multiple prescribers ("doctor shopping")**

Douglas C. McDonald and Kenneth E. Carlson  
Volume 23, Issue 12, December 2014, Pages: 1258-1267

For more information on these top papers and other journal features, please visit


[www.pdsjournal.org](http://www.pdsjournal.org)

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2015 Volume: 24 • Frequency: Monthly

# 3-2-1 Connect Hotel & Complex Map

*Signature*  
**BOSTON**  
Remarkable experiences.  
Imagination realized.

**ONE**  
THREE  
TWO  
**CONNECT**



Public Transportation



Street Entrance



Taxi Stand





Access to Parking Garage





Walking Connector Path

# HYNES CONVENTION CENTER

## Plaza Level



## Level 2



## Third Level

